6	ELIQUIS.xml:S1:4:1	O
ADVERSE	ELIQUIS.xml:S1:6:7	O
REACTIONS	ELIQUIS.xml:S1:14:9	O

The	ELIQUIS.xml:S1:27:3	O
following	ELIQUIS.xml:S1:31:9	O
serious	ELIQUIS.xml:S1:41:7	O
adverse	ELIQUIS.xml:S1:49:7	O
reactions	ELIQUIS.xml:S1:57:9	O
are	ELIQUIS.xml:S1:67:3	O
discussed	ELIQUIS.xml:S1:71:9	O
in	ELIQUIS.xml:S1:81:2	O
greater	ELIQUIS.xml:S1:84:7	O
detail	ELIQUIS.xml:S1:92:6	O
in	ELIQUIS.xml:S1:99:2	O
other	ELIQUIS.xml:S1:102:5	O
sections	ELIQUIS.xml:S1:108:8	O
of	ELIQUIS.xml:S1:117:2	O
the	ELIQUIS.xml:S1:120:3	O
prescribing	ELIQUIS.xml:S1:124:11	O
information	ELIQUIS.xml:S1:136:11	O
.	ELIQUIS.xml:S1:147:1	O

?	ELIQUIS.xml:S1:156:1	O

Increased	ELIQUIS.xml:S1:159:9	O
risk	ELIQUIS.xml:S1:169:4	B-Factor
of	ELIQUIS.xml:S1:174:2	O
thrombotic	ELIQUIS.xml:S1:177:10	B-AdverseReaction
events	ELIQUIS.xml:S1:188:6	I-AdverseReaction
after	ELIQUIS.xml:S1:195:5	O
premature	ELIQUIS.xml:S1:201:9	O
discontinuation	ELIQUIS.xml:S1:211:15	O
[	ELIQUIS.xml:S1:227:1	O
seeWarnings	ELIQUIS.xml:S1:228:11	O
and	ELIQUIS.xml:S1:240:3	O
Precautions	ELIQUIS.xml:S1:244:11	O
(	ELIQUIS.xml:S1:256:1	O
5.1	ELIQUIS.xml:S1:257:3	O
)]	ELIQUIS.xml:S1:260:2	O

?	ELIQUIS.xml:S1:269:1	O

Bleeding	ELIQUIS.xml:S1:272:8	B-AdverseReaction
[	ELIQUIS.xml:S1:281:1	O
seeWarnings	ELIQUIS.xml:S1:282:11	O
and	ELIQUIS.xml:S1:294:3	O
Precautions	ELIQUIS.xml:S1:298:11	O
(	ELIQUIS.xml:S1:310:1	O
5.2	ELIQUIS.xml:S1:311:3	O
)]	ELIQUIS.xml:S1:314:2	O

?	ELIQUIS.xml:S1:323:1	O

Spinal	ELIQUIS.xml:S1:326:6	O
epidural	ELIQUIS.xml:S1:333:8	O
anesthesia	ELIQUIS.xml:S1:342:10	O
or	ELIQUIS.xml:S1:353:2	O
puncture	ELIQUIS.xml:S1:356:8	O
[	ELIQUIS.xml:S1:365:1	O
seeWarnings	ELIQUIS.xml:S1:366:11	O
and	ELIQUIS.xml:S1:378:3	O
Precautions	ELIQUIS.xml:S1:382:11	O
(	ELIQUIS.xml:S1:394:1	O
5.3	ELIQUIS.xml:S1:395:3	O
)]	ELIQUIS.xml:S1:398:2	O

EXCERPT	ELIQUIS.xml:S1:409:7	O
:	ELIQUIS.xml:S1:416:1	O
Most	ELIQUIS.xml:S1:420:4	O
common	ELIQUIS.xml:S1:425:6	O
adverse	ELIQUIS.xml:S1:432:7	O
reactions	ELIQUIS.xml:S1:440:9	O
(	ELIQUIS.xml:S1:450:1	O
1%	ELIQUIS.xml:S1:452:2	O
)	ELIQUIS.xml:S1:454:1	O
are	ELIQUIS.xml:S1:456:3	O
related	ELIQUIS.xml:S1:460:7	O
to	ELIQUIS.xml:S1:468:2	O
bleeding	ELIQUIS.xml:S1:471:8	B-AdverseReaction
.	ELIQUIS.xml:S1:479:1	O

(	ELIQUIS.xml:S1:480:1	O
6.1	ELIQUIS.xml:S1:481:3	O
)	ELIQUIS.xml:S1:484:1	O

To	ELIQUIS.xml:S1:492:2	O

report	ELIQUIS.xml:S1:495:6	O
SUSPECTED	ELIQUIS.xml:S1:502:9	O
ADVERSE	ELIQUIS.xml:S1:512:7	O
REACTIONS	ELIQUIS.xml:S1:520:9	O
,	ELIQUIS.xml:S1:529:1	O
contact	ELIQUIS.xml:S1:531:7	O
Bristol	ELIQUIS.xml:S1:539:7	O
-	ELIQUIS.xml:S1:546:1	O
Myers	ELIQUIS.xml:S1:547:5	O
Squibb	ELIQUIS.xml:S1:553:6	O
at	ELIQUIS.xml:S1:560:2	O
1	ELIQUIS.xml:S1:563:1	O
-	ELIQUIS.xml:S1:564:1	O
800	ELIQUIS.xml:S1:565:3	O
-	ELIQUIS.xml:S1:568:1	O
721	ELIQUIS.xml:S1:569:3	O
-	ELIQUIS.xml:S1:572:1	O
5072	ELIQUIS.xml:S1:573:4	O
or	ELIQUIS.xml:S1:578:2	O
FDA	ELIQUIS.xml:S1:581:3	O
at	ELIQUIS.xml:S1:585:2	O
1	ELIQUIS.xml:S1:588:1	O
-	ELIQUIS.xml:S1:589:1	O
800	ELIQUIS.xml:S1:590:3	O
-	ELIQUIS.xml:S1:593:1	O
FDA	ELIQUIS.xml:S1:594:3	O
-	ELIQUIS.xml:S1:597:1	O
1088	ELIQUIS.xml:S1:598:4	O
or	ELIQUIS.xml:S1:603:2	O
www	ELIQUIS.xml:S1:609:3	O
.	ELIQUIS.xml:S1:612:1	O
fda	ELIQUIS.xml:S1:613:3	O
.	ELIQUIS.xml:S1:616:1	O
gov	ELIQUIS.xml:S1:617:3	O
medwatch	ELIQUIS.xml:S1:621:8	O
.	ELIQUIS.xml:S1:633:1	O

6.1	ELIQUIS.xml:S1:645:3	O

Clinical	ELIQUIS.xml:S1:649:8	O
Trials	ELIQUIS.xml:S1:658:6	O
Experience	ELIQUIS.xml:S1:665:10	O

Because	ELIQUIS.xml:S1:679:7	O
clinical	ELIQUIS.xml:S1:687:8	O
trials	ELIQUIS.xml:S1:696:6	O
are	ELIQUIS.xml:S1:703:3	O
conducted	ELIQUIS.xml:S1:707:9	O
under	ELIQUIS.xml:S1:717:5	O
widely	ELIQUIS.xml:S1:723:6	O
varying	ELIQUIS.xml:S1:730:7	O
conditions	ELIQUIS.xml:S1:738:10	O
,	ELIQUIS.xml:S1:748:1	O
adverse	ELIQUIS.xml:S1:750:7	O
reaction	ELIQUIS.xml:S1:758:8	O
rates	ELIQUIS.xml:S1:767:5	O
observed	ELIQUIS.xml:S1:773:8	O
in	ELIQUIS.xml:S1:782:2	O
the	ELIQUIS.xml:S1:785:3	O
clinical	ELIQUIS.xml:S1:789:8	O
trials	ELIQUIS.xml:S1:798:6	O
of	ELIQUIS.xml:S1:805:2	O
a	ELIQUIS.xml:S1:808:1	O
drug	ELIQUIS.xml:S1:810:4	O
cannot	ELIQUIS.xml:S1:815:6	O
be	ELIQUIS.xml:S1:822:2	O
directly	ELIQUIS.xml:S1:825:8	O
compared	ELIQUIS.xml:S1:834:8	O
to	ELIQUIS.xml:S1:843:2	O
rates	ELIQUIS.xml:S1:846:5	O
in	ELIQUIS.xml:S1:852:2	O
the	ELIQUIS.xml:S1:855:3	O
clinical	ELIQUIS.xml:S1:859:8	O
trials	ELIQUIS.xml:S1:868:6	O
of	ELIQUIS.xml:S1:875:2	O
another	ELIQUIS.xml:S1:878:7	O
drug	ELIQUIS.xml:S1:886:4	O
and	ELIQUIS.xml:S1:891:3	O
may	ELIQUIS.xml:S1:895:3	O
not	ELIQUIS.xml:S1:899:3	O
reflect	ELIQUIS.xml:S1:903:7	O
the	ELIQUIS.xml:S1:911:3	O
rates	ELIQUIS.xml:S1:915:5	O
observed	ELIQUIS.xml:S1:921:8	O
in	ELIQUIS.xml:S1:930:2	O
practice	ELIQUIS.xml:S1:933:8	O
.	ELIQUIS.xml:S1:941:1	O

Reduction	ELIQUIS.xml:S1:954:9	O

of	ELIQUIS.xml:S1:964:2	O
Risk	ELIQUIS.xml:S1:967:4	O
of	ELIQUIS.xml:S1:972:2	O
Stroke	ELIQUIS.xml:S1:975:6	O
and	ELIQUIS.xml:S1:982:3	O
Systemic	ELIQUIS.xml:S1:986:8	O
Embolism	ELIQUIS.xml:S1:995:8	O
in	ELIQUIS.xml:S1:1004:2	O
Patients	ELIQUIS.xml:S1:1007:8	O
with	ELIQUIS.xml:S1:1016:4	O
Nonvalvular	ELIQUIS.xml:S1:1021:11	O
Atrial	ELIQUIS.xml:S1:1033:6	O
Fibrillation	ELIQUIS.xml:S1:1040:12	O

The	ELIQUIS.xml:S1:1056:3	O
safety	ELIQUIS.xml:S1:1060:6	O
of	ELIQUIS.xml:S1:1067:2	O
ELIQUIS	ELIQUIS.xml:S1:1070:7	O
was	ELIQUIS.xml:S1:1078:3	O
evaluated	ELIQUIS.xml:S1:1082:9	O
in	ELIQUIS.xml:S1:1092:2	O
the	ELIQUIS.xml:S1:1095:3	O
ARISTOTLE	ELIQUIS.xml:S1:1099:9	O
and	ELIQUIS.xml:S1:1109:3	O
AVERROES	ELIQUIS.xml:S1:1113:8	O
studies	ELIQUIS.xml:S1:1122:7	O
[	ELIQUIS.xml:S1:1131:1	O
seeClinical	ELIQUIS.xml:S1:1132:11	O
Studies	ELIQUIS.xml:S1:1144:7	O
(	ELIQUIS.xml:S1:1152:1	O
14	ELIQUIS.xml:S1:1153:2	O
)]	ELIQUIS.xml:S1:1155:2	O
,	ELIQUIS.xml:S1:1159:1	O
including	ELIQUIS.xml:S1:1161:9	O
11	ELIQUIS.xml:S1:1171:2	O
,	ELIQUIS.xml:S1:1173:1	O
284	ELIQUIS.xml:S1:1174:3	O
patients	ELIQUIS.xml:S1:1178:8	O
exposed	ELIQUIS.xml:S1:1187:7	O
to	ELIQUIS.xml:S1:1195:2	O
ELIQUIS	ELIQUIS.xml:S1:1198:7	O
5	ELIQUIS.xml:S1:1206:1	O
mg	ELIQUIS.xml:S1:1208:2	O
twice	ELIQUIS.xml:S1:1211:5	O
daily	ELIQUIS.xml:S1:1217:5	O
and	ELIQUIS.xml:S1:1223:3	O
602	ELIQUIS.xml:S1:1227:3	O
patients	ELIQUIS.xml:S1:1231:8	O
exposed	ELIQUIS.xml:S1:1240:7	O
to	ELIQUIS.xml:S1:1248:2	O
ELIQUIS	ELIQUIS.xml:S1:1251:7	O
2.5	ELIQUIS.xml:S1:1259:3	O
mg	ELIQUIS.xml:S1:1263:2	O
twice	ELIQUIS.xml:S1:1266:5	O
daily	ELIQUIS.xml:S1:1272:5	O
.	ELIQUIS.xml:S1:1277:1	O

The	ELIQUIS.xml:S1:1279:3	O
duration	ELIQUIS.xml:S1:1283:8	O
of	ELIQUIS.xml:S1:1292:2	O
ELIQUIS	ELIQUIS.xml:S1:1295:7	O
exposure	ELIQUIS.xml:S1:1303:8	O
was	ELIQUIS.xml:S1:1312:3	O
12	ELIQUIS.xml:S1:1318:2	O
months	ELIQUIS.xml:S1:1321:6	O
for	ELIQUIS.xml:S1:1328:3	O
9375	ELIQUIS.xml:S1:1332:4	O
patients	ELIQUIS.xml:S1:1337:8	O
and	ELIQUIS.xml:S1:1346:3	O
24	ELIQUIS.xml:S1:1352:2	O
months	ELIQUIS.xml:S1:1355:6	O
for	ELIQUIS.xml:S1:1362:3	O
3369	ELIQUIS.xml:S1:1366:4	O
patients	ELIQUIS.xml:S1:1371:8	O
in	ELIQUIS.xml:S1:1380:2	O
the	ELIQUIS.xml:S1:1383:3	O
two	ELIQUIS.xml:S1:1387:3	O
studies	ELIQUIS.xml:S1:1391:7	O
.	ELIQUIS.xml:S1:1398:1	O

In	ELIQUIS.xml:S1:1400:2	O
ARISTOTLE	ELIQUIS.xml:S1:1403:9	O
,	ELIQUIS.xml:S1:1412:1	O
the	ELIQUIS.xml:S1:1414:3	O
mean	ELIQUIS.xml:S1:1418:4	O
duration	ELIQUIS.xml:S1:1423:8	O
of	ELIQUIS.xml:S1:1432:2	O
exposure	ELIQUIS.xml:S1:1435:8	O
was	ELIQUIS.xml:S1:1444:3	O
89	ELIQUIS.xml:S1:1448:2	O
weeks	ELIQUIS.xml:S1:1451:5	O
(	ELIQUIS.xml:S1:1457:1	O
15	ELIQUIS.xml:S1:1459:2	O
,	ELIQUIS.xml:S1:1461:1	O
000	ELIQUIS.xml:S1:1462:3	O
patient	ELIQUIS.xml:S1:1466:7	O
-	ELIQUIS.xml:S1:1473:1	O
years	ELIQUIS.xml:S1:1474:5	O
)	ELIQUIS.xml:S1:1479:1	O
.	ELIQUIS.xml:S1:1480:1	O

In	ELIQUIS.xml:S1:1482:2	O
AVERROES	ELIQUIS.xml:S1:1485:8	O
,	ELIQUIS.xml:S1:1493:1	O
the	ELIQUIS.xml:S1:1495:3	O
mean	ELIQUIS.xml:S1:1499:4	O
duration	ELIQUIS.xml:S1:1504:8	O
of	ELIQUIS.xml:S1:1513:2	O
exposure	ELIQUIS.xml:S1:1516:8	O
was	ELIQUIS.xml:S1:1525:3	O
approximately	ELIQUIS.xml:S1:1529:13	O
59	ELIQUIS.xml:S1:1543:2	O
weeks	ELIQUIS.xml:S1:1546:5	O
(	ELIQUIS.xml:S1:1552:1	O
3000	ELIQUIS.xml:S1:1554:4	O
patient	ELIQUIS.xml:S1:1559:7	O
-	ELIQUIS.xml:S1:1566:1	O
years	ELIQUIS.xml:S1:1567:5	O
)	ELIQUIS.xml:S1:1572:1	O
.	ELIQUIS.xml:S1:1573:1	O

The	ELIQUIS.xml:S1:1579:3	O
most	ELIQUIS.xml:S1:1583:4	O
common	ELIQUIS.xml:S1:1588:6	O
reason	ELIQUIS.xml:S1:1595:6	O
for	ELIQUIS.xml:S1:1602:3	O
treatment	ELIQUIS.xml:S1:1606:9	O
discontinuation	ELIQUIS.xml:S1:1616:15	O
in	ELIQUIS.xml:S1:1632:2	O
both	ELIQUIS.xml:S1:1635:4	O
studies	ELIQUIS.xml:S1:1640:7	O
was	ELIQUIS.xml:S1:1648:3	O
for	ELIQUIS.xml:S1:1652:3	O
bleeding	ELIQUIS.xml:S1:1656:8	B-AdverseReaction
-	ELIQUIS.xml:S1:1664:1	I-AdverseReaction
related	ELIQUIS.xml:S1:1665:7	I-AdverseReaction
adverse	ELIQUIS.xml:S1:1673:7	I-AdverseReaction
reactions	ELIQUIS.xml:S1:1681:9	I-AdverseReaction
;	ELIQUIS.xml:S1:1690:1	O
in	ELIQUIS.xml:S1:1692:2	O
ARISTOTLE	ELIQUIS.xml:S1:1695:9	O
this	ELIQUIS.xml:S1:1705:4	O
occurred	ELIQUIS.xml:S1:1710:8	O
in	ELIQUIS.xml:S1:1719:2	O
1.7%	ELIQUIS.xml:S1:1722:4	O
and	ELIQUIS.xml:S1:1727:3	O
2.5%	ELIQUIS.xml:S1:1731:4	O
of	ELIQUIS.xml:S1:1736:2	O
patients	ELIQUIS.xml:S1:1739:8	O
treated	ELIQUIS.xml:S1:1748:7	O
with	ELIQUIS.xml:S1:1756:4	O
ELIQUIS	ELIQUIS.xml:S1:1761:7	O
and	ELIQUIS.xml:S1:1769:3	O
warfarin	ELIQUIS.xml:S1:1773:8	O
,	ELIQUIS.xml:S1:1781:1	O
respectively	ELIQUIS.xml:S1:1783:12	O
,	ELIQUIS.xml:S1:1795:1	O
and	ELIQUIS.xml:S1:1797:3	O
in	ELIQUIS.xml:S1:1801:2	O
AVERROES	ELIQUIS.xml:S1:1804:8	O
,	ELIQUIS.xml:S1:1812:1	O
in	ELIQUIS.xml:S1:1814:2	O
1.5%	ELIQUIS.xml:S1:1817:4	O
and	ELIQUIS.xml:S1:1822:3	O
1.3%	ELIQUIS.xml:S1:1826:4	O
on	ELIQUIS.xml:S1:1831:2	O
ELIQUIS	ELIQUIS.xml:S1:1834:7	O
and	ELIQUIS.xml:S1:1842:3	O
aspirin	ELIQUIS.xml:S1:1846:7	O
,	ELIQUIS.xml:S1:1853:1	O
respectively	ELIQUIS.xml:S1:1855:12	O
.	ELIQUIS.xml:S1:1867:1	O

Bleeding	ELIQUIS.xml:S1:1875:8	O
in	ELIQUIS.xml:S1:1884:2	O
Patients	ELIQUIS.xml:S1:1887:8	O
with	ELIQUIS.xml:S1:1896:4	O
Nonvalvular	ELIQUIS.xml:S1:1901:11	O
Atrial	ELIQUIS.xml:S1:1913:6	O
Fibrillation	ELIQUIS.xml:S1:1920:12	O
in	ELIQUIS.xml:S1:1933:2	O
ARISTOTLE	ELIQUIS.xml:S1:1936:9	O
and	ELIQUIS.xml:S1:1946:3	O
AVERROES	ELIQUIS.xml:S1:1950:8	O

Tables	ELIQUIS.xml:S1:1962:6	O
1	ELIQUIS.xml:S1:1969:1	O
and	ELIQUIS.xml:S1:1971:3	O
2	ELIQUIS.xml:S1:1975:1	O
show	ELIQUIS.xml:S1:1977:4	O
the	ELIQUIS.xml:S1:1982:3	O
number	ELIQUIS.xml:S1:1986:6	O
of	ELIQUIS.xml:S1:1993:2	O
patients	ELIQUIS.xml:S1:1996:8	O
experiencing	ELIQUIS.xml:S1:2005:12	O
major	ELIQUIS.xml:S1:2018:5	B-Severity
bleeding	ELIQUIS.xml:S1:2024:8	B-AdverseReaction
during	ELIQUIS.xml:S1:2033:6	O
the	ELIQUIS.xml:S1:2040:3	O
treatment	ELIQUIS.xml:S1:2044:9	O
period	ELIQUIS.xml:S1:2054:6	O
and	ELIQUIS.xml:S1:2061:3	O
the	ELIQUIS.xml:S1:2065:3	O
bleeding	ELIQUIS.xml:S1:2069:8	B-AdverseReaction
rate	ELIQUIS.xml:S1:2078:4	O
(	ELIQUIS.xml:S1:2083:1	O
percentage	ELIQUIS.xml:S1:2084:10	O
of	ELIQUIS.xml:S1:2095:2	O
subjects	ELIQUIS.xml:S1:2098:8	O
with	ELIQUIS.xml:S1:2107:4	O
at	ELIQUIS.xml:S1:2112:2	O
least	ELIQUIS.xml:S1:2115:5	O
one	ELIQUIS.xml:S1:2121:3	O
bleeding	ELIQUIS.xml:S1:2125:8	B-AdverseReaction
event	ELIQUIS.xml:S1:2134:5	O
per	ELIQUIS.xml:S1:2140:3	O
100	ELIQUIS.xml:S1:2144:3	O
patient	ELIQUIS.xml:S1:2148:7	O
-	ELIQUIS.xml:S1:2155:1	O
years	ELIQUIS.xml:S1:2156:5	O
)	ELIQUIS.xml:S1:2161:1	O
in	ELIQUIS.xml:S1:2163:2	O
ARISTOTLE	ELIQUIS.xml:S1:2166:9	O
and	ELIQUIS.xml:S1:2176:3	O
AVERROES	ELIQUIS.xml:S1:2180:8	O
.	ELIQUIS.xml:S1:2188:1	O

Table	ELIQUIS.xml:S1:2194:5	O
1	ELIQUIS.xml:S1:2200:1	O
:	ELIQUIS.xml:S1:2201:1	O
Bleeding	ELIQUIS.xml:S1:2207:8	B-AdverseReaction
Events	ELIQUIS.xml:S1:2216:6	O
in	ELIQUIS.xml:S1:2223:2	O
Patients	ELIQUIS.xml:S1:2226:8	O
with	ELIQUIS.xml:S1:2235:4	O
Nonvalvular	ELIQUIS.xml:S1:2240:11	O
Atrial	ELIQUIS.xml:S1:2252:6	O
Fibrillation	ELIQUIS.xml:S1:2259:12	O
in	ELIQUIS.xml:S1:2272:2	O
ARISTOTLE	ELIQUIS.xml:S1:2275:9	O

ELIQUISN	ELIQUIS.xml:S1:2315:8	O
9088	ELIQUIS.xml:S1:2324:4	O
n	ELIQUIS.xml:S1:2328:1	O
(	ELIQUIS.xml:S1:2330:1	O
per	ELIQUIS.xml:S1:2331:3	O
100	ELIQUIS.xml:S1:2335:3	O
pt	ELIQUIS.xml:S1:2339:2	O
-	ELIQUIS.xml:S1:2341:1	O
year	ELIQUIS.xml:S1:2342:4	O
)	ELIQUIS.xml:S1:2346:1	O
WarfarinN	ELIQUIS.xml:S1:2349:9	O
9052	ELIQUIS.xml:S1:2359:4	O
n	ELIQUIS.xml:S1:2363:1	O
(	ELIQUIS.xml:S1:2365:1	O
per	ELIQUIS.xml:S1:2366:3	O
100	ELIQUIS.xml:S1:2370:3	O
pt	ELIQUIS.xml:S1:2374:2	O
-	ELIQUIS.xml:S1:2376:1	O
year	ELIQUIS.xml:S1:2377:4	O
)	ELIQUIS.xml:S1:2381:1	O
Hazard	ELIQUIS.xml:S1:2384:6	O
Ratio	ELIQUIS.xml:S1:2391:5	O
(	ELIQUIS.xml:S1:2396:1	O
95%	ELIQUIS.xml:S1:2397:3	O
CI	ELIQUIS.xml:S1:2401:2	O
)	ELIQUIS.xml:S1:2403:1	O
P	ELIQUIS.xml:S1:2406:1	O
-	ELIQUIS.xml:S1:2407:1	O
value	ELIQUIS.xml:S1:2408:5	O

Bleeding	ELIQUIS.xml:S1:2432:8	B-AdverseReaction

events	ELIQUIS.xml:S1:2441:6	O
within	ELIQUIS.xml:S1:2448:6	O
each	ELIQUIS.xml:S1:2455:4	O
subcategory	ELIQUIS.xml:S1:2460:11	O
were	ELIQUIS.xml:S1:2472:4	O
counted	ELIQUIS.xml:S1:2477:7	O
once	ELIQUIS.xml:S1:2485:4	O
per	ELIQUIS.xml:S1:2490:3	O
subject	ELIQUIS.xml:S1:2494:7	O
,	ELIQUIS.xml:S1:2501:1	O
but	ELIQUIS.xml:S1:2503:3	O
subjects	ELIQUIS.xml:S1:2507:8	O
may	ELIQUIS.xml:S1:2516:3	O
have	ELIQUIS.xml:S1:2520:4	O
contributed	ELIQUIS.xml:S1:2525:11	O
events	ELIQUIS.xml:S1:2537:6	O
to	ELIQUIS.xml:S1:2544:2	O
multiple	ELIQUIS.xml:S1:2547:8	O
endpoints	ELIQUIS.xml:S1:2556:9	O
.	ELIQUIS.xml:S1:2565:1	O

Bleeding	ELIQUIS.xml:S1:2567:8	B-AdverseReaction
events	ELIQUIS.xml:S1:2576:6	O
were	ELIQUIS.xml:S1:2583:4	O
counted	ELIQUIS.xml:S1:2588:7	O
during	ELIQUIS.xml:S1:2596:6	O
treatment	ELIQUIS.xml:S1:2603:9	O
or	ELIQUIS.xml:S1:2613:2	O
within	ELIQUIS.xml:S1:2616:6	O
2	ELIQUIS.xml:S1:2623:1	O
days	ELIQUIS.xml:S1:2625:4	O
of	ELIQUIS.xml:S1:2630:2	O
stopping	ELIQUIS.xml:S1:2633:8	O
study	ELIQUIS.xml:S1:2642:5	O
treatment	ELIQUIS.xml:S1:2648:9	O
(	ELIQUIS.xml:S1:2658:1	O
on	ELIQUIS.xml:S1:2659:2	O
-	ELIQUIS.xml:S1:2661:1	O
treatment	ELIQUIS.xml:S1:2662:9	O
period	ELIQUIS.xml:S1:2672:6	O
)	ELIQUIS.xml:S1:2678:1	O
.	ELIQUIS.xml:S1:2679:1	O

Defined	ELIQUIS.xml:S1:2687:7	O
as	ELIQUIS.xml:S1:2695:2	O
clinically	ELIQUIS.xml:S1:2698:10	O
overt	ELIQUIS.xml:S1:2709:5	O
bleeding	ELIQUIS.xml:S1:2715:8	B-AdverseReaction
accompanied	ELIQUIS.xml:S1:2724:11	O
by	ELIQUIS.xml:S1:2736:2	O
one	ELIQUIS.xml:S1:2739:3	O
or	ELIQUIS.xml:S1:2743:2	O
more	ELIQUIS.xml:S1:2746:4	O
of	ELIQUIS.xml:S1:2751:2	O
the	ELIQUIS.xml:S1:2754:3	O
following	ELIQUIS.xml:S1:2758:9	O
:	ELIQUIS.xml:S1:2767:1	O
a	ELIQUIS.xml:S1:2769:1	O
decrease	ELIQUIS.xml:S1:2771:8	B-AdverseReaction
in	ELIQUIS.xml:S1:2780:2	I-AdverseReaction
hemoglobin	ELIQUIS.xml:S1:2783:10	I-AdverseReaction
of	ELIQUIS.xml:S1:2794:2	O
2	ELIQUIS.xml:S1:2799:1	B-Severity
g	ELIQUIS.xml:S1:2801:1	I-Severity
dL	ELIQUIS.xml:S1:2803:2	I-Severity
,	ELIQUIS.xml:S1:2805:1	O
a	ELIQUIS.xml:S1:2807:1	O
transfusion	ELIQUIS.xml:S1:2809:11	O
of	ELIQUIS.xml:S1:2821:2	O
2	ELIQUIS.xml:S1:2824:1	O
or	ELIQUIS.xml:S1:2826:2	O
more	ELIQUIS.xml:S1:2829:4	O
units	ELIQUIS.xml:S1:2834:5	O
of	ELIQUIS.xml:S1:2840:2	O
packed	ELIQUIS.xml:S1:2843:6	O
red	ELIQUIS.xml:S1:2850:3	O
blood	ELIQUIS.xml:S1:2854:5	O
cells	ELIQUIS.xml:S1:2860:5	O
,	ELIQUIS.xml:S1:2865:1	O
bleeding	ELIQUIS.xml:S1:2867:8	B-AdverseReaction
at	ELIQUIS.xml:S1:2876:2	I-AdverseReaction
a	ELIQUIS.xml:S1:2879:1	I-AdverseReaction
critical	ELIQUIS.xml:S1:2881:8	I-AdverseReaction
site	ELIQUIS.xml:S1:2890:4	I-AdverseReaction
:	ELIQUIS.xml:S1:2894:1	O
intracranial	ELIQUIS.xml:S1:2896:12	I-AdverseReaction
,	ELIQUIS.xml:S1:2908:1	O
intraspinal	ELIQUIS.xml:S1:2910:11	I-AdverseReaction
,	ELIQUIS.xml:S1:2921:1	O
intraocular	ELIQUIS.xml:S1:2923:11	I-AdverseReaction
,	ELIQUIS.xml:S1:2934:1	O
pericardial	ELIQUIS.xml:S1:2936:11	I-AdverseReaction
,	ELIQUIS.xml:S1:2947:1	O
intra	ELIQUIS.xml:S1:2949:5	I-AdverseReaction
-	ELIQUIS.xml:S1:2954:1	I-AdverseReaction
articular	ELIQUIS.xml:S1:2955:9	I-AdverseReaction
,	ELIQUIS.xml:S1:2964:1	O
intramuscular	ELIQUIS.xml:S1:2966:13	I-AdverseReaction
with	ELIQUIS.xml:S1:2980:4	O
compartment	ELIQUIS.xml:S1:2985:11	B-AdverseReaction
syndrome	ELIQUIS.xml:S1:2997:8	I-AdverseReaction
,	ELIQUIS.xml:S1:3005:1	O
retroperitoneal	ELIQUIS.xml:S1:3007:15	I-AdverseReaction
or	ELIQUIS.xml:S1:3023:2	O
with	ELIQUIS.xml:S1:3026:4	O
fatal	ELIQUIS.xml:S1:3031:5	B-AdverseReaction
outcome	ELIQUIS.xml:S1:3037:7	I-AdverseReaction
.	ELIQUIS.xml:S1:3044:1	O

?	ELIQUIS.xml:S1:3047:1	O

Intracranial	ELIQUIS.xml:S1:3053:12	B-AdverseReaction
bleed	ELIQUIS.xml:S1:3066:5	I-AdverseReaction
includes	ELIQUIS.xml:S1:3072:8	O
intracerebral	ELIQUIS.xml:S1:3081:13	B-AdverseReaction
,	ELIQUIS.xml:S1:3094:1	O
intraventricular	ELIQUIS.xml:S1:3096:16	B-AdverseReaction
,	ELIQUIS.xml:S1:3112:1	O
subdural	ELIQUIS.xml:S1:3114:8	B-AdverseReaction
,	ELIQUIS.xml:S1:3122:1	O
and	ELIQUIS.xml:S1:3124:3	O
subarachnoid	ELIQUIS.xml:S1:3128:12	B-AdverseReaction
bleeding	ELIQUIS.xml:S1:3141:8	I-AdverseReaction
.	ELIQUIS.xml:S1:3149:1	O

Any	ELIQUIS.xml:S1:3151:3	O
type	ELIQUIS.xml:S1:3155:4	O
of	ELIQUIS.xml:S1:3160:2	O
hemorrhagic	ELIQUIS.xml:S1:3163:11	B-AdverseReaction
stroke	ELIQUIS.xml:S1:3175:6	I-AdverseReaction
was	ELIQUIS.xml:S1:3182:3	O
adjudicated	ELIQUIS.xml:S1:3186:11	O
and	ELIQUIS.xml:S1:3198:3	O
counted	ELIQUIS.xml:S1:3202:7	O
as	ELIQUIS.xml:S1:3210:2	O
an	ELIQUIS.xml:S1:3213:2	O
intracranial	ELIQUIS.xml:S1:3216:12	B-AdverseReaction
major	ELIQUIS.xml:S1:3229:5	B-Severity
bleed	ELIQUIS.xml:S1:3235:5	I-AdverseReaction
.	ELIQUIS.xml:S1:3240:1	O

S	ELIQUIS.xml:S1:3243:1	O
On	ELIQUIS.xml:S1:3249:2	O
-	ELIQUIS.xml:S1:3251:1	O
treatment	ELIQUIS.xml:S1:3252:9	O
analysis	ELIQUIS.xml:S1:3262:8	O
based	ELIQUIS.xml:S1:3271:5	O
on	ELIQUIS.xml:S1:3277:2	O
the	ELIQUIS.xml:S1:3280:3	O
safety	ELIQUIS.xml:S1:3284:6	O
population	ELIQUIS.xml:S1:3291:10	O
,	ELIQUIS.xml:S1:3301:1	O
compared	ELIQUIS.xml:S1:3303:8	O
to	ELIQUIS.xml:S1:3312:2	O
ITT	ELIQUIS.xml:S1:3315:3	O
analysis	ELIQUIS.xml:S1:3319:8	O
presented	ELIQUIS.xml:S1:3328:9	O
in	ELIQUIS.xml:S1:3338:2	O
Section	ELIQUIS.xml:S1:3341:7	O
14	ELIQUIS.xml:S1:3349:2	O
.	ELIQUIS.xml:S1:3351:1	O

GI	ELIQUIS.xml:S1:3360:2	B-AdverseReaction
bleed	ELIQUIS.xml:S1:3363:5	I-AdverseReaction
includes	ELIQUIS.xml:S1:3369:8	O
upper	ELIQUIS.xml:S1:3378:5	B-AdverseReaction
GI	ELIQUIS.xml:S1:3384:2	I-AdverseReaction
,	ELIQUIS.xml:S1:3386:1	O
lower	ELIQUIS.xml:S1:3388:5	B-AdverseReaction
GI	ELIQUIS.xml:S1:3394:2	I-AdverseReaction
,	ELIQUIS.xml:S1:3396:1	O
and	ELIQUIS.xml:S1:3398:3	O
rectal	ELIQUIS.xml:S1:3402:6	B-AdverseReaction
bleeding	ELIQUIS.xml:S1:3409:8	I-AdverseReaction
.	ELIQUIS.xml:S1:3417:1	O

Fatal	ELIQUIS.xml:S1:3422:5	B-AdverseReaction
bleeding	ELIQUIS.xml:S1:3428:8	B-AdverseReaction
is	ELIQUIS.xml:S1:3437:2	O
an	ELIQUIS.xml:S1:3440:2	O
adjudicated	ELIQUIS.xml:S1:3443:11	O
death	ELIQUIS.xml:S1:3455:5	B-AdverseReaction
with	ELIQUIS.xml:S1:3461:4	O
the	ELIQUIS.xml:S1:3466:3	O
primary	ELIQUIS.xml:S1:3470:7	O
cause	ELIQUIS.xml:S1:3478:5	O
of	ELIQUIS.xml:S1:3484:2	O
death	ELIQUIS.xml:S1:3487:5	B-AdverseReaction
as	ELIQUIS.xml:S1:3493:2	O
intracranial	ELIQUIS.xml:S1:3496:12	B-AdverseReaction
bleeding	ELIQUIS.xml:S1:3509:8	I-AdverseReaction
or	ELIQUIS.xml:S1:3518:2	O
non	ELIQUIS.xml:S1:3521:3	B-AdverseReaction
-	ELIQUIS.xml:S1:3524:1	I-AdverseReaction
intracranial	ELIQUIS.xml:S1:3525:12	I-AdverseReaction
bleeding	ELIQUIS.xml:S1:3538:8	I-AdverseReaction
during	ELIQUIS.xml:S1:3547:6	O
the	ELIQUIS.xml:S1:3554:3	O
on	ELIQUIS.xml:S1:3558:2	O
-	ELIQUIS.xml:S1:3560:1	O
treatment	ELIQUIS.xml:S1:3561:9	O
period	ELIQUIS.xml:S1:3571:6	O
.	ELIQUIS.xml:S1:3577:1	O

Major	ELIQUIS.xml:S1:3587:5	O

327	ELIQUIS.xml:S1:3614:3	O
(	ELIQUIS.xml:S1:3618:1	O
2.13	ELIQUIS.xml:S1:3619:4	O
)	ELIQUIS.xml:S1:3623:1	O
462	ELIQUIS.xml:S1:3637:3	O
(	ELIQUIS.xml:S1:3641:1	O
3.09	ELIQUIS.xml:S1:3642:4	O
)	ELIQUIS.xml:S1:3646:1	O
0.69	ELIQUIS.xml:S1:3658:4	O
(	ELIQUIS.xml:S1:3663:1	O
0.60	ELIQUIS.xml:S1:3664:4	O
,	ELIQUIS.xml:S1:3668:1	O
0.80	ELIQUIS.xml:S1:3670:4	O
)	ELIQUIS.xml:S1:3674:1	O
0.0001	ELIQUIS.xml:S1:3681:6	O

Intracranial	ELIQUIS.xml:S1:3702:12	O
(	ELIQUIS.xml:S1:3715:1	O
ICH	ELIQUIS.xml:S1:3716:3	B-AdverseReaction
)	ELIQUIS.xml:S1:3719:1	O
?	ELIQUIS.xml:S1:3720:1	O

52	ELIQUIS.xml:S1:3727:2	O
(	ELIQUIS.xml:S1:3730:1	O
0.33	ELIQUIS.xml:S1:3731:4	O
)	ELIQUIS.xml:S1:3735:1	O
125	ELIQUIS.xml:S1:3750:3	O
(	ELIQUIS.xml:S1:3754:1	O
0.82	ELIQUIS.xml:S1:3755:4	O
)	ELIQUIS.xml:S1:3759:1	O
0.41	ELIQUIS.xml:S1:3771:4	O
(	ELIQUIS.xml:S1:3776:1	O
0.30	ELIQUIS.xml:S1:3777:4	O
,	ELIQUIS.xml:S1:3781:1	O
0.57	ELIQUIS.xml:S1:3783:4	O
)	ELIQUIS.xml:S1:3787:1	O
-	ELIQUIS.xml:S1:3793:1	O

Hemorrhagic	ELIQUIS.xml:S1:3817:11	B-AdverseReaction
strokeS	ELIQUIS.xml:S1:3829:7	I-AdverseReaction
38	ELIQUIS.xml:S1:3840:2	O
(	ELIQUIS.xml:S1:3843:1	O
0.24	ELIQUIS.xml:S1:3844:4	O
)	ELIQUIS.xml:S1:3848:1	O
74	ELIQUIS.xml:S1:3863:2	O
(	ELIQUIS.xml:S1:3866:1	O
0.49	ELIQUIS.xml:S1:3867:4	O
)	ELIQUIS.xml:S1:3871:1	O
0.51	ELIQUIS.xml:S1:3884:4	O
(	ELIQUIS.xml:S1:3889:1	O
0.34	ELIQUIS.xml:S1:3890:4	O
,	ELIQUIS.xml:S1:3894:1	O
0.75	ELIQUIS.xml:S1:3896:4	O
)	ELIQUIS.xml:S1:3900:1	O
-	ELIQUIS.xml:S1:3906:1	O

Other	ELIQUIS.xml:S1:3930:5	O
ICH	ELIQUIS.xml:S1:3936:3	B-AdverseReaction
15	ELIQUIS.xml:S1:3953:2	O
(	ELIQUIS.xml:S1:3956:1	O
0.10	ELIQUIS.xml:S1:3957:4	O
)	ELIQUIS.xml:S1:3961:1	O
51	ELIQUIS.xml:S1:3976:2	O
(	ELIQUIS.xml:S1:3979:1	O
0.34	ELIQUIS.xml:S1:3980:4	O
)	ELIQUIS.xml:S1:3984:1	O
0.29	ELIQUIS.xml:S1:3997:4	O
(	ELIQUIS.xml:S1:4002:1	O
0.16	ELIQUIS.xml:S1:4003:4	O
,	ELIQUIS.xml:S1:4007:1	O
0.51	ELIQUIS.xml:S1:4009:4	O
)	ELIQUIS.xml:S1:4013:1	O
-	ELIQUIS.xml:S1:4019:1	O

Gastrointestinal	ELIQUIS.xml:S1:4041:16	O
(	ELIQUIS.xml:S1:4058:1	O
GI	ELIQUIS.xml:S1:4059:2	O
)	ELIQUIS.xml:S1:4061:1	O
128	ELIQUIS.xml:S1:4067:3	O
(	ELIQUIS.xml:S1:4071:1	O
0.83	ELIQUIS.xml:S1:4072:4	O
)	ELIQUIS.xml:S1:4076:1	O
141	ELIQUIS.xml:S1:4090:3	O
(	ELIQUIS.xml:S1:4094:1	O
0.93	ELIQUIS.xml:S1:4095:4	O
)	ELIQUIS.xml:S1:4099:1	O
0.89	ELIQUIS.xml:S1:4111:4	O
(	ELIQUIS.xml:S1:4116:1	O
0.70	ELIQUIS.xml:S1:4117:4	O
,	ELIQUIS.xml:S1:4121:1	O
1.14	ELIQUIS.xml:S1:4123:4	O
)	ELIQUIS.xml:S1:4127:1	O
-	ELIQUIS.xml:S1:4133:1	O

Fatal	ELIQUIS.xml:S1:4155:5	B-AdverseReaction
10	ELIQUIS.xml:S1:4180:2	O
(	ELIQUIS.xml:S1:4183:1	O
0.06	ELIQUIS.xml:S1:4184:4	O
)	ELIQUIS.xml:S1:4188:1	O
37	ELIQUIS.xml:S1:4203:2	O
(	ELIQUIS.xml:S1:4206:1	O
0.24	ELIQUIS.xml:S1:4207:4	O
)	ELIQUIS.xml:S1:4211:1	O
0.27	ELIQUIS.xml:S1:4224:4	O
(	ELIQUIS.xml:S1:4229:1	O
0.13	ELIQUIS.xml:S1:4230:4	O
,	ELIQUIS.xml:S1:4234:1	O
0.53	ELIQUIS.xml:S1:4236:4	O
)	ELIQUIS.xml:S1:4240:1	O
-	ELIQUIS.xml:S1:4246:1	O

Intracranial	ELIQUIS.xml:S1:4270:12	O
4	ELIQUIS.xml:S1:4293:1	O
(	ELIQUIS.xml:S1:4295:1	O
0.03	ELIQUIS.xml:S1:4296:4	O
)	ELIQUIS.xml:S1:4300:1	O
30	ELIQUIS.xml:S1:4316:2	O
(	ELIQUIS.xml:S1:4319:1	O
0.20	ELIQUIS.xml:S1:4320:4	O
)	ELIQUIS.xml:S1:4324:1	O
0.13	ELIQUIS.xml:S1:4337:4	O
(	ELIQUIS.xml:S1:4342:1	O
0.05	ELIQUIS.xml:S1:4343:4	O
,	ELIQUIS.xml:S1:4347:1	O
0.37	ELIQUIS.xml:S1:4349:4	O
)	ELIQUIS.xml:S1:4353:1	O
-	ELIQUIS.xml:S1:4359:1	O

Non	ELIQUIS.xml:S1:4383:3	O
-	ELIQUIS.xml:S1:4386:1	O
intracranial	ELIQUIS.xml:S1:4387:12	O
6	ELIQUIS.xml:S1:4406:1	O
(	ELIQUIS.xml:S1:4408:1	O
0.04	ELIQUIS.xml:S1:4409:4	O
)	ELIQUIS.xml:S1:4413:1	O
7	ELIQUIS.xml:S1:4429:1	O
(	ELIQUIS.xml:S1:4431:1	O
0.05	ELIQUIS.xml:S1:4432:4	O
)	ELIQUIS.xml:S1:4436:1	O
0.84	ELIQUIS.xml:S1:4450:4	O
(	ELIQUIS.xml:S1:4455:1	O
0.28	ELIQUIS.xml:S1:4456:4	O
,	ELIQUIS.xml:S1:4460:1	O
2.15	ELIQUIS.xml:S1:4462:4	O
)	ELIQUIS.xml:S1:4466:1	O
-	ELIQUIS.xml:S1:4472:1	O

In	ELIQUIS.xml:S1:4501:2	O
ARISTOTLE	ELIQUIS.xml:S1:4504:9	O
,	ELIQUIS.xml:S1:4513:1	O
the	ELIQUIS.xml:S1:4515:3	O
results	ELIQUIS.xml:S1:4519:7	O
for	ELIQUIS.xml:S1:4527:3	O
major	ELIQUIS.xml:S1:4531:5	B-Severity
bleeding	ELIQUIS.xml:S1:4537:8	B-AdverseReaction
were	ELIQUIS.xml:S1:4546:4	O
generally	ELIQUIS.xml:S1:4551:9	O
consistent	ELIQUIS.xml:S1:4561:10	O
across	ELIQUIS.xml:S1:4572:6	O
most	ELIQUIS.xml:S1:4579:4	O
major	ELIQUIS.xml:S1:4584:5	O
subgroups	ELIQUIS.xml:S1:4590:9	O
including	ELIQUIS.xml:S1:4600:9	O
age	ELIQUIS.xml:S1:4610:3	O
,	ELIQUIS.xml:S1:4613:1	O
weight	ELIQUIS.xml:S1:4615:6	O
,	ELIQUIS.xml:S1:4621:1	O
CHADS2score	ELIQUIS.xml:S1:4623:11	O
(	ELIQUIS.xml:S1:4635:1	O
a	ELIQUIS.xml:S1:4636:1	O
scale	ELIQUIS.xml:S1:4638:5	O
from	ELIQUIS.xml:S1:4644:4	O
0	ELIQUIS.xml:S1:4649:1	O
to	ELIQUIS.xml:S1:4651:2	O
6	ELIQUIS.xml:S1:4654:1	O
used	ELIQUIS.xml:S1:4656:4	O
to	ELIQUIS.xml:S1:4661:2	O
estimate	ELIQUIS.xml:S1:4664:8	O
risk	ELIQUIS.xml:S1:4673:4	O
of	ELIQUIS.xml:S1:4678:2	O
stroke	ELIQUIS.xml:S1:4681:6	O
,	ELIQUIS.xml:S1:4687:1	O
with	ELIQUIS.xml:S1:4689:4	O
higher	ELIQUIS.xml:S1:4694:6	O
scores	ELIQUIS.xml:S1:4701:6	O
predicting	ELIQUIS.xml:S1:4708:10	O
greater	ELIQUIS.xml:S1:4719:7	O
risk	ELIQUIS.xml:S1:4727:4	O
)	ELIQUIS.xml:S1:4731:1	O
,	ELIQUIS.xml:S1:4732:1	O
prior	ELIQUIS.xml:S1:4734:5	O
warfarin	ELIQUIS.xml:S1:4740:8	O
use	ELIQUIS.xml:S1:4749:3	O
,	ELIQUIS.xml:S1:4752:1	O
geographic	ELIQUIS.xml:S1:4754:10	O
region	ELIQUIS.xml:S1:4765:6	O
,	ELIQUIS.xml:S1:4771:1	O
and	ELIQUIS.xml:S1:4773:3	O
aspirin	ELIQUIS.xml:S1:4777:7	O
use	ELIQUIS.xml:S1:4785:3	O
at	ELIQUIS.xml:S1:4789:2	O
randomization	ELIQUIS.xml:S1:4792:13	O
(	ELIQUIS.xml:S1:4806:1	O
Figure	ELIQUIS.xml:S1:4807:6	O
1	ELIQUIS.xml:S1:4814:1	O
)	ELIQUIS.xml:S1:4815:1	O
.	ELIQUIS.xml:S1:4816:1	O

Subjects	ELIQUIS.xml:S1:4818:8	O
treated	ELIQUIS.xml:S1:4827:7	O
with	ELIQUIS.xml:S1:4835:4	O
apixaban	ELIQUIS.xml:S1:4840:8	O
with	ELIQUIS.xml:S1:4849:4	O
diabetes	ELIQUIS.xml:S1:4854:8	O
bled	ELIQUIS.xml:S1:4863:4	B-AdverseReaction
more	ELIQUIS.xml:S1:4868:4	O
(	ELIQUIS.xml:S1:4873:1	O
3.0%	ELIQUIS.xml:S1:4874:4	O
per	ELIQUIS.xml:S1:4879:3	O
year	ELIQUIS.xml:S1:4883:4	O
)	ELIQUIS.xml:S1:4887:1	O
than	ELIQUIS.xml:S1:4889:4	O
did	ELIQUIS.xml:S1:4894:3	O
subjects	ELIQUIS.xml:S1:4898:8	O
without	ELIQUIS.xml:S1:4907:7	O
diabetes	ELIQUIS.xml:S1:4915:8	O
(	ELIQUIS.xml:S1:4924:1	O
1.9%	ELIQUIS.xml:S1:4925:4	O
per	ELIQUIS.xml:S1:4930:3	O
year	ELIQUIS.xml:S1:4934:4	O
)	ELIQUIS.xml:S1:4938:1	O
.	ELIQUIS.xml:S1:4939:1	O

Figure	ELIQUIS.xml:S1:4945:6	O

1	ELIQUIS.xml:S1:4952:1	O
:	ELIQUIS.xml:S1:4953:1	O
Major	ELIQUIS.xml:S1:4959:5	B-Severity
Bleeding	ELIQUIS.xml:S1:4965:8	B-AdverseReaction
Hazard	ELIQUIS.xml:S1:4974:6	O
Ratios	ELIQUIS.xml:S1:4981:6	O
by	ELIQUIS.xml:S1:4988:2	O
Baseline	ELIQUIS.xml:S1:4991:8	O
Characteristics	ELIQUIS.xml:S1:5000:15	O
-	ELIQUIS.xml:S1:5016:1	O
ARISTOTLE	ELIQUIS.xml:S1:5018:9	O
Study	ELIQUIS.xml:S1:5028:5	O

Note	ELIQUIS.xml:S1:5038:4	O
:	ELIQUIS.xml:S1:5042:1	O
The	ELIQUIS.xml:S1:5044:3	O
figure	ELIQUIS.xml:S1:5048:6	O
above	ELIQUIS.xml:S1:5055:5	O
presents	ELIQUIS.xml:S1:5061:8	O
effects	ELIQUIS.xml:S1:5070:7	O
in	ELIQUIS.xml:S1:5078:2	O
various	ELIQUIS.xml:S1:5081:7	O
subgroups	ELIQUIS.xml:S1:5089:9	O
,	ELIQUIS.xml:S1:5098:1	O
all	ELIQUIS.xml:S1:5100:3	O
of	ELIQUIS.xml:S1:5104:2	O
which	ELIQUIS.xml:S1:5107:5	O
are	ELIQUIS.xml:S1:5113:3	O
baseline	ELIQUIS.xml:S1:5117:8	O
characteristics	ELIQUIS.xml:S1:5126:15	O
and	ELIQUIS.xml:S1:5142:3	O
all	ELIQUIS.xml:S1:5146:3	O
of	ELIQUIS.xml:S1:5150:2	O
which	ELIQUIS.xml:S1:5153:5	O
were	ELIQUIS.xml:S1:5159:4	O
pre	ELIQUIS.xml:S1:5164:3	O
-	ELIQUIS.xml:S1:5167:1	O
specified	ELIQUIS.xml:S1:5168:9	O
,	ELIQUIS.xml:S1:5177:1	O
if	ELIQUIS.xml:S1:5179:2	O
not	ELIQUIS.xml:S1:5182:3	O
the	ELIQUIS.xml:S1:5186:3	O
groupings	ELIQUIS.xml:S1:5190:9	O
.	ELIQUIS.xml:S1:5199:1	O

The	ELIQUIS.xml:S1:5201:3	O
95%	ELIQUIS.xml:S1:5205:3	O
confidence	ELIQUIS.xml:S1:5209:10	O
limits	ELIQUIS.xml:S1:5220:6	O
that	ELIQUIS.xml:S1:5227:4	O
are	ELIQUIS.xml:S1:5232:3	O
shown	ELIQUIS.xml:S1:5236:5	O
do	ELIQUIS.xml:S1:5242:2	O
not	ELIQUIS.xml:S1:5245:3	O
take	ELIQUIS.xml:S1:5249:4	O
into	ELIQUIS.xml:S1:5254:4	O
account	ELIQUIS.xml:S1:5259:7	O
how	ELIQUIS.xml:S1:5267:3	O
many	ELIQUIS.xml:S1:5271:4	O
comparisons	ELIQUIS.xml:S1:5276:11	O
were	ELIQUIS.xml:S1:5288:4	O
made	ELIQUIS.xml:S1:5293:4	O
,	ELIQUIS.xml:S1:5297:1	O
nor	ELIQUIS.xml:S1:5299:3	O
do	ELIQUIS.xml:S1:5303:2	O
they	ELIQUIS.xml:S1:5306:4	O
reflect	ELIQUIS.xml:S1:5311:7	O
the	ELIQUIS.xml:S1:5319:3	O
effect	ELIQUIS.xml:S1:5323:6	O
of	ELIQUIS.xml:S1:5330:2	O
a	ELIQUIS.xml:S1:5333:1	O
particular	ELIQUIS.xml:S1:5335:10	O
factor	ELIQUIS.xml:S1:5346:6	O
after	ELIQUIS.xml:S1:5353:5	O
adjustment	ELIQUIS.xml:S1:5359:10	O
for	ELIQUIS.xml:S1:5370:3	O
all	ELIQUIS.xml:S1:5374:3	O
other	ELIQUIS.xml:S1:5378:5	O
factors	ELIQUIS.xml:S1:5384:7	O
.	ELIQUIS.xml:S1:5391:1	O

Apparent	ELIQUIS.xml:S1:5393:8	O
homogeneity	ELIQUIS.xml:S1:5402:11	O
or	ELIQUIS.xml:S1:5414:2	O
heterogeneity	ELIQUIS.xml:S1:5417:13	O
among	ELIQUIS.xml:S1:5431:5	O
groups	ELIQUIS.xml:S1:5437:6	O
should	ELIQUIS.xml:S1:5444:6	O
not	ELIQUIS.xml:S1:5451:3	O
be	ELIQUIS.xml:S1:5455:2	O
over	ELIQUIS.xml:S1:5458:4	O
-	ELIQUIS.xml:S1:5462:1	O
interpreted	ELIQUIS.xml:S1:5463:11	O
.	ELIQUIS.xml:S1:5474:1	O

Table	ELIQUIS.xml:S1:5480:5	O
2	ELIQUIS.xml:S1:5486:1	O
:	ELIQUIS.xml:S1:5487:1	O
Bleeding	ELIQUIS.xml:S1:5494:8	B-AdverseReaction
Events	ELIQUIS.xml:S1:5503:6	O
in	ELIQUIS.xml:S1:5510:2	O
Patients	ELIQUIS.xml:S1:5513:8	O
with	ELIQUIS.xml:S1:5522:4	O
Nonvalvular	ELIQUIS.xml:S1:5527:11	O
Atrial	ELIQUIS.xml:S1:5539:6	O
Fibrillation	ELIQUIS.xml:S1:5546:12	O
in	ELIQUIS.xml:S1:5559:2	O
AVERROES	ELIQUIS.xml:S1:5562:8	O

ELIQUISN	ELIQUIS.xml:S1:5600:8	O
2798	ELIQUIS.xml:S1:5609:4	O
n	ELIQUIS.xml:S1:5613:1	O
(	ELIQUIS.xml:S1:5615:1	O
year	ELIQUIS.xml:S1:5618:4	O
)	ELIQUIS.xml:S1:5622:1	O
AspirinN	ELIQUIS.xml:S1:5625:8	O
2780	ELIQUIS.xml:S1:5634:4	O
n	ELIQUIS.xml:S1:5638:1	O
(	ELIQUIS.xml:S1:5640:1	O
year	ELIQUIS.xml:S1:5643:4	O
)	ELIQUIS.xml:S1:5647:1	O
Hazard	ELIQUIS.xml:S1:5650:6	O
Ratio	ELIQUIS.xml:S1:5657:5	O
(	ELIQUIS.xml:S1:5662:1	O
95%	ELIQUIS.xml:S1:5663:3	O
CI	ELIQUIS.xml:S1:5667:2	O
)	ELIQUIS.xml:S1:5669:1	O
P	ELIQUIS.xml:S1:5672:1	O
-	ELIQUIS.xml:S1:5673:1	O
value	ELIQUIS.xml:S1:5674:5	O

Events	ELIQUIS.xml:S1:5695:6	O

associated	ELIQUIS.xml:S1:5702:10	O
with	ELIQUIS.xml:S1:5713:4	O
each	ELIQUIS.xml:S1:5718:4	O
endpoint	ELIQUIS.xml:S1:5723:8	O
were	ELIQUIS.xml:S1:5732:4	O
counted	ELIQUIS.xml:S1:5737:7	O
once	ELIQUIS.xml:S1:5745:4	O
per	ELIQUIS.xml:S1:5750:3	O
subject	ELIQUIS.xml:S1:5754:7	O
,	ELIQUIS.xml:S1:5761:1	O
but	ELIQUIS.xml:S1:5763:3	O
subjects	ELIQUIS.xml:S1:5767:8	O
may	ELIQUIS.xml:S1:5776:3	O
have	ELIQUIS.xml:S1:5780:4	O
contributed	ELIQUIS.xml:S1:5785:11	O
events	ELIQUIS.xml:S1:5797:6	O
to	ELIQUIS.xml:S1:5804:2	O
multiple	ELIQUIS.xml:S1:5807:8	O
endpoints	ELIQUIS.xml:S1:5816:9	O
.	ELIQUIS.xml:S1:5825:1	O

Major	ELIQUIS.xml:S1:5835:5	O

45	ELIQUIS.xml:S1:5862:2	O
(	ELIQUIS.xml:S1:5865:1	O
1.41	ELIQUIS.xml:S1:5866:4	O
)	ELIQUIS.xml:S1:5870:1	O
29	ELIQUIS.xml:S1:5884:2	O
(	ELIQUIS.xml:S1:5887:1	O
0.92	ELIQUIS.xml:S1:5888:4	O
)	ELIQUIS.xml:S1:5892:1	O
1.54	ELIQUIS.xml:S1:5906:4	O
(	ELIQUIS.xml:S1:5911:1	O
0.96	ELIQUIS.xml:S1:5912:4	O
,	ELIQUIS.xml:S1:5916:1	O
2.45	ELIQUIS.xml:S1:5918:4	O
)	ELIQUIS.xml:S1:5922:1	O
0.07	ELIQUIS.xml:S1:5928:4	O

Fatal	ELIQUIS.xml:S1:5952:5	B-AdverseReaction
5	ELIQUIS.xml:S1:5975:1	O
(	ELIQUIS.xml:S1:5977:1	O
0.16	ELIQUIS.xml:S1:5978:4	O
)	ELIQUIS.xml:S1:5982:1	O
5	ELIQUIS.xml:S1:5997:1	O
(	ELIQUIS.xml:S1:5999:1	O
0.16	ELIQUIS.xml:S1:6000:4	O
)	ELIQUIS.xml:S1:6004:1	O
0.99	ELIQUIS.xml:S1:6019:4	O
(	ELIQUIS.xml:S1:6024:1	O
0.23	ELIQUIS.xml:S1:6025:4	O
,	ELIQUIS.xml:S1:6029:1	O
4.29	ELIQUIS.xml:S1:6031:4	O
)	ELIQUIS.xml:S1:6035:1	O
-	ELIQUIS.xml:S1:6041:1	O

Intracranial	ELIQUIS.xml:S1:6065:12	O
11	ELIQUIS.xml:S1:6088:2	O
(	ELIQUIS.xml:S1:6091:1	O
0.34	ELIQUIS.xml:S1:6092:4	O
)	ELIQUIS.xml:S1:6096:1	O
11	ELIQUIS.xml:S1:6110:2	O
(	ELIQUIS.xml:S1:6113:1	O
0.35	ELIQUIS.xml:S1:6114:4	O
)	ELIQUIS.xml:S1:6118:1	O
0.99	ELIQUIS.xml:S1:6132:4	O
(	ELIQUIS.xml:S1:6137:1	O
0.39	ELIQUIS.xml:S1:6138:4	O
,	ELIQUIS.xml:S1:6142:1	O
2.51	ELIQUIS.xml:S1:6144:4	O
)	ELIQUIS.xml:S1:6148:1	O
-	ELIQUIS.xml:S1:6154:1	O

ARISTOTLE	ELIQUIS.xml:S1:6184:9	O
Major	ELIQUIS.xml:S1:6194:5	B-Severity
Bleeding	ELIQUIS.xml:S1:6200:8	B-AdverseReaction
Forest	ELIQUIS.xml:S1:6209:6	O
Plot	ELIQUIS.xml:S1:6216:4	O
Other	ELIQUIS.xml:S1:6223:5	O
Adverse	ELIQUIS.xml:S1:6229:7	O
Reactions	ELIQUIS.xml:S1:6237:9	O

Hypersensitivity	ELIQUIS.xml:S1:6250:16	B-AdverseReaction
reactions	ELIQUIS.xml:S1:6267:9	I-AdverseReaction
(	ELIQUIS.xml:S1:6277:1	O
including	ELIQUIS.xml:S1:6278:9	O
drug	ELIQUIS.xml:S1:6288:4	B-AdverseReaction
hypersensitivity	ELIQUIS.xml:S1:6293:16	I-AdverseReaction
,	ELIQUIS.xml:S1:6309:1	O
such	ELIQUIS.xml:S1:6311:4	O
as	ELIQUIS.xml:S1:6316:2	O
skin	ELIQUIS.xml:S1:6319:4	B-AdverseReaction
rash	ELIQUIS.xml:S1:6324:4	I-AdverseReaction
,	ELIQUIS.xml:S1:6328:1	O
and	ELIQUIS.xml:S1:6330:3	O
anaphylactic	ELIQUIS.xml:S1:6334:12	B-AdverseReaction
reactions	ELIQUIS.xml:S1:6347:9	I-AdverseReaction
,	ELIQUIS.xml:S1:6356:1	O
such	ELIQUIS.xml:S1:6358:4	O
as	ELIQUIS.xml:S1:6363:2	O
allergic	ELIQUIS.xml:S1:6366:8	B-AdverseReaction
edema	ELIQUIS.xml:S1:6375:5	I-AdverseReaction
)	ELIQUIS.xml:S1:6380:1	O
and	ELIQUIS.xml:S1:6382:3	O
syncope	ELIQUIS.xml:S1:6386:7	B-AdverseReaction
were	ELIQUIS.xml:S1:6394:4	O
reported	ELIQUIS.xml:S1:6399:8	O
in	ELIQUIS.xml:S1:6408:2	O
1%	ELIQUIS.xml:S1:6412:2	O
of	ELIQUIS.xml:S1:6415:2	O
patients	ELIQUIS.xml:S1:6418:8	O
receiving	ELIQUIS.xml:S1:6427:9	O
ELIQUIS	ELIQUIS.xml:S1:6437:7	O
.	ELIQUIS.xml:S1:6444:1	O

Prophylaxis	ELIQUIS.xml:S1:6452:11	O
of	ELIQUIS.xml:S1:6464:2	O
Deep	ELIQUIS.xml:S1:6467:4	O
Vein	ELIQUIS.xml:S1:6472:4	O
Thrombosis	ELIQUIS.xml:S1:6477:10	O
Following	ELIQUIS.xml:S1:6488:9	O
Hip	ELIQUIS.xml:S1:6498:3	O
or	ELIQUIS.xml:S1:6502:2	O
Knee	ELIQUIS.xml:S1:6505:4	O
Replacement	ELIQUIS.xml:S1:6510:11	O
Surgery	ELIQUIS.xml:S1:6522:7	O

The	ELIQUIS.xml:S1:6533:3	O
safety	ELIQUIS.xml:S1:6537:6	O
of	ELIQUIS.xml:S1:6544:2	O
ELIQUIS	ELIQUIS.xml:S1:6547:7	O
has	ELIQUIS.xml:S1:6555:3	O
been	ELIQUIS.xml:S1:6559:4	O
evaluated	ELIQUIS.xml:S1:6564:9	O
in	ELIQUIS.xml:S1:6574:2	O
1	ELIQUIS.xml:S1:6577:1	O
Phase	ELIQUIS.xml:S1:6579:5	O
II	ELIQUIS.xml:S1:6585:2	O
and	ELIQUIS.xml:S1:6588:3	O
3	ELIQUIS.xml:S1:6592:1	O
Phase	ELIQUIS.xml:S1:6594:5	O
III	ELIQUIS.xml:S1:6600:3	O
studies	ELIQUIS.xml:S1:6604:7	O
including	ELIQUIS.xml:S1:6612:9	O
5924	ELIQUIS.xml:S1:6622:4	O
patients	ELIQUIS.xml:S1:6627:8	O
exposed	ELIQUIS.xml:S1:6636:7	O
to	ELIQUIS.xml:S1:6644:2	O
ELIQUIS	ELIQUIS.xml:S1:6647:7	O
2.5	ELIQUIS.xml:S1:6655:3	O
mg	ELIQUIS.xml:S1:6659:2	O
twice	ELIQUIS.xml:S1:6662:5	O
daily	ELIQUIS.xml:S1:6668:5	O
undergoing	ELIQUIS.xml:S1:6674:10	O
major	ELIQUIS.xml:S1:6685:5	O
orthopedic	ELIQUIS.xml:S1:6691:10	O
surgery	ELIQUIS.xml:S1:6702:7	O
of	ELIQUIS.xml:S1:6710:2	O
the	ELIQUIS.xml:S1:6713:3	O
lower	ELIQUIS.xml:S1:6717:5	O
limbs	ELIQUIS.xml:S1:6723:5	O
(	ELIQUIS.xml:S1:6729:1	O
elective	ELIQUIS.xml:S1:6730:8	O
hip	ELIQUIS.xml:S1:6739:3	O
replacement	ELIQUIS.xml:S1:6743:11	O
or	ELIQUIS.xml:S1:6755:2	O
elective	ELIQUIS.xml:S1:6758:8	O
knee	ELIQUIS.xml:S1:6767:4	O
replacement	ELIQUIS.xml:S1:6772:11	O
)	ELIQUIS.xml:S1:6783:1	O
treated	ELIQUIS.xml:S1:6785:7	O
for	ELIQUIS.xml:S1:6793:3	O
up	ELIQUIS.xml:S1:6797:2	O
to	ELIQUIS.xml:S1:6800:2	O
38	ELIQUIS.xml:S1:6803:2	O
days	ELIQUIS.xml:S1:6806:4	O
.	ELIQUIS.xml:S1:6810:1	O

In	ELIQUIS.xml:S1:6816:2	O
total	ELIQUIS.xml:S1:6819:5	O
,	ELIQUIS.xml:S1:6824:1	O
11%	ELIQUIS.xml:S1:6826:3	O
of	ELIQUIS.xml:S1:6830:2	O
the	ELIQUIS.xml:S1:6833:3	O
patients	ELIQUIS.xml:S1:6837:8	O
treated	ELIQUIS.xml:S1:6846:7	O
with	ELIQUIS.xml:S1:6854:4	O
ELIQUIS	ELIQUIS.xml:S1:6859:7	O
2.5	ELIQUIS.xml:S1:6867:3	O
mg	ELIQUIS.xml:S1:6871:2	O
twice	ELIQUIS.xml:S1:6874:5	O
daily	ELIQUIS.xml:S1:6880:5	O
experienced	ELIQUIS.xml:S1:6886:11	O
adverse	ELIQUIS.xml:S1:6898:7	O
reactions	ELIQUIS.xml:S1:6906:9	O
.	ELIQUIS.xml:S1:6915:1	O

Bleeding	ELIQUIS.xml:S1:6921:8	B-AdverseReaction
results	ELIQUIS.xml:S1:6930:7	O
during	ELIQUIS.xml:S1:6938:6	O
the	ELIQUIS.xml:S1:6945:3	O
treatment	ELIQUIS.xml:S1:6949:9	O
period	ELIQUIS.xml:S1:6959:6	O
in	ELIQUIS.xml:S1:6966:2	O
the	ELIQUIS.xml:S1:6969:3	O
Phase	ELIQUIS.xml:S1:6973:5	O
III	ELIQUIS.xml:S1:6979:3	O
studies	ELIQUIS.xml:S1:6983:7	O
are	ELIQUIS.xml:S1:6991:3	O
shown	ELIQUIS.xml:S1:6995:5	O
in	ELIQUIS.xml:S1:7001:2	O
Table	ELIQUIS.xml:S1:7004:5	O
3	ELIQUIS.xml:S1:7010:1	O
.	ELIQUIS.xml:S1:7011:1	O

Bleeding	ELIQUIS.xml:S1:7013:8	B-AdverseReaction
was	ELIQUIS.xml:S1:7022:3	O
assessed	ELIQUIS.xml:S1:7026:8	O
in	ELIQUIS.xml:S1:7035:2	O
each	ELIQUIS.xml:S1:7038:4	O
study	ELIQUIS.xml:S1:7043:5	O
beginning	ELIQUIS.xml:S1:7049:9	O
with	ELIQUIS.xml:S1:7059:4	O
the	ELIQUIS.xml:S1:7064:3	O
first	ELIQUIS.xml:S1:7068:5	O
dose	ELIQUIS.xml:S1:7074:4	O
of	ELIQUIS.xml:S1:7079:2	O
double	ELIQUIS.xml:S1:7082:6	O
-	ELIQUIS.xml:S1:7088:1	O
blind	ELIQUIS.xml:S1:7089:5	O
study	ELIQUIS.xml:S1:7095:5	O
drug	ELIQUIS.xml:S1:7101:4	O
.	ELIQUIS.xml:S1:7105:1	O

Table	ELIQUIS.xml:S1:7111:5	O
3	ELIQUIS.xml:S1:7117:1	O
:	ELIQUIS.xml:S1:7118:1	O
Bleeding	ELIQUIS.xml:S1:7124:8	B-AdverseReaction
During	ELIQUIS.xml:S1:7133:6	O
the	ELIQUIS.xml:S1:7140:3	O
Treatment	ELIQUIS.xml:S1:7144:9	O
Period	ELIQUIS.xml:S1:7154:6	O
in	ELIQUIS.xml:S1:7161:2	O
Patients	ELIQUIS.xml:S1:7164:8	O
Undergoing	ELIQUIS.xml:S1:7173:10	O
Elective	ELIQUIS.xml:S1:7184:8	O
Hip	ELIQUIS.xml:S1:7193:3	O
or	ELIQUIS.xml:S1:7197:2	O
Knee	ELIQUIS.xml:S1:7200:4	O
Replacement	ELIQUIS.xml:S1:7205:11	O
Surgery	ELIQUIS.xml:S1:7217:7	O

Bleeding	ELIQUIS.xml:S1:7229:8	O
Endpoint	ELIQUIS.xml:S1:7238:8	O
ADVANCE	ELIQUIS.xml:S1:7253:7	O
-	ELIQUIS.xml:S1:7260:1	O
3	ELIQUIS.xml:S1:7261:1	O
Hip	ELIQUIS.xml:S1:7262:3	O
Replacement	ELIQUIS.xml:S1:7266:11	O
Surgery	ELIQUIS.xml:S1:7278:7	O
ADVANCE	ELIQUIS.xml:S1:7291:7	O
-	ELIQUIS.xml:S1:7298:1	O
2	ELIQUIS.xml:S1:7299:1	O
Knee	ELIQUIS.xml:S1:7300:4	O
Replacement	ELIQUIS.xml:S1:7305:11	O
Surgery	ELIQUIS.xml:S1:7317:7	O
ADVANCE	ELIQUIS.xml:S1:7330:7	O
-	ELIQUIS.xml:S1:7337:1	O
1	ELIQUIS.xml:S1:7338:1	O
Knee	ELIQUIS.xml:S1:7339:4	O
Replacement	ELIQUIS.xml:S1:7344:11	O
Surgery	ELIQUIS.xml:S1:7356:7	O

All	ELIQUIS.xml:S1:7377:3	O

bleeding	ELIQUIS.xml:S1:7381:8	B-AdverseReaction
criteria	ELIQUIS.xml:S1:7390:8	O
included	ELIQUIS.xml:S1:7399:8	O
surgical	ELIQUIS.xml:S1:7408:8	B-AdverseReaction
site	ELIQUIS.xml:S1:7417:4	I-AdverseReaction
bleeding	ELIQUIS.xml:S1:7422:8	I-AdverseReaction
.	ELIQUIS.xml:S1:7430:1	O

Includes	ELIQUIS.xml:S1:7438:8	O
13	ELIQUIS.xml:S1:7447:2	O
subjects	ELIQUIS.xml:S1:7450:8	O
with	ELIQUIS.xml:S1:7459:4	O
major	ELIQUIS.xml:S1:7464:5	B-Severity
bleeding	ELIQUIS.xml:S1:7470:8	B-AdverseReaction
events	ELIQUIS.xml:S1:7479:6	O
that	ELIQUIS.xml:S1:7486:4	O
occurred	ELIQUIS.xml:S1:7491:8	O
before	ELIQUIS.xml:S1:7500:6	B-Negation
the	ELIQUIS.xml:S1:7507:3	I-Negation
first	ELIQUIS.xml:S1:7511:5	I-Negation
dose	ELIQUIS.xml:S1:7517:4	I-Negation
of	ELIQUIS.xml:S1:7522:2	O
apixaban	ELIQUIS.xml:S1:7525:8	O
(	ELIQUIS.xml:S1:7534:1	O
administered	ELIQUIS.xml:S1:7535:12	O
12	ELIQUIS.xml:S1:7548:2	O
to	ELIQUIS.xml:S1:7551:2	O
24	ELIQUIS.xml:S1:7554:2	O
hours	ELIQUIS.xml:S1:7557:5	O
post	ELIQUIS.xml:S1:7563:4	O
surgery	ELIQUIS.xml:S1:7568:7	O
)	ELIQUIS.xml:S1:7575:1	O
.	ELIQUIS.xml:S1:7576:1	O

?	ELIQUIS.xml:S1:7579:1	O

Includes	ELIQUIS.xml:S1:7585:8	O
5	ELIQUIS.xml:S1:7594:1	O
subjects	ELIQUIS.xml:S1:7596:8	O
with	ELIQUIS.xml:S1:7605:4	O
major	ELIQUIS.xml:S1:7610:5	B-Severity
bleeding	ELIQUIS.xml:S1:7616:8	B-AdverseReaction
events	ELIQUIS.xml:S1:7625:6	O
that	ELIQUIS.xml:S1:7632:4	O
occurred	ELIQUIS.xml:S1:7637:8	O
before	ELIQUIS.xml:S1:7646:6	B-Negation
the	ELIQUIS.xml:S1:7653:3	I-Negation
first	ELIQUIS.xml:S1:7657:5	I-Negation
dose	ELIQUIS.xml:S1:7663:4	I-Negation
of	ELIQUIS.xml:S1:7668:2	O
apixaban	ELIQUIS.xml:S1:7671:8	O
(	ELIQUIS.xml:S1:7680:1	O
administered	ELIQUIS.xml:S1:7681:12	O
12	ELIQUIS.xml:S1:7694:2	O
to	ELIQUIS.xml:S1:7697:2	O
24	ELIQUIS.xml:S1:7700:2	O
hours	ELIQUIS.xml:S1:7703:5	O
post	ELIQUIS.xml:S1:7709:4	O
surgery	ELIQUIS.xml:S1:7714:7	O
)	ELIQUIS.xml:S1:7721:1	O
.	ELIQUIS.xml:S1:7722:1	O

S	ELIQUIS.xml:S1:7725:1	O
Intracranial	ELIQUIS.xml:S1:7731:12	O
,	ELIQUIS.xml:S1:7743:1	O
intraspinal	ELIQUIS.xml:S1:7745:11	O
,	ELIQUIS.xml:S1:7756:1	O
intraocular	ELIQUIS.xml:S1:7758:11	O
,	ELIQUIS.xml:S1:7769:1	O
pericardial	ELIQUIS.xml:S1:7771:11	O
,	ELIQUIS.xml:S1:7782:1	O
an	ELIQUIS.xml:S1:7784:2	O
operated	ELIQUIS.xml:S1:7787:8	O
joint	ELIQUIS.xml:S1:7796:5	O
requiring	ELIQUIS.xml:S1:7802:9	O
re	ELIQUIS.xml:S1:7812:2	O
-	ELIQUIS.xml:S1:7814:1	O
operation	ELIQUIS.xml:S1:7815:9	O
or	ELIQUIS.xml:S1:7825:2	O
intervention	ELIQUIS.xml:S1:7828:12	O
,	ELIQUIS.xml:S1:7840:1	O
intramuscular	ELIQUIS.xml:S1:7842:13	O
with	ELIQUIS.xml:S1:7856:4	O
compartment	ELIQUIS.xml:S1:7861:11	O
syndrome	ELIQUIS.xml:S1:7873:8	O
,	ELIQUIS.xml:S1:7881:1	O
or	ELIQUIS.xml:S1:7883:2	O
retroperitoneal	ELIQUIS.xml:S1:7886:15	O
.	ELIQUIS.xml:S1:7901:1	O

Bleeding	ELIQUIS.xml:S1:7903:8	B-AdverseReaction
into	ELIQUIS.xml:S1:7912:4	I-AdverseReaction
an	ELIQUIS.xml:S1:7917:2	I-AdverseReaction
operated	ELIQUIS.xml:S1:7920:8	I-AdverseReaction
joint	ELIQUIS.xml:S1:7929:5	I-AdverseReaction
requiring	ELIQUIS.xml:S1:7935:9	O
re	ELIQUIS.xml:S1:7945:2	O
-	ELIQUIS.xml:S1:7947:1	O
operation	ELIQUIS.xml:S1:7948:9	O
or	ELIQUIS.xml:S1:7958:2	O
intervention	ELIQUIS.xml:S1:7961:12	O
was	ELIQUIS.xml:S1:7974:3	O
present	ELIQUIS.xml:S1:7978:7	O
in	ELIQUIS.xml:S1:7986:2	O
all	ELIQUIS.xml:S1:7989:3	O
patients	ELIQUIS.xml:S1:7993:8	O
with	ELIQUIS.xml:S1:8002:4	O
this	ELIQUIS.xml:S1:8007:4	O
category	ELIQUIS.xml:S1:8012:8	O
of	ELIQUIS.xml:S1:8021:2	O
bleeding	ELIQUIS.xml:S1:8024:8	B-AdverseReaction
.	ELIQUIS.xml:S1:8032:1	O

Events	ELIQUIS.xml:S1:8034:6	O
and	ELIQUIS.xml:S1:8041:3	O
event	ELIQUIS.xml:S1:8045:5	O
rates	ELIQUIS.xml:S1:8051:5	O
include	ELIQUIS.xml:S1:8057:7	O
one	ELIQUIS.xml:S1:8065:3	O
enoxaparin	ELIQUIS.xml:S1:8069:10	O
-	ELIQUIS.xml:S1:8079:1	O
treated	ELIQUIS.xml:S1:8080:7	O
patient	ELIQUIS.xml:S1:8088:7	O
in	ELIQUIS.xml:S1:8096:2	O
ADVANCE	ELIQUIS.xml:S1:8099:7	O
-	ELIQUIS.xml:S1:8106:1	O
1	ELIQUIS.xml:S1:8107:1	O
who	ELIQUIS.xml:S1:8109:3	O
also	ELIQUIS.xml:S1:8113:4	O
had	ELIQUIS.xml:S1:8118:3	O
intracranial	ELIQUIS.xml:S1:8122:12	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:8135:10	I-AdverseReaction
.	ELIQUIS.xml:S1:8145:1	O

CRNM	ELIQUIS.xml:S1:8154:4	O
clinically	ELIQUIS.xml:S1:8161:10	O
relevant	ELIQUIS.xml:S1:8172:8	O
nonmajor	ELIQUIS.xml:S1:8181:8	O
.	ELIQUIS.xml:S1:8189:1	O

ELIQUIS2	ELIQUIS.xml:S1:8215:8	O

.	ELIQUIS.xml:S1:8223:1	O
5	ELIQUIS.xml:S1:8224:1	O
mg	ELIQUIS.xml:S1:8226:2	O
po	ELIQUIS.xml:S1:8229:2	O
bid35	ELIQUIS.xml:S1:8232:5	O
-	ELIQUIS.xml:S1:8239:1	O
3	ELIQUIS.xml:S1:8240:1	O
days	ELIQUIS.xml:S1:8242:4	O
Enoxaparin	ELIQUIS.xml:S1:8250:10	O
40	ELIQUIS.xml:S1:8261:2	O
mg	ELIQUIS.xml:S1:8264:2	O
sc	ELIQUIS.xml:S1:8267:2	O
qd	ELIQUIS.xml:S1:8270:2	O
35	ELIQUIS.xml:S1:8273:2	O
-	ELIQUIS.xml:S1:8277:1	O
3	ELIQUIS.xml:S1:8278:1	O
days	ELIQUIS.xml:S1:8280:4	O
ELIQUIS	ELIQUIS.xml:S1:8288:7	O
2.5	ELIQUIS.xml:S1:8296:3	O
mg	ELIQUIS.xml:S1:8300:2	O
po	ELIQUIS.xml:S1:8303:2	O
bid	ELIQUIS.xml:S1:8306:3	O
12	ELIQUIS.xml:S1:8310:2	O
-	ELIQUIS.xml:S1:8314:1	O
2	ELIQUIS.xml:S1:8315:1	O
days	ELIQUIS.xml:S1:8317:4	O
Enoxaparin	ELIQUIS.xml:S1:8325:10	O
40	ELIQUIS.xml:S1:8336:2	O
mg	ELIQUIS.xml:S1:8339:2	O
sc	ELIQUIS.xml:S1:8342:2	O
qd	ELIQUIS.xml:S1:8345:2	O
12	ELIQUIS.xml:S1:8348:2	O
-	ELIQUIS.xml:S1:8352:1	O
2	ELIQUIS.xml:S1:8353:1	O
days	ELIQUIS.xml:S1:8355:4	O
ELIQUIS	ELIQUIS.xml:S1:8363:7	O
2.5	ELIQUIS.xml:S1:8371:3	O
mg	ELIQUIS.xml:S1:8375:2	O
po	ELIQUIS.xml:S1:8378:2	O
bid	ELIQUIS.xml:S1:8381:3	O
12	ELIQUIS.xml:S1:8385:2	O
-	ELIQUIS.xml:S1:8389:1	O
2	ELIQUIS.xml:S1:8390:1	O
days	ELIQUIS.xml:S1:8392:4	O
Enoxaparin	ELIQUIS.xml:S1:8400:10	O
30	ELIQUIS.xml:S1:8411:2	O
mg	ELIQUIS.xml:S1:8414:2	O
sc	ELIQUIS.xml:S1:8417:2	O
q12h	ELIQUIS.xml:S1:8420:4	O
12	ELIQUIS.xml:S1:8425:2	O
-	ELIQUIS.xml:S1:8429:1	O
2	ELIQUIS.xml:S1:8430:1	O
days	ELIQUIS.xml:S1:8432:4	O

First	ELIQUIS.xml:S1:8443:5	O
dose	ELIQUIS.xml:S1:8449:4	O
12	ELIQUIS.xml:S1:8454:2	O
to	ELIQUIS.xml:S1:8457:2	O
24	ELIQUIS.xml:S1:8460:2	O
hours	ELIQUIS.xml:S1:8463:5	O
post	ELIQUIS.xml:S1:8469:4	O
surgery	ELIQUIS.xml:S1:8474:7	O
First	ELIQUIS.xml:S1:8485:5	O
dose	ELIQUIS.xml:S1:8491:4	O
9	ELIQUIS.xml:S1:8496:1	O
to	ELIQUIS.xml:S1:8498:2	O
15	ELIQUIS.xml:S1:8501:2	O
hours	ELIQUIS.xml:S1:8504:5	O
prior	ELIQUIS.xml:S1:8510:5	O
to	ELIQUIS.xml:S1:8516:2	O
surgery	ELIQUIS.xml:S1:8519:7	O
First	ELIQUIS.xml:S1:8530:5	O
dose	ELIQUIS.xml:S1:8536:4	O
12	ELIQUIS.xml:S1:8541:2	O
to	ELIQUIS.xml:S1:8544:2	O
24	ELIQUIS.xml:S1:8547:2	O
hours	ELIQUIS.xml:S1:8550:5	O
post	ELIQUIS.xml:S1:8556:4	O
surgery	ELIQUIS.xml:S1:8561:7	O
First	ELIQUIS.xml:S1:8572:5	O
dose	ELIQUIS.xml:S1:8578:4	O
9	ELIQUIS.xml:S1:8583:1	O
to	ELIQUIS.xml:S1:8585:2	O
15	ELIQUIS.xml:S1:8588:2	O
hours	ELIQUIS.xml:S1:8591:5	O
prior	ELIQUIS.xml:S1:8597:5	O
to	ELIQUIS.xml:S1:8603:2	O
surgery	ELIQUIS.xml:S1:8606:7	O
First	ELIQUIS.xml:S1:8617:5	O
dose	ELIQUIS.xml:S1:8623:4	O
12	ELIQUIS.xml:S1:8628:2	O
to	ELIQUIS.xml:S1:8631:2	O
24	ELIQUIS.xml:S1:8634:2	O
hours	ELIQUIS.xml:S1:8637:5	O
post	ELIQUIS.xml:S1:8643:4	O
surgery	ELIQUIS.xml:S1:8648:7	O
First	ELIQUIS.xml:S1:8659:5	O
dose	ELIQUIS.xml:S1:8665:4	O
12	ELIQUIS.xml:S1:8670:2	O
to	ELIQUIS.xml:S1:8673:2	O
24	ELIQUIS.xml:S1:8676:2	O
hours	ELIQUIS.xml:S1:8679:5	O
post	ELIQUIS.xml:S1:8685:4	O
surgery	ELIQUIS.xml:S1:8690:7	O

All	ELIQUIS.xml:S1:8704:3	O
treated	ELIQUIS.xml:S1:8708:7	O
N	ELIQUIS.xml:S1:8720:1	O
2673	ELIQUIS.xml:S1:8722:4	O
N	ELIQUIS.xml:S1:8737:1	O
2659	ELIQUIS.xml:S1:8739:4	O
N	ELIQUIS.xml:S1:8753:1	O
1501	ELIQUIS.xml:S1:8755:4	O
N	ELIQUIS.xml:S1:8770:1	O
1508	ELIQUIS.xml:S1:8772:4	O
N	ELIQUIS.xml:S1:8785:1	O
1596	ELIQUIS.xml:S1:8787:4	O
N	ELIQUIS.xml:S1:8802:1	O
1588	ELIQUIS.xml:S1:8804:4	O

Major	ELIQUIS.xml:S1:8822:5	O
(	ELIQUIS.xml:S1:8828:1	O
including	ELIQUIS.xml:S1:8829:9	O
surgical	ELIQUIS.xml:S1:8839:8	O
site	ELIQUIS.xml:S1:8848:4	O
)	ELIQUIS.xml:S1:8852:1	O
22	ELIQUIS.xml:S1:8857:2	O
(	ELIQUIS.xml:S1:8860:1	O
0.82%	ELIQUIS.xml:S1:8861:5	O
)	ELIQUIS.xml:S1:8866:1	O
18	ELIQUIS.xml:S1:8874:2	O
(	ELIQUIS.xml:S1:8877:1	O
0.68%	ELIQUIS.xml:S1:8878:5	O
)	ELIQUIS.xml:S1:8883:1	O
9	ELIQUIS.xml:S1:8890:1	O
(	ELIQUIS.xml:S1:8892:1	O
0.60%	ELIQUIS.xml:S1:8893:5	O
)	ELIQUIS.xml:S1:8898:1	O
?	ELIQUIS.xml:S1:8899:1	O

14	ELIQUIS.xml:S1:8907:2	O
(	ELIQUIS.xml:S1:8910:1	O
0.93%	ELIQUIS.xml:S1:8911:5	O
)	ELIQUIS.xml:S1:8916:1	O
11	ELIQUIS.xml:S1:8922:2	O
(	ELIQUIS.xml:S1:8925:1	O
0.69%	ELIQUIS.xml:S1:8926:5	O
)	ELIQUIS.xml:S1:8931:1	O
22	ELIQUIS.xml:S1:8939:2	O
(	ELIQUIS.xml:S1:8942:1	O
1.39%	ELIQUIS.xml:S1:8943:5	O
)	ELIQUIS.xml:S1:8948:1	O

Fatal	ELIQUIS.xml:S1:8961:5	B-AdverseReaction
0	ELIQUIS.xml:S1:8975:1	O
0	ELIQUIS.xml:S1:8992:1	O
0	ELIQUIS.xml:S1:9008:1	O
0	ELIQUIS.xml:S1:9025:1	O
0	ELIQUIS.xml:S1:9040:1	O
1	ELIQUIS.xml:S1:9057:1	O
(	ELIQUIS.xml:S1:9059:1	O
0.06%	ELIQUIS.xml:S1:9060:5	O
)	ELIQUIS.xml:S1:9065:1	O

Hgb	ELIQUIS.xml:S1:9079:3	B-AdverseReaction
decrease	ELIQUIS.xml:S1:9083:8	I-AdverseReaction
2	ELIQUIS.xml:S1:9094:1	B-Severity
g	ELIQUIS.xml:S1:9096:1	I-Severity
dL	ELIQUIS.xml:S1:9098:2	I-Severity
13	ELIQUIS.xml:S1:9104:2	O
(	ELIQUIS.xml:S1:9107:1	O
0.49%	ELIQUIS.xml:S1:9108:5	O
)	ELIQUIS.xml:S1:9113:1	O
10	ELIQUIS.xml:S1:9121:2	O
(	ELIQUIS.xml:S1:9124:1	O
0.38%	ELIQUIS.xml:S1:9125:5	O
)	ELIQUIS.xml:S1:9130:1	O
8	ELIQUIS.xml:S1:9137:1	O
(	ELIQUIS.xml:S1:9139:1	O
0.53%	ELIQUIS.xml:S1:9140:5	O
)	ELIQUIS.xml:S1:9145:1	O
9	ELIQUIS.xml:S1:9154:1	O
(	ELIQUIS.xml:S1:9156:1	O
0.60%	ELIQUIS.xml:S1:9157:5	O
)	ELIQUIS.xml:S1:9162:1	O
10	ELIQUIS.xml:S1:9169:2	O
(	ELIQUIS.xml:S1:9172:1	O
0.63%	ELIQUIS.xml:S1:9173:5	O
)	ELIQUIS.xml:S1:9178:1	O
16	ELIQUIS.xml:S1:9186:2	O
(	ELIQUIS.xml:S1:9189:1	O
1.01%	ELIQUIS.xml:S1:9190:5	O
)	ELIQUIS.xml:S1:9195:1	O

Transfusion	ELIQUIS.xml:S1:9208:11	O
of	ELIQUIS.xml:S1:9220:2	O
2	ELIQUIS.xml:S1:9225:1	O
units	ELIQUIS.xml:S1:9227:5	O
RBC	ELIQUIS.xml:S1:9233:3	O
16	ELIQUIS.xml:S1:9240:2	O
(	ELIQUIS.xml:S1:9243:1	O
0.60%	ELIQUIS.xml:S1:9244:5	O
)	ELIQUIS.xml:S1:9249:1	O
14	ELIQUIS.xml:S1:9257:2	O
(	ELIQUIS.xml:S1:9260:1	O
0.53%	ELIQUIS.xml:S1:9261:5	O
)	ELIQUIS.xml:S1:9266:1	O
5	ELIQUIS.xml:S1:9273:1	O
(	ELIQUIS.xml:S1:9275:1	O
0.33%	ELIQUIS.xml:S1:9276:5	O
)	ELIQUIS.xml:S1:9281:1	O
9	ELIQUIS.xml:S1:9290:1	O
(	ELIQUIS.xml:S1:9292:1	O
0.60%	ELIQUIS.xml:S1:9293:5	O
)	ELIQUIS.xml:S1:9298:1	O
9	ELIQUIS.xml:S1:9305:1	O
(	ELIQUIS.xml:S1:9307:1	O
0.56%	ELIQUIS.xml:S1:9308:5	O
)	ELIQUIS.xml:S1:9313:1	O
18	ELIQUIS.xml:S1:9322:2	O
(	ELIQUIS.xml:S1:9325:1	O
1.13%	ELIQUIS.xml:S1:9326:5	O
)	ELIQUIS.xml:S1:9331:1	O

Bleed	ELIQUIS.xml:S1:9344:5	B-AdverseReaction
at	ELIQUIS.xml:S1:9350:2	I-AdverseReaction
critical	ELIQUIS.xml:S1:9353:8	I-AdverseReaction
siteS	ELIQUIS.xml:S1:9362:5	I-AdverseReaction
1	ELIQUIS.xml:S1:9371:1	O
(	ELIQUIS.xml:S1:9373:1	O
0.04%	ELIQUIS.xml:S1:9374:5	O
)	ELIQUIS.xml:S1:9379:1	O
1	ELIQUIS.xml:S1:9388:1	O
(	ELIQUIS.xml:S1:9390:1	O
0.04%	ELIQUIS.xml:S1:9391:5	O
)	ELIQUIS.xml:S1:9396:1	O
1	ELIQUIS.xml:S1:9404:1	O
(	ELIQUIS.xml:S1:9406:1	O
0.07%	ELIQUIS.xml:S1:9407:5	O
)	ELIQUIS.xml:S1:9412:1	O
2	ELIQUIS.xml:S1:9421:1	O
(	ELIQUIS.xml:S1:9423:1	O
0.13%	ELIQUIS.xml:S1:9424:5	O
)	ELIQUIS.xml:S1:9429:1	O
1	ELIQUIS.xml:S1:9436:1	O
(	ELIQUIS.xml:S1:9438:1	O
0.06%	ELIQUIS.xml:S1:9439:5	O
)	ELIQUIS.xml:S1:9444:1	O
4	ELIQUIS.xml:S1:9453:1	O
(	ELIQUIS.xml:S1:9455:1	O
0.25%	ELIQUIS.xml:S1:9456:5	O
)	ELIQUIS.xml:S1:9461:1	O

Major	ELIQUIS.xml:S1:9473:5	O
CRNM	ELIQUIS.xml:S1:9480:4	O
129	ELIQUIS.xml:S1:9489:3	O
(	ELIQUIS.xml:S1:9493:1	O
4.83%	ELIQUIS.xml:S1:9494:5	O
)	ELIQUIS.xml:S1:9499:1	O
134	ELIQUIS.xml:S1:9506:3	O
(	ELIQUIS.xml:S1:9510:1	O
5.04%	ELIQUIS.xml:S1:9511:5	O
)	ELIQUIS.xml:S1:9516:1	O
53	ELIQUIS.xml:S1:9522:2	O
(	ELIQUIS.xml:S1:9525:1	O
3.53%	ELIQUIS.xml:S1:9526:5	O
)	ELIQUIS.xml:S1:9531:1	O
72	ELIQUIS.xml:S1:9539:2	O
(	ELIQUIS.xml:S1:9542:1	O
4.77%	ELIQUIS.xml:S1:9543:5	O
)	ELIQUIS.xml:S1:9548:1	O
46	ELIQUIS.xml:S1:9554:2	O
(	ELIQUIS.xml:S1:9557:1	O
2.88%	ELIQUIS.xml:S1:9558:5	O
)	ELIQUIS.xml:S1:9563:1	O
68	ELIQUIS.xml:S1:9571:2	O
(	ELIQUIS.xml:S1:9574:1	O
4.28%	ELIQUIS.xml:S1:9575:5	O
)	ELIQUIS.xml:S1:9580:1	O

All	ELIQUIS.xml:S1:9591:3	O
313	ELIQUIS.xml:S1:9607:3	O
(	ELIQUIS.xml:S1:9611:1	O
11.71%	ELIQUIS.xml:S1:9612:6	O
)	ELIQUIS.xml:S1:9618:1	O
334	ELIQUIS.xml:S1:9624:3	O
(	ELIQUIS.xml:S1:9628:1	O
12.56%	ELIQUIS.xml:S1:9629:6	O
)	ELIQUIS.xml:S1:9635:1	O
104	ELIQUIS.xml:S1:9640:3	O
(	ELIQUIS.xml:S1:9644:1	O
6.93%	ELIQUIS.xml:S1:9645:5	O
)	ELIQUIS.xml:S1:9650:1	O
126	ELIQUIS.xml:S1:9657:3	O
(	ELIQUIS.xml:S1:9661:1	O
8.36%	ELIQUIS.xml:S1:9662:5	O
)	ELIQUIS.xml:S1:9667:1	O
85	ELIQUIS.xml:S1:9672:2	O
(	ELIQUIS.xml:S1:9675:1	O
5.33%	ELIQUIS.xml:S1:9676:5	O
)	ELIQUIS.xml:S1:9681:1	O
108	ELIQUIS.xml:S1:9689:3	O
(	ELIQUIS.xml:S1:9693:1	O
6.80%	ELIQUIS.xml:S1:9694:5	O
)	ELIQUIS.xml:S1:9699:1	O

Adverse	ELIQUIS.xml:S1:9720:7	O
reactions	ELIQUIS.xml:S1:9728:9	O
occurring	ELIQUIS.xml:S1:9738:9	O
in	ELIQUIS.xml:S1:9748:2	O
1%	ELIQUIS.xml:S1:9753:2	O
of	ELIQUIS.xml:S1:9756:2	O
patients	ELIQUIS.xml:S1:9759:8	O
undergoing	ELIQUIS.xml:S1:9768:10	O
hip	ELIQUIS.xml:S1:9779:3	O
or	ELIQUIS.xml:S1:9783:2	O
knee	ELIQUIS.xml:S1:9786:4	O
replacement	ELIQUIS.xml:S1:9791:11	O
surgery	ELIQUIS.xml:S1:9803:7	O
in	ELIQUIS.xml:S1:9811:2	O
the	ELIQUIS.xml:S1:9814:3	O
1	ELIQUIS.xml:S1:9818:1	O
Phase	ELIQUIS.xml:S1:9820:5	O
II	ELIQUIS.xml:S1:9826:2	O
study	ELIQUIS.xml:S1:9829:5	O
and	ELIQUIS.xml:S1:9835:3	O
the	ELIQUIS.xml:S1:9839:3	O
3	ELIQUIS.xml:S1:9843:1	O
Phase	ELIQUIS.xml:S1:9845:5	O
III	ELIQUIS.xml:S1:9851:3	O
studies	ELIQUIS.xml:S1:9855:7	O
are	ELIQUIS.xml:S1:9863:3	O
listed	ELIQUIS.xml:S1:9867:6	O
in	ELIQUIS.xml:S1:9874:2	O
Table	ELIQUIS.xml:S1:9877:5	O
4	ELIQUIS.xml:S1:9883:1	O
.	ELIQUIS.xml:S1:9884:1	O

Table	ELIQUIS.xml:S1:9890:5	O

4	ELIQUIS.xml:S1:9896:1	O
:	ELIQUIS.xml:S1:9897:1	O
Adverse	ELIQUIS.xml:S1:9903:7	O
Reactions	ELIQUIS.xml:S1:9911:9	O
Occurring	ELIQUIS.xml:S1:9921:9	O
in	ELIQUIS.xml:S1:9931:2	O
1%	ELIQUIS.xml:S1:9936:2	O
of	ELIQUIS.xml:S1:9939:2	O
Patients	ELIQUIS.xml:S1:9942:8	O
in	ELIQUIS.xml:S1:9951:2	O
Either	ELIQUIS.xml:S1:9954:6	O
Group	ELIQUIS.xml:S1:9961:5	O
Undergoing	ELIQUIS.xml:S1:9967:10	O
Hip	ELIQUIS.xml:S1:9978:3	O
or	ELIQUIS.xml:S1:9982:2	O
Knee	ELIQUIS.xml:S1:9985:4	O
Replacement	ELIQUIS.xml:S1:9990:11	O
Surgery	ELIQUIS.xml:S1:10002:7	O

ELIQUIS	ELIQUIS.xml:S1:10071:7	O
,	ELIQUIS.xml:S1:10078:1	O
n	ELIQUIS.xml:S1:10080:1	O
(	ELIQUIS.xml:S1:10082:1	O
)	ELIQUIS.xml:S1:10084:1	O
2.5	ELIQUIS.xml:S1:10085:3	O
mg	ELIQUIS.xml:S1:10089:2	O
po	ELIQUIS.xml:S1:10092:2	O
bidN	ELIQUIS.xml:S1:10095:4	O
5924	ELIQUIS.xml:S1:10100:4	O
Enoxaparin	ELIQUIS.xml:S1:10110:10	O
,	ELIQUIS.xml:S1:10120:1	O
n	ELIQUIS.xml:S1:10122:1	O
(	ELIQUIS.xml:S1:10124:1	O
)	ELIQUIS.xml:S1:10126:1	O
40	ELIQUIS.xml:S1:10127:2	O
mg	ELIQUIS.xml:S1:10130:2	O
sc	ELIQUIS.xml:S1:10133:2	O
qd	ELIQUIS.xml:S1:10136:2	O
or30	ELIQUIS.xml:S1:10139:4	O
mg	ELIQUIS.xml:S1:10144:2	O
sc	ELIQUIS.xml:S1:10147:2	O
q12hN	ELIQUIS.xml:S1:10150:5	O
5904	ELIQUIS.xml:S1:10156:4	O

Nausea	ELIQUIS.xml:S1:10171:6	B-AdverseReaction

153	ELIQUIS.xml:S1:10228:3	O
(	ELIQUIS.xml:S1:10232:1	O
2.6	ELIQUIS.xml:S1:10233:3	O
)	ELIQUIS.xml:S1:10236:1	O
159	ELIQUIS.xml:S1:10250:3	O
(	ELIQUIS.xml:S1:10254:1	O
2.7	ELIQUIS.xml:S1:10255:3	O
)	ELIQUIS.xml:S1:10258:1	O

Anemia	ELIQUIS.xml:S1:10280:6	B-AdverseReaction
(	ELIQUIS.xml:S1:10287:1	O
including	ELIQUIS.xml:S1:10288:9	O
postoperative	ELIQUIS.xml:S1:10298:13	B-AdverseReaction
and	ELIQUIS.xml:S1:10312:3	O
hemorrhagic	ELIQUIS.xml:S1:10316:11	B-AdverseReaction
anemia	ELIQUIS.xml:S1:10328:6	I-AdverseReaction
,	ELIQUIS.xml:S1:10334:1	O
and	ELIQUIS.xml:S1:10336:3	O
respective	ELIQUIS.xml:S1:10340:10	O
laboratory	ELIQUIS.xml:S1:10351:10	O
parameters	ELIQUIS.xml:S1:10362:10	O
)	ELIQUIS.xml:S1:10372:1	O
153	ELIQUIS.xml:S1:10377:3	O
(	ELIQUIS.xml:S1:10381:1	O
2.6	ELIQUIS.xml:S1:10382:3	O
)	ELIQUIS.xml:S1:10385:1	O
178	ELIQUIS.xml:S1:10399:3	O
(	ELIQUIS.xml:S1:10403:1	O
3.0	ELIQUIS.xml:S1:10404:3	O
)	ELIQUIS.xml:S1:10407:1	O

Contusion	ELIQUIS.xml:S1:10429:9	B-AdverseReaction
83	ELIQUIS.xml:S1:10486:2	O
(	ELIQUIS.xml:S1:10489:1	O
1.4	ELIQUIS.xml:S1:10490:3	O
)	ELIQUIS.xml:S1:10493:1	O
115	ELIQUIS.xml:S1:10508:3	O
(	ELIQUIS.xml:S1:10512:1	O
1.9	ELIQUIS.xml:S1:10513:3	O
)	ELIQUIS.xml:S1:10516:1	O

Hemorrhage	ELIQUIS.xml:S1:10538:10	B-AdverseReaction
(	ELIQUIS.xml:S1:10549:1	O
including	ELIQUIS.xml:S1:10550:9	O
hematoma	ELIQUIS.xml:S1:10560:8	B-AdverseReaction
,	ELIQUIS.xml:S1:10568:1	O
and	ELIQUIS.xml:S1:10570:3	O
vaginal	ELIQUIS.xml:S1:10574:7	B-AdverseReaction
and	ELIQUIS.xml:S1:10582:3	O
urethral	ELIQUIS.xml:S1:10586:8	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:10595:10	I-AdverseReaction
)	ELIQUIS.xml:S1:10605:1	O
67	ELIQUIS.xml:S1:10610:2	O
(	ELIQUIS.xml:S1:10613:1	O
1.1	ELIQUIS.xml:S1:10614:3	O
)	ELIQUIS.xml:S1:10617:1	O
81	ELIQUIS.xml:S1:10632:2	O
(	ELIQUIS.xml:S1:10635:1	O
1.4	ELIQUIS.xml:S1:10636:3	O
)	ELIQUIS.xml:S1:10639:1	O

Postprocedural	ELIQUIS.xml:S1:10662:14	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:10677:10	I-AdverseReaction
(	ELIQUIS.xml:S1:10688:1	O
including	ELIQUIS.xml:S1:10689:9	O
postprocedural	ELIQUIS.xml:S1:10699:14	B-AdverseReaction
hematoma	ELIQUIS.xml:S1:10714:8	I-AdverseReaction
,	ELIQUIS.xml:S1:10722:1	O
wound	ELIQUIS.xml:S1:10724:5	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:10730:10	I-AdverseReaction
,	ELIQUIS.xml:S1:10740:1	O
vessel	ELIQUIS.xml:S1:10742:6	B-AdverseReaction
puncture	ELIQUIS.xml:S1:10749:8	I-AdverseReaction
site	ELIQUIS.xml:S1:10758:4	I-AdverseReaction
hematoma	ELIQUIS.xml:S1:10763:8	I-AdverseReaction
and	ELIQUIS.xml:S1:10772:3	O
catheter	ELIQUIS.xml:S1:10776:8	B-AdverseReaction
site	ELIQUIS.xml:S1:10785:4	I-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:10790:10	I-AdverseReaction
)	ELIQUIS.xml:S1:10800:1	O
54	ELIQUIS.xml:S1:10805:2	O
(	ELIQUIS.xml:S1:10808:1	O
0.9	ELIQUIS.xml:S1:10809:3	O
)	ELIQUIS.xml:S1:10812:1	O
60	ELIQUIS.xml:S1:10827:2	O
(	ELIQUIS.xml:S1:10830:1	O
1.0	ELIQUIS.xml:S1:10831:3	O
)	ELIQUIS.xml:S1:10834:1	O

Transaminases	ELIQUIS.xml:S1:10857:13	B-AdverseReaction
increased	ELIQUIS.xml:S1:10871:9	I-AdverseReaction
(	ELIQUIS.xml:S1:10881:1	O
including	ELIQUIS.xml:S1:10882:9	O
alanine	ELIQUIS.xml:S1:10892:7	B-AdverseReaction
aminotransferase	ELIQUIS.xml:S1:10900:16	I-AdverseReaction
increased	ELIQUIS.xml:S1:10917:9	I-AdverseReaction
and	ELIQUIS.xml:S1:10927:3	O
alanine	ELIQUIS.xml:S1:10931:7	B-AdverseReaction
aminotransferase	ELIQUIS.xml:S1:10939:16	I-AdverseReaction
abnormal	ELIQUIS.xml:S1:10956:8	I-AdverseReaction
)	ELIQUIS.xml:S1:10964:1	O
50	ELIQUIS.xml:S1:10969:2	O
(	ELIQUIS.xml:S1:10972:1	O
0.8	ELIQUIS.xml:S1:10973:3	O
)	ELIQUIS.xml:S1:10976:1	O
71	ELIQUIS.xml:S1:10991:2	O
(	ELIQUIS.xml:S1:10994:1	O
1.2	ELIQUIS.xml:S1:10995:3	O
)	ELIQUIS.xml:S1:10998:1	O

Aspartate	ELIQUIS.xml:S1:11021:9	B-AdverseReaction
aminotransferase	ELIQUIS.xml:S1:11031:16	I-AdverseReaction
increased	ELIQUIS.xml:S1:11048:9	I-AdverseReaction
47	ELIQUIS.xml:S1:11078:2	O
(	ELIQUIS.xml:S1:11081:1	O
0.8	ELIQUIS.xml:S1:11082:3	O
)	ELIQUIS.xml:S1:11085:1	O
69	ELIQUIS.xml:S1:11100:2	O
(	ELIQUIS.xml:S1:11103:1	O
1.2	ELIQUIS.xml:S1:11104:3	O
)	ELIQUIS.xml:S1:11107:1	O

Gamma	ELIQUIS.xml:S1:11130:5	B-AdverseReaction
-	ELIQUIS.xml:S1:11135:1	I-AdverseReaction
glutamyltransferase	ELIQUIS.xml:S1:11136:19	I-AdverseReaction
increased	ELIQUIS.xml:S1:11156:9	I-AdverseReaction
38	ELIQUIS.xml:S1:11187:2	O
(	ELIQUIS.xml:S1:11190:1	O
0.6	ELIQUIS.xml:S1:11191:3	O
)	ELIQUIS.xml:S1:11194:1	O
65	ELIQUIS.xml:S1:11209:2	O
(	ELIQUIS.xml:S1:11212:1	O
1.1	ELIQUIS.xml:S1:11213:3	O
)	ELIQUIS.xml:S1:11216:1	O

Less	ELIQUIS.xml:S1:11246:4	O
common	ELIQUIS.xml:S1:11251:6	O
adverse	ELIQUIS.xml:S1:11258:7	O
reactions	ELIQUIS.xml:S1:11266:9	O
in	ELIQUIS.xml:S1:11276:2	O
apixaban	ELIQUIS.xml:S1:11279:8	O
-	ELIQUIS.xml:S1:11287:1	O
treated	ELIQUIS.xml:S1:11288:7	O
patients	ELIQUIS.xml:S1:11296:8	O
undergoing	ELIQUIS.xml:S1:11305:10	O
hip	ELIQUIS.xml:S1:11316:3	O
or	ELIQUIS.xml:S1:11320:2	O
knee	ELIQUIS.xml:S1:11323:4	O
replacement	ELIQUIS.xml:S1:11328:11	O
surgery	ELIQUIS.xml:S1:11340:7	O
occurring	ELIQUIS.xml:S1:11348:9	O
at	ELIQUIS.xml:S1:11358:2	O
a	ELIQUIS.xml:S1:11361:1	O
frequency	ELIQUIS.xml:S1:11363:9	O
of	ELIQUIS.xml:S1:11373:2	O
0.1%	ELIQUIS.xml:S1:11378:4	O
to	ELIQUIS.xml:S1:11383:2	O
1%	ELIQUIS.xml:S1:11387:2	O
:	ELIQUIS.xml:S1:11389:1	O

Blood	ELIQUIS.xml:S1:11397:5	O

and	ELIQUIS.xml:S1:11403:3	O
lymphatic	ELIQUIS.xml:S1:11407:9	O
system	ELIQUIS.xml:S1:11417:6	O
disorders	ELIQUIS.xml:S1:11424:9	O
:	ELIQUIS.xml:S1:11433:1	O
thrombocytopenia	ELIQUIS.xml:S1:11436:16	B-AdverseReaction
(	ELIQUIS.xml:S1:11453:1	O
including	ELIQUIS.xml:S1:11454:9	O
platelet	ELIQUIS.xml:S1:11464:8	B-AdverseReaction
count	ELIQUIS.xml:S1:11473:5	I-AdverseReaction
decreases	ELIQUIS.xml:S1:11479:9	I-AdverseReaction
)	ELIQUIS.xml:S1:11488:1	O

Vascular	ELIQUIS.xml:S1:11496:8	O
disorders	ELIQUIS.xml:S1:11505:9	O
:	ELIQUIS.xml:S1:11514:1	O
hypotension	ELIQUIS.xml:S1:11517:11	B-AdverseReaction
(	ELIQUIS.xml:S1:11529:1	O
including	ELIQUIS.xml:S1:11530:9	O
procedural	ELIQUIS.xml:S1:11540:10	B-AdverseReaction
hypotension	ELIQUIS.xml:S1:11551:11	I-AdverseReaction
)	ELIQUIS.xml:S1:11562:1	O

Respiratory	ELIQUIS.xml:S1:11570:11	O
,	ELIQUIS.xml:S1:11581:1	O
thoracic	ELIQUIS.xml:S1:11583:8	O
,	ELIQUIS.xml:S1:11591:1	O
and	ELIQUIS.xml:S1:11593:3	O
mediastinal	ELIQUIS.xml:S1:11597:11	O
disorders	ELIQUIS.xml:S1:11609:9	O
:	ELIQUIS.xml:S1:11618:1	O
epistaxis	ELIQUIS.xml:S1:11621:9	B-AdverseReaction

Gastrointestinal	ELIQUIS.xml:S1:11637:16	O
disorders	ELIQUIS.xml:S1:11654:9	O
:	ELIQUIS.xml:S1:11663:1	O
gastrointestinal	ELIQUIS.xml:S1:11666:16	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:11683:10	I-AdverseReaction
(	ELIQUIS.xml:S1:11694:1	O
including	ELIQUIS.xml:S1:11695:9	O
hematemesis	ELIQUIS.xml:S1:11705:11	B-AdverseReaction
and	ELIQUIS.xml:S1:11717:3	O
melena	ELIQUIS.xml:S1:11721:6	B-AdverseReaction
)	ELIQUIS.xml:S1:11727:1	O
,	ELIQUIS.xml:S1:11728:1	O
hematochezia	ELIQUIS.xml:S1:11730:12	B-AdverseReaction

Hepatobiliary	ELIQUIS.xml:S1:11749:13	O
disorders	ELIQUIS.xml:S1:11763:9	O
:	ELIQUIS.xml:S1:11772:1	O
liver	ELIQUIS.xml:S1:11775:5	B-AdverseReaction
function	ELIQUIS.xml:S1:11781:8	I-AdverseReaction
test	ELIQUIS.xml:S1:11790:4	I-AdverseReaction
abnormal	ELIQUIS.xml:S1:11795:8	I-AdverseReaction
,	ELIQUIS.xml:S1:11803:1	O
blood	ELIQUIS.xml:S1:11805:5	B-AdverseReaction
alkaline	ELIQUIS.xml:S1:11811:8	I-AdverseReaction
phosphatase	ELIQUIS.xml:S1:11820:11	I-AdverseReaction
increased	ELIQUIS.xml:S1:11832:9	I-AdverseReaction
,	ELIQUIS.xml:S1:11841:1	O
blood	ELIQUIS.xml:S1:11843:5	B-AdverseReaction
bilirubin	ELIQUIS.xml:S1:11849:9	I-AdverseReaction
increased	ELIQUIS.xml:S1:11859:9	I-AdverseReaction

Renal	ELIQUIS.xml:S1:11875:5	O
and	ELIQUIS.xml:S1:11881:3	O
urinary	ELIQUIS.xml:S1:11885:7	O
disorders	ELIQUIS.xml:S1:11893:9	O
:	ELIQUIS.xml:S1:11902:1	O
hematuria	ELIQUIS.xml:S1:11905:9	B-AdverseReaction
(	ELIQUIS.xml:S1:11915:1	O
including	ELIQUIS.xml:S1:11916:9	O
respective	ELIQUIS.xml:S1:11926:10	O
laboratory	ELIQUIS.xml:S1:11937:10	O
parameters	ELIQUIS.xml:S1:11948:10	O
)	ELIQUIS.xml:S1:11958:1	O

Injury	ELIQUIS.xml:S1:11966:6	O
,	ELIQUIS.xml:S1:11972:1	O
poisoning	ELIQUIS.xml:S1:11974:9	O
,	ELIQUIS.xml:S1:11983:1	O
and	ELIQUIS.xml:S1:11985:3	O
procedural	ELIQUIS.xml:S1:11989:10	O
complications	ELIQUIS.xml:S1:12000:13	O
:	ELIQUIS.xml:S1:12013:1	O
wound	ELIQUIS.xml:S1:12016:5	B-AdverseReaction
secretion	ELIQUIS.xml:S1:12022:9	I-AdverseReaction
,	ELIQUIS.xml:S1:12031:1	O
incision	ELIQUIS.xml:S1:12033:8	B-AdverseReaction
-	ELIQUIS.xml:S1:12041:1	I-AdverseReaction
site	ELIQUIS.xml:S1:12042:4	I-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:12047:10	I-AdverseReaction
(	ELIQUIS.xml:S1:12058:1	O
including	ELIQUIS.xml:S1:12059:9	O
incision	ELIQUIS.xml:S1:12069:8	B-AdverseReaction
-	ELIQUIS.xml:S1:12077:1	I-AdverseReaction
site	ELIQUIS.xml:S1:12078:4	I-AdverseReaction
hematoma	ELIQUIS.xml:S1:12083:8	I-AdverseReaction
)	ELIQUIS.xml:S1:12091:1	O
,	ELIQUIS.xml:S1:12092:1	O
operative	ELIQUIS.xml:S1:12094:9	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:12104:10	I-AdverseReaction

Less	ELIQUIS.xml:S1:12119:4	O
common	ELIQUIS.xml:S1:12124:6	O
adverse	ELIQUIS.xml:S1:12131:7	O
reactions	ELIQUIS.xml:S1:12139:9	O
in	ELIQUIS.xml:S1:12149:2	O
apixaban	ELIQUIS.xml:S1:12152:8	O
-	ELIQUIS.xml:S1:12160:1	O
treated	ELIQUIS.xml:S1:12161:7	O
patients	ELIQUIS.xml:S1:12169:8	O
undergoing	ELIQUIS.xml:S1:12178:10	O
hip	ELIQUIS.xml:S1:12189:3	O
or	ELIQUIS.xml:S1:12193:2	O
knee	ELIQUIS.xml:S1:12196:4	O
replacement	ELIQUIS.xml:S1:12201:11	O
surgery	ELIQUIS.xml:S1:12213:7	O
occurring	ELIQUIS.xml:S1:12221:9	O
at	ELIQUIS.xml:S1:12231:2	O
a	ELIQUIS.xml:S1:12234:1	O
frequency	ELIQUIS.xml:S1:12236:9	O
of	ELIQUIS.xml:S1:12246:2	O
0.1%	ELIQUIS.xml:S1:12250:4	O
:	ELIQUIS.xml:S1:12254:1	O

Gingival	ELIQUIS.xml:S1:12260:8	B-AdverseReaction
bleeding	ELIQUIS.xml:S1:12269:8	I-AdverseReaction
,	ELIQUIS.xml:S1:12277:1	O
hemoptysis	ELIQUIS.xml:S1:12279:10	B-AdverseReaction
,	ELIQUIS.xml:S1:12289:1	O
hypersensitivity	ELIQUIS.xml:S1:12291:16	B-AdverseReaction
,	ELIQUIS.xml:S1:12307:1	O
muscle	ELIQUIS.xml:S1:12309:6	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:12316:10	I-AdverseReaction
,	ELIQUIS.xml:S1:12326:1	O
ocular	ELIQUIS.xml:S1:12328:6	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:12335:10	I-AdverseReaction
(	ELIQUIS.xml:S1:12346:1	O
including	ELIQUIS.xml:S1:12347:9	O
conjunctival	ELIQUIS.xml:S1:12357:12	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:12370:10	I-AdverseReaction
)	ELIQUIS.xml:S1:12380:1	O
,	ELIQUIS.xml:S1:12381:1	O
rectal	ELIQUIS.xml:S1:12383:6	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:12390:10	I-AdverseReaction

Treatment	ELIQUIS.xml:S1:12407:9	O
of	ELIQUIS.xml:S1:12417:2	O
DVT	ELIQUIS.xml:S1:12420:3	O
and	ELIQUIS.xml:S1:12424:3	O
PE	ELIQUIS.xml:S1:12428:2	O
and	ELIQUIS.xml:S1:12431:3	O
Reduction	ELIQUIS.xml:S1:12435:9	O
in	ELIQUIS.xml:S1:12445:2	O
the	ELIQUIS.xml:S1:12448:3	O
Risk	ELIQUIS.xml:S1:12452:4	O
of	ELIQUIS.xml:S1:12457:2	O
Recurrence	ELIQUIS.xml:S1:12460:10	O
of	ELIQUIS.xml:S1:12471:2	O
DVT	ELIQUIS.xml:S1:12474:3	O
or	ELIQUIS.xml:S1:12478:2	O
PE	ELIQUIS.xml:S1:12481:2	O

The	ELIQUIS.xml:S1:12487:3	O
safety	ELIQUIS.xml:S1:12491:6	O
of	ELIQUIS.xml:S1:12498:2	O
ELIQUIS	ELIQUIS.xml:S1:12501:7	O
has	ELIQUIS.xml:S1:12509:3	O
been	ELIQUIS.xml:S1:12513:4	O
evaluated	ELIQUIS.xml:S1:12518:9	O
in	ELIQUIS.xml:S1:12528:2	O
the	ELIQUIS.xml:S1:12531:3	O
AMPLIFY	ELIQUIS.xml:S1:12535:7	O
and	ELIQUIS.xml:S1:12543:3	O
AMPLIFY	ELIQUIS.xml:S1:12547:7	O
-	ELIQUIS.xml:S1:12554:1	O
EXT	ELIQUIS.xml:S1:12555:3	O
studies	ELIQUIS.xml:S1:12559:7	O
,	ELIQUIS.xml:S1:12566:1	O
including	ELIQUIS.xml:S1:12568:9	O
2676	ELIQUIS.xml:S1:12578:4	O
patients	ELIQUIS.xml:S1:12583:8	O
exposed	ELIQUIS.xml:S1:12592:7	O
to	ELIQUIS.xml:S1:12600:2	O
ELIQUIS	ELIQUIS.xml:S1:12603:7	O
10	ELIQUIS.xml:S1:12611:2	O
mg	ELIQUIS.xml:S1:12614:2	O
twice	ELIQUIS.xml:S1:12617:5	O
daily	ELIQUIS.xml:S1:12623:5	O
,	ELIQUIS.xml:S1:12628:1	O
3359	ELIQUIS.xml:S1:12630:4	O
patients	ELIQUIS.xml:S1:12635:8	O
exposed	ELIQUIS.xml:S1:12644:7	O
to	ELIQUIS.xml:S1:12652:2	O
ELIQUIS	ELIQUIS.xml:S1:12655:7	O
5	ELIQUIS.xml:S1:12663:1	O
mg	ELIQUIS.xml:S1:12665:2	O
twice	ELIQUIS.xml:S1:12668:5	O
daily	ELIQUIS.xml:S1:12674:5	O
,	ELIQUIS.xml:S1:12679:1	O
and	ELIQUIS.xml:S1:12681:3	O
840	ELIQUIS.xml:S1:12685:3	O
patients	ELIQUIS.xml:S1:12689:8	O
exposed	ELIQUIS.xml:S1:12698:7	O
to	ELIQUIS.xml:S1:12706:2	O
ELIQUIS	ELIQUIS.xml:S1:12709:7	O
2.5	ELIQUIS.xml:S1:12717:3	O
mg	ELIQUIS.xml:S1:12721:2	O
twice	ELIQUIS.xml:S1:12724:5	O
daily	ELIQUIS.xml:S1:12730:5	O
.	ELIQUIS.xml:S1:12735:1	O

Common	ELIQUIS.xml:S1:12741:6	O
adverse	ELIQUIS.xml:S1:12748:7	O
reactions	ELIQUIS.xml:S1:12756:9	O
(	ELIQUIS.xml:S1:12766:1	O
1%	ELIQUIS.xml:S1:12769:2	O
)	ELIQUIS.xml:S1:12771:1	O
were	ELIQUIS.xml:S1:12773:4	O
gingival	ELIQUIS.xml:S1:12778:8	B-AdverseReaction
bleeding	ELIQUIS.xml:S1:12787:8	I-AdverseReaction
,	ELIQUIS.xml:S1:12795:1	O
epistaxis	ELIQUIS.xml:S1:12797:9	B-AdverseReaction
,	ELIQUIS.xml:S1:12806:1	O
contusion	ELIQUIS.xml:S1:12808:9	B-AdverseReaction
,	ELIQUIS.xml:S1:12817:1	O
hematuria	ELIQUIS.xml:S1:12819:9	B-AdverseReaction
,	ELIQUIS.xml:S1:12828:1	O
rectal	ELIQUIS.xml:S1:12830:6	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:12837:10	I-AdverseReaction
,	ELIQUIS.xml:S1:12847:1	O
hematoma	ELIQUIS.xml:S1:12849:8	B-AdverseReaction
,	ELIQUIS.xml:S1:12857:1	O
menorrhagia	ELIQUIS.xml:S1:12859:11	B-AdverseReaction
,	ELIQUIS.xml:S1:12870:1	O
and	ELIQUIS.xml:S1:12872:3	O
hemoptysis	ELIQUIS.xml:S1:12876:10	B-AdverseReaction
.	ELIQUIS.xml:S1:12886:1	O

AMPLIFY	ELIQUIS.xml:S1:12894:7	O
Study	ELIQUIS.xml:S1:12902:5	O

The	ELIQUIS.xml:S1:12911:3	O
mean	ELIQUIS.xml:S1:12915:4	O
duration	ELIQUIS.xml:S1:12920:8	O
of	ELIQUIS.xml:S1:12929:2	O
exposure	ELIQUIS.xml:S1:12932:8	O
to	ELIQUIS.xml:S1:12941:2	O
ELIQUIS	ELIQUIS.xml:S1:12944:7	O
was	ELIQUIS.xml:S1:12952:3	O
154	ELIQUIS.xml:S1:12956:3	O
days	ELIQUIS.xml:S1:12960:4	O
and	ELIQUIS.xml:S1:12965:3	O
to	ELIQUIS.xml:S1:12969:2	O
enoxaparin	ELIQUIS.xml:S1:12972:10	O
warfarin	ELIQUIS.xml:S1:12983:8	O
was	ELIQUIS.xml:S1:12992:3	O
152	ELIQUIS.xml:S1:12996:3	O
days	ELIQUIS.xml:S1:13000:4	O
in	ELIQUIS.xml:S1:13005:2	O
the	ELIQUIS.xml:S1:13008:3	O
AMPLIFY	ELIQUIS.xml:S1:13012:7	O
study	ELIQUIS.xml:S1:13020:5	O
.	ELIQUIS.xml:S1:13025:1	O

Adverse	ELIQUIS.xml:S1:13027:7	O
reactions	ELIQUIS.xml:S1:13035:9	O
related	ELIQUIS.xml:S1:13045:7	O
to	ELIQUIS.xml:S1:13053:2	O
bleeding	ELIQUIS.xml:S1:13056:8	B-AdverseReaction
occurred	ELIQUIS.xml:S1:13065:8	O
in	ELIQUIS.xml:S1:13074:2	O
417	ELIQUIS.xml:S1:13077:3	O
(	ELIQUIS.xml:S1:13081:1	O
15.6%	ELIQUIS.xml:S1:13082:5	O
)	ELIQUIS.xml:S1:13087:1	O
ELIQUIS	ELIQUIS.xml:S1:13089:7	O
-	ELIQUIS.xml:S1:13096:1	O
treated	ELIQUIS.xml:S1:13097:7	O
patients	ELIQUIS.xml:S1:13105:8	O
compared	ELIQUIS.xml:S1:13114:8	O
to	ELIQUIS.xml:S1:13123:2	O
661	ELIQUIS.xml:S1:13126:3	O
(	ELIQUIS.xml:S1:13130:1	O
24.6%	ELIQUIS.xml:S1:13131:5	O
)	ELIQUIS.xml:S1:13136:1	O
enoxaparin	ELIQUIS.xml:S1:13138:10	O
warfarin	ELIQUIS.xml:S1:13149:8	O
-	ELIQUIS.xml:S1:13157:1	O
treated	ELIQUIS.xml:S1:13158:7	O
patients	ELIQUIS.xml:S1:13166:8	O
.	ELIQUIS.xml:S1:13174:1	O

The	ELIQUIS.xml:S1:13176:3	O
discontinuation	ELIQUIS.xml:S1:13180:15	O
rate	ELIQUIS.xml:S1:13196:4	O
due	ELIQUIS.xml:S1:13201:3	O
to	ELIQUIS.xml:S1:13205:2	O
bleeding	ELIQUIS.xml:S1:13208:8	B-AdverseReaction
events	ELIQUIS.xml:S1:13217:6	O
was	ELIQUIS.xml:S1:13224:3	O
0.7%	ELIQUIS.xml:S1:13228:4	O
in	ELIQUIS.xml:S1:13233:2	O
the	ELIQUIS.xml:S1:13236:3	O
ELIQUIS	ELIQUIS.xml:S1:13240:7	O
-	ELIQUIS.xml:S1:13247:1	O
treated	ELIQUIS.xml:S1:13248:7	O
patients	ELIQUIS.xml:S1:13256:8	O
compared	ELIQUIS.xml:S1:13265:8	O
to	ELIQUIS.xml:S1:13274:2	O
1.7%	ELIQUIS.xml:S1:13277:4	O
in	ELIQUIS.xml:S1:13282:2	O
enoxaparin	ELIQUIS.xml:S1:13285:10	O
warfarin	ELIQUIS.xml:S1:13296:8	O
-	ELIQUIS.xml:S1:13304:1	O
treated	ELIQUIS.xml:S1:13305:7	O
patients	ELIQUIS.xml:S1:13313:8	O
in	ELIQUIS.xml:S1:13322:2	O
the	ELIQUIS.xml:S1:13325:3	O
AMPLIFY	ELIQUIS.xml:S1:13329:7	O
study	ELIQUIS.xml:S1:13337:5	O
.	ELIQUIS.xml:S1:13342:1	O

In	ELIQUIS.xml:S1:13348:2	O
the	ELIQUIS.xml:S1:13351:3	O
AMPLIFY	ELIQUIS.xml:S1:13355:7	O
study	ELIQUIS.xml:S1:13363:5	O
,	ELIQUIS.xml:S1:13368:1	O
ELIQUIS	ELIQUIS.xml:S1:13370:7	O
was	ELIQUIS.xml:S1:13378:3	O
statistically	ELIQUIS.xml:S1:13382:13	O
superior	ELIQUIS.xml:S1:13396:8	O
to	ELIQUIS.xml:S1:13405:2	O
enoxaparin	ELIQUIS.xml:S1:13408:10	O
warfarin	ELIQUIS.xml:S1:13419:8	O
in	ELIQUIS.xml:S1:13428:2	O
the	ELIQUIS.xml:S1:13431:3	O
primary	ELIQUIS.xml:S1:13435:7	O
safety	ELIQUIS.xml:S1:13443:6	O
endpoint	ELIQUIS.xml:S1:13450:8	O
of	ELIQUIS.xml:S1:13459:2	O
major	ELIQUIS.xml:S1:13462:5	B-Severity
bleeding	ELIQUIS.xml:S1:13468:8	B-AdverseReaction
(	ELIQUIS.xml:S1:13477:1	O
relative	ELIQUIS.xml:S1:13478:8	O
risk	ELIQUIS.xml:S1:13487:4	O
0.31	ELIQUIS.xml:S1:13492:4	O
,	ELIQUIS.xml:S1:13496:1	O
95%	ELIQUIS.xml:S1:13498:3	O
CI	ELIQUIS.xml:S1:13502:2	O
[	ELIQUIS.xml:S1:13505:1	O
0.17	ELIQUIS.xml:S1:13506:4	O
,	ELIQUIS.xml:S1:13510:1	O
0.55	ELIQUIS.xml:S1:13512:4	O
]	ELIQUIS.xml:S1:13516:1	O
,	ELIQUIS.xml:S1:13517:1	O
P	ELIQUIS.xml:S1:13519:1	O
-	ELIQUIS.xml:S1:13520:1	O
value	ELIQUIS.xml:S1:13521:5	O
0.0001	ELIQUIS.xml:S1:13528:6	O
)	ELIQUIS.xml:S1:13534:1	O
.	ELIQUIS.xml:S1:13535:1	O

Bleeding	ELIQUIS.xml:S1:13541:8	B-AdverseReaction
results	ELIQUIS.xml:S1:13550:7	O
from	ELIQUIS.xml:S1:13558:4	O
the	ELIQUIS.xml:S1:13563:3	O
AMPLIFY	ELIQUIS.xml:S1:13567:7	O
study	ELIQUIS.xml:S1:13575:5	O
are	ELIQUIS.xml:S1:13581:3	O
summarized	ELIQUIS.xml:S1:13585:10	O
in	ELIQUIS.xml:S1:13596:2	O
Table	ELIQUIS.xml:S1:13599:5	O
5	ELIQUIS.xml:S1:13605:1	O
.	ELIQUIS.xml:S1:13606:1	O

Table	ELIQUIS.xml:S1:13612:5	O
5	ELIQUIS.xml:S1:13618:1	O
:	ELIQUIS.xml:S1:13619:1	O
Bleeding	ELIQUIS.xml:S1:13625:8	B-AdverseReaction
Results	ELIQUIS.xml:S1:13634:7	O
in	ELIQUIS.xml:S1:13642:2	O
the	ELIQUIS.xml:S1:13645:3	O
AMPLIFY	ELIQUIS.xml:S1:13649:7	O
Study	ELIQUIS.xml:S1:13657:5	O

ELIQUISN	ELIQUIS.xml:S1:13696:8	O
2676	ELIQUIS.xml:S1:13705:4	O
n	ELIQUIS.xml:S1:13709:1	O
(	ELIQUIS.xml:S1:13711:1	O
)	ELIQUIS.xml:S1:13713:1	O
Enoxaparin	ELIQUIS.xml:S1:13722:10	O
WarfarinN	ELIQUIS.xml:S1:13733:9	O
2689	ELIQUIS.xml:S1:13743:4	O
n	ELIQUIS.xml:S1:13747:1	O
(	ELIQUIS.xml:S1:13749:1	O
)	ELIQUIS.xml:S1:13751:1	O
Relative	ELIQUIS.xml:S1:13754:8	O
Risk	ELIQUIS.xml:S1:13763:4	O
(	ELIQUIS.xml:S1:13768:1	O
95%	ELIQUIS.xml:S1:13769:3	O
CI	ELIQUIS.xml:S1:13773:2	O
)	ELIQUIS.xml:S1:13775:1	O

CRNM	ELIQUIS.xml:S1:13791:4	B-AdverseReaction

clinically	ELIQUIS.xml:S1:13798:10	B-AdverseReaction
relevant	ELIQUIS.xml:S1:13809:8	I-AdverseReaction
nonmajor	ELIQUIS.xml:S1:13818:8	I-AdverseReaction
bleeding	ELIQUIS.xml:S1:13827:8	I-AdverseReaction
.	ELIQUIS.xml:S1:13835:1	O
Events	ELIQUIS.xml:S1:13836:6	O
associated	ELIQUIS.xml:S1:13843:10	O
with	ELIQUIS.xml:S1:13854:4	O
each	ELIQUIS.xml:S1:13859:4	O
endpoint	ELIQUIS.xml:S1:13864:8	O
were	ELIQUIS.xml:S1:13873:4	O
counted	ELIQUIS.xml:S1:13878:7	O
once	ELIQUIS.xml:S1:13886:4	O
per	ELIQUIS.xml:S1:13891:3	O
subject	ELIQUIS.xml:S1:13895:7	O
,	ELIQUIS.xml:S1:13902:1	O
but	ELIQUIS.xml:S1:13904:3	O
subjects	ELIQUIS.xml:S1:13908:8	O
may	ELIQUIS.xml:S1:13917:3	O
have	ELIQUIS.xml:S1:13921:4	O
contributed	ELIQUIS.xml:S1:13926:11	O
events	ELIQUIS.xml:S1:13938:6	O
to	ELIQUIS.xml:S1:13945:2	O
multiple	ELIQUIS.xml:S1:13948:8	O
endpoints	ELIQUIS.xml:S1:13957:9	O
.	ELIQUIS.xml:S1:13966:1	O

Major	ELIQUIS.xml:S1:13976:5	O

15	ELIQUIS.xml:S1:14007:2	O
(	ELIQUIS.xml:S1:14010:1	O
0.6	ELIQUIS.xml:S1:14011:3	O
)	ELIQUIS.xml:S1:14014:1	O
49	ELIQUIS.xml:S1:14033:2	O
(	ELIQUIS.xml:S1:14036:1	O
1.8	ELIQUIS.xml:S1:14037:3	O
)	ELIQUIS.xml:S1:14040:1	O
0.31	ELIQUIS.xml:S1:14058:4	O
(	ELIQUIS.xml:S1:14063:1	O
0.17	ELIQUIS.xml:S1:14064:4	O
,	ELIQUIS.xml:S1:14068:1	O
0.55	ELIQUIS.xml:S1:14070:4	O
)	ELIQUIS.xml:S1:14074:1	O
p	ELIQUIS.xml:S1:14075:1	O
0.0001	ELIQUIS.xml:S1:14077:6	O

CRNM	ELIQUIS.xml:S1:14090:4	B-AdverseReaction
103	ELIQUIS.xml:S1:14121:3	O
(	ELIQUIS.xml:S1:14125:1	O
3.9	ELIQUIS.xml:S1:14126:3	O
)	ELIQUIS.xml:S1:14129:1	O
215	ELIQUIS.xml:S1:14147:3	O
(	ELIQUIS.xml:S1:14151:1	O
8.0	ELIQUIS.xml:S1:14152:3	O
)	ELIQUIS.xml:S1:14155:1	O

Major	ELIQUIS.xml:S1:14202:5	O
CRNM	ELIQUIS.xml:S1:14210:4	B-AdverseReaction
115	ELIQUIS.xml:S1:14233:3	O
(	ELIQUIS.xml:S1:14237:1	O
4.3	ELIQUIS.xml:S1:14238:3	O
)	ELIQUIS.xml:S1:14241:1	O
261	ELIQUIS.xml:S1:14259:3	O
(	ELIQUIS.xml:S1:14263:1	O
9.7	ELIQUIS.xml:S1:14264:3	O
)	ELIQUIS.xml:S1:14267:1	O

Minor	ELIQUIS.xml:S1:14314:5	O
313	ELIQUIS.xml:S1:14345:3	O
(	ELIQUIS.xml:S1:14349:1	O
11.7	ELIQUIS.xml:S1:14350:4	O
)	ELIQUIS.xml:S1:14354:1	O
505	ELIQUIS.xml:S1:14371:3	O
(	ELIQUIS.xml:S1:14375:1	O
18.8	ELIQUIS.xml:S1:14376:4	O
)	ELIQUIS.xml:S1:14380:1	O

All	ELIQUIS.xml:S1:14426:3	O
402	ELIQUIS.xml:S1:14457:3	O
(	ELIQUIS.xml:S1:14461:1	O
15.0	ELIQUIS.xml:S1:14462:4	O
)	ELIQUIS.xml:S1:14466:1	O
676	ELIQUIS.xml:S1:14483:3	O
(	ELIQUIS.xml:S1:14487:1	O
25.1	ELIQUIS.xml:S1:14488:4	O
)	ELIQUIS.xml:S1:14492:1	O

Adverse	ELIQUIS.xml:S1:14546:7	O
reactions	ELIQUIS.xml:S1:14554:9	O
occurring	ELIQUIS.xml:S1:14564:9	O
in	ELIQUIS.xml:S1:14574:2	O
1%	ELIQUIS.xml:S1:14579:2	O
of	ELIQUIS.xml:S1:14582:2	O
patients	ELIQUIS.xml:S1:14585:8	O
in	ELIQUIS.xml:S1:14594:2	O
the	ELIQUIS.xml:S1:14597:3	O
AMPLIFY	ELIQUIS.xml:S1:14601:7	O
study	ELIQUIS.xml:S1:14609:5	O
are	ELIQUIS.xml:S1:14615:3	O
listed	ELIQUIS.xml:S1:14619:6	O
in	ELIQUIS.xml:S1:14626:2	O
Table	ELIQUIS.xml:S1:14629:5	O
6	ELIQUIS.xml:S1:14635:1	O
.	ELIQUIS.xml:S1:14636:1	O

Table	ELIQUIS.xml:S1:14642:5	O

6	ELIQUIS.xml:S1:14648:1	O
:	ELIQUIS.xml:S1:14649:1	O
Adverse	ELIQUIS.xml:S1:14655:7	O
Reactions	ELIQUIS.xml:S1:14663:9	O
Occurring	ELIQUIS.xml:S1:14673:9	O
in	ELIQUIS.xml:S1:14683:2	O
1%	ELIQUIS.xml:S1:14688:2	O
of	ELIQUIS.xml:S1:14691:2	O
Patients	ELIQUIS.xml:S1:14694:8	O
Treated	ELIQUIS.xml:S1:14703:7	O
for	ELIQUIS.xml:S1:14711:3	O
DVT	ELIQUIS.xml:S1:14715:3	O
and	ELIQUIS.xml:S1:14719:3	O
PE	ELIQUIS.xml:S1:14723:2	O
in	ELIQUIS.xml:S1:14726:2	O
the	ELIQUIS.xml:S1:14729:3	O
AMPLIFY	ELIQUIS.xml:S1:14733:7	O
Study	ELIQUIS.xml:S1:14741:5	O

ELIQUISN	ELIQUIS.xml:S1:14784:8	O
2676	ELIQUIS.xml:S1:14793:4	O
n	ELIQUIS.xml:S1:14797:1	O
(	ELIQUIS.xml:S1:14799:1	O
)	ELIQUIS.xml:S1:14801:1	O
Enoxaparin	ELIQUIS.xml:S1:14819:10	O
WarfarinN	ELIQUIS.xml:S1:14830:9	O
2689	ELIQUIS.xml:S1:14840:4	O
n	ELIQUIS.xml:S1:14844:1	O
(	ELIQUIS.xml:S1:14846:1	O
)	ELIQUIS.xml:S1:14848:1	O

Epistaxis	ELIQUIS.xml:S1:14861:9	B-AdverseReaction

77	ELIQUIS.xml:S1:14896:2	O
(	ELIQUIS.xml:S1:14899:1	O
2.9	ELIQUIS.xml:S1:14900:3	O
)	ELIQUIS.xml:S1:14903:1	O
146	ELIQUIS.xml:S1:14931:3	O
(	ELIQUIS.xml:S1:14935:1	O
5.4	ELIQUIS.xml:S1:14936:3	O
)	ELIQUIS.xml:S1:14939:1	O

Contusion	ELIQUIS.xml:S1:14969:9	B-AdverseReaction
49	ELIQUIS.xml:S1:15004:2	O
(	ELIQUIS.xml:S1:15007:1	O
1.8	ELIQUIS.xml:S1:15008:3	O
)	ELIQUIS.xml:S1:15011:1	O
97	ELIQUIS.xml:S1:15039:2	O
(	ELIQUIS.xml:S1:15042:1	O
3.6	ELIQUIS.xml:S1:15043:3	O
)	ELIQUIS.xml:S1:15046:1	O

Hematuria	ELIQUIS.xml:S1:15077:9	B-AdverseReaction
46	ELIQUIS.xml:S1:15112:2	O
(	ELIQUIS.xml:S1:15115:1	O
1.7	ELIQUIS.xml:S1:15116:3	O
)	ELIQUIS.xml:S1:15119:1	O
102	ELIQUIS.xml:S1:15147:3	O
(	ELIQUIS.xml:S1:15151:1	O
3.8	ELIQUIS.xml:S1:15152:3	O
)	ELIQUIS.xml:S1:15155:1	O

Menorrhagia	ELIQUIS.xml:S1:15185:11	B-AdverseReaction
38	ELIQUIS.xml:S1:15220:2	O
(	ELIQUIS.xml:S1:15223:1	O
1.4	ELIQUIS.xml:S1:15224:3	O
)	ELIQUIS.xml:S1:15227:1	O
30	ELIQUIS.xml:S1:15255:2	O
(	ELIQUIS.xml:S1:15258:1	O
1.1	ELIQUIS.xml:S1:15259:3	O
)	ELIQUIS.xml:S1:15262:1	O

Hematoma	ELIQUIS.xml:S1:15293:8	B-AdverseReaction
35	ELIQUIS.xml:S1:15328:2	O
(	ELIQUIS.xml:S1:15331:1	O
1.3	ELIQUIS.xml:S1:15332:3	O
)	ELIQUIS.xml:S1:15335:1	O
76	ELIQUIS.xml:S1:15363:2	O
(	ELIQUIS.xml:S1:15366:1	O
2.8	ELIQUIS.xml:S1:15367:3	O
)	ELIQUIS.xml:S1:15370:1	O

Hemoptysis	ELIQUIS.xml:S1:15401:10	B-AdverseReaction
32	ELIQUIS.xml:S1:15436:2	O
(	ELIQUIS.xml:S1:15439:1	O
1.2	ELIQUIS.xml:S1:15440:3	O
)	ELIQUIS.xml:S1:15443:1	O
31	ELIQUIS.xml:S1:15471:2	O
(	ELIQUIS.xml:S1:15474:1	O
1.2	ELIQUIS.xml:S1:15475:3	O
)	ELIQUIS.xml:S1:15478:1	O

Rectal	ELIQUIS.xml:S1:15509:6	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:15516:10	I-AdverseReaction
26	ELIQUIS.xml:S1:15544:2	O
(	ELIQUIS.xml:S1:15547:1	O
1.0	ELIQUIS.xml:S1:15548:3	O
)	ELIQUIS.xml:S1:15551:1	O
39	ELIQUIS.xml:S1:15579:2	O
(	ELIQUIS.xml:S1:15582:1	O
1.5	ELIQUIS.xml:S1:15583:3	O
)	ELIQUIS.xml:S1:15586:1	O

Gingival	ELIQUIS.xml:S1:15617:8	B-AdverseReaction
bleeding	ELIQUIS.xml:S1:15626:8	I-AdverseReaction
26	ELIQUIS.xml:S1:15652:2	O
(	ELIQUIS.xml:S1:15655:1	O
1.0	ELIQUIS.xml:S1:15656:3	O
)	ELIQUIS.xml:S1:15659:1	O
50	ELIQUIS.xml:S1:15687:2	O
(	ELIQUIS.xml:S1:15690:1	O
1.9	ELIQUIS.xml:S1:15691:3	O
)	ELIQUIS.xml:S1:15694:1	O

AMPLIFY	ELIQUIS.xml:S1:15734:7	O
-	ELIQUIS.xml:S1:15741:1	O
EXT	ELIQUIS.xml:S1:15742:3	O
Study	ELIQUIS.xml:S1:15746:5	O

The	ELIQUIS.xml:S1:15755:3	O
mean	ELIQUIS.xml:S1:15759:4	O
duration	ELIQUIS.xml:S1:15764:8	O
of	ELIQUIS.xml:S1:15773:2	O
exposure	ELIQUIS.xml:S1:15776:8	O
to	ELIQUIS.xml:S1:15785:2	O
ELIQUIS	ELIQUIS.xml:S1:15788:7	O
was	ELIQUIS.xml:S1:15796:3	O
approximately	ELIQUIS.xml:S1:15800:13	O
330	ELIQUIS.xml:S1:15814:3	O
days	ELIQUIS.xml:S1:15818:4	O
and	ELIQUIS.xml:S1:15823:3	O
to	ELIQUIS.xml:S1:15827:2	O
placebo	ELIQUIS.xml:S1:15830:7	O
was	ELIQUIS.xml:S1:15838:3	O
312	ELIQUIS.xml:S1:15842:3	O
days	ELIQUIS.xml:S1:15846:4	O
in	ELIQUIS.xml:S1:15851:2	O
the	ELIQUIS.xml:S1:15854:3	O
AMPLIFY	ELIQUIS.xml:S1:15858:7	O
-	ELIQUIS.xml:S1:15865:1	O
EXT	ELIQUIS.xml:S1:15866:3	O
study	ELIQUIS.xml:S1:15870:5	O
.	ELIQUIS.xml:S1:15875:1	O

Adverse	ELIQUIS.xml:S1:15877:7	O
reactions	ELIQUIS.xml:S1:15885:9	O
related	ELIQUIS.xml:S1:15895:7	O
to	ELIQUIS.xml:S1:15903:2	O
bleeding	ELIQUIS.xml:S1:15906:8	B-AdverseReaction
occurred	ELIQUIS.xml:S1:15915:8	O
in	ELIQUIS.xml:S1:15924:2	O
219	ELIQUIS.xml:S1:15927:3	O
(	ELIQUIS.xml:S1:15931:1	O
13.3%	ELIQUIS.xml:S1:15932:5	O
)	ELIQUIS.xml:S1:15937:1	O
ELIQUIS	ELIQUIS.xml:S1:15939:7	O
-	ELIQUIS.xml:S1:15946:1	O
treated	ELIQUIS.xml:S1:15947:7	O
patients	ELIQUIS.xml:S1:15955:8	O
compared	ELIQUIS.xml:S1:15964:8	O
to	ELIQUIS.xml:S1:15973:2	O
72	ELIQUIS.xml:S1:15976:2	O
(	ELIQUIS.xml:S1:15979:1	O
8.7%	ELIQUIS.xml:S1:15980:4	O
)	ELIQUIS.xml:S1:15984:1	O
placebo	ELIQUIS.xml:S1:15986:7	O
-	ELIQUIS.xml:S1:15993:1	O
treated	ELIQUIS.xml:S1:15994:7	O
patients	ELIQUIS.xml:S1:16002:8	O
.	ELIQUIS.xml:S1:16010:1	O

The	ELIQUIS.xml:S1:16012:3	O
discontinuation	ELIQUIS.xml:S1:16016:15	O
rate	ELIQUIS.xml:S1:16032:4	O
due	ELIQUIS.xml:S1:16037:3	O
to	ELIQUIS.xml:S1:16041:2	O
bleeding	ELIQUIS.xml:S1:16044:8	B-AdverseReaction
events	ELIQUIS.xml:S1:16053:6	O
was	ELIQUIS.xml:S1:16060:3	O
approximately	ELIQUIS.xml:S1:16064:13	O
1%	ELIQUIS.xml:S1:16078:2	O
in	ELIQUIS.xml:S1:16081:2	O
the	ELIQUIS.xml:S1:16084:3	O
ELIQUIS	ELIQUIS.xml:S1:16088:7	O
-	ELIQUIS.xml:S1:16095:1	O
treated	ELIQUIS.xml:S1:16096:7	O
patients	ELIQUIS.xml:S1:16104:8	O
compared	ELIQUIS.xml:S1:16113:8	O
to	ELIQUIS.xml:S1:16122:2	O
0.4%	ELIQUIS.xml:S1:16125:4	O
in	ELIQUIS.xml:S1:16130:2	O
those	ELIQUIS.xml:S1:16133:5	O
patients	ELIQUIS.xml:S1:16139:8	O
in	ELIQUIS.xml:S1:16148:2	O
the	ELIQUIS.xml:S1:16151:3	O
placebo	ELIQUIS.xml:S1:16155:7	O
group	ELIQUIS.xml:S1:16163:5	O
in	ELIQUIS.xml:S1:16169:2	O
the	ELIQUIS.xml:S1:16172:3	O
AMPLIFY	ELIQUIS.xml:S1:16176:7	O
-	ELIQUIS.xml:S1:16183:1	O
EXT	ELIQUIS.xml:S1:16184:3	O
study	ELIQUIS.xml:S1:16188:5	O
.	ELIQUIS.xml:S1:16193:1	O

Bleeding	ELIQUIS.xml:S1:16199:8	B-AdverseReaction
results	ELIQUIS.xml:S1:16208:7	O
from	ELIQUIS.xml:S1:16216:4	O
the	ELIQUIS.xml:S1:16221:3	O
AMPLIFY	ELIQUIS.xml:S1:16225:7	O
-	ELIQUIS.xml:S1:16232:1	O
EXT	ELIQUIS.xml:S1:16233:3	O
study	ELIQUIS.xml:S1:16237:5	O
are	ELIQUIS.xml:S1:16243:3	O
summarized	ELIQUIS.xml:S1:16247:10	O
in	ELIQUIS.xml:S1:16258:2	O
Table	ELIQUIS.xml:S1:16261:5	O
7	ELIQUIS.xml:S1:16267:1	O
.	ELIQUIS.xml:S1:16268:1	O

Table	ELIQUIS.xml:S1:16274:5	O
7	ELIQUIS.xml:S1:16280:1	O
:	ELIQUIS.xml:S1:16281:1	O
Bleeding	ELIQUIS.xml:S1:16287:8	B-AdverseReaction
Results	ELIQUIS.xml:S1:16296:7	O
in	ELIQUIS.xml:S1:16304:2	O
the	ELIQUIS.xml:S1:16307:3	O
AMPLIFY	ELIQUIS.xml:S1:16311:7	O
-	ELIQUIS.xml:S1:16318:1	O
EXT	ELIQUIS.xml:S1:16319:3	O
Study	ELIQUIS.xml:S1:16323:5	O

ELIQUIS	ELIQUIS.xml:S1:16361:7	O
2.5	ELIQUIS.xml:S1:16369:3	O
mg	ELIQUIS.xml:S1:16373:2	O
bidN	ELIQUIS.xml:S1:16376:4	O
840	ELIQUIS.xml:S1:16381:3	O
n	ELIQUIS.xml:S1:16384:1	O
(	ELIQUIS.xml:S1:16386:1	O
)	ELIQUIS.xml:S1:16388:1	O
ELIQUIS	ELIQUIS.xml:S1:16391:7	O
5	ELIQUIS.xml:S1:16399:1	O
mg	ELIQUIS.xml:S1:16401:2	O
bidN	ELIQUIS.xml:S1:16404:4	O
811	ELIQUIS.xml:S1:16409:3	O
n	ELIQUIS.xml:S1:16412:1	O
(	ELIQUIS.xml:S1:16414:1	O
)	ELIQUIS.xml:S1:16416:1	O
PlaceboN	ELIQUIS.xml:S1:16419:8	O
826	ELIQUIS.xml:S1:16428:3	O
n	ELIQUIS.xml:S1:16431:1	O
(	ELIQUIS.xml:S1:16433:1	O
)	ELIQUIS.xml:S1:16435:1	O

CRNM	ELIQUIS.xml:S1:16455:4	B-AdverseReaction

clinically	ELIQUIS.xml:S1:16462:10	B-AdverseReaction
relevant	ELIQUIS.xml:S1:16473:8	I-AdverseReaction
nonmajor	ELIQUIS.xml:S1:16482:8	I-AdverseReaction
bleeding	ELIQUIS.xml:S1:16491:8	I-AdverseReaction
.	ELIQUIS.xml:S1:16499:1	O
Events	ELIQUIS.xml:S1:16500:6	O
associated	ELIQUIS.xml:S1:16507:10	O
with	ELIQUIS.xml:S1:16518:4	O
each	ELIQUIS.xml:S1:16523:4	O
endpoint	ELIQUIS.xml:S1:16528:8	O
were	ELIQUIS.xml:S1:16537:4	O
counted	ELIQUIS.xml:S1:16542:7	O
once	ELIQUIS.xml:S1:16550:4	O
per	ELIQUIS.xml:S1:16555:3	O
subject	ELIQUIS.xml:S1:16559:7	O
,	ELIQUIS.xml:S1:16566:1	O
but	ELIQUIS.xml:S1:16568:3	O
subjects	ELIQUIS.xml:S1:16572:8	O
may	ELIQUIS.xml:S1:16581:3	O
have	ELIQUIS.xml:S1:16585:4	O
contributed	ELIQUIS.xml:S1:16590:11	O
events	ELIQUIS.xml:S1:16602:6	O
to	ELIQUIS.xml:S1:16609:2	O
multiple	ELIQUIS.xml:S1:16612:8	O
endpoints	ELIQUIS.xml:S1:16621:9	O
.	ELIQUIS.xml:S1:16630:1	O

Major	ELIQUIS.xml:S1:16640:5	O

2	ELIQUIS.xml:S1:16670:1	O
(	ELIQUIS.xml:S1:16672:1	O
0.2	ELIQUIS.xml:S1:16673:3	O
)	ELIQUIS.xml:S1:16676:1	O
1	ELIQUIS.xml:S1:16697:1	O
(	ELIQUIS.xml:S1:16699:1	O
0.1	ELIQUIS.xml:S1:16700:3	O
)	ELIQUIS.xml:S1:16703:1	O
4	ELIQUIS.xml:S1:16723:1	O
(	ELIQUIS.xml:S1:16725:1	O
0.5	ELIQUIS.xml:S1:16726:3	O
)	ELIQUIS.xml:S1:16729:1	O

CRNM	ELIQUIS.xml:S1:16752:4	B-AdverseReaction
25	ELIQUIS.xml:S1:16782:2	O
(	ELIQUIS.xml:S1:16785:1	O
3.0	ELIQUIS.xml:S1:16786:3	O
)	ELIQUIS.xml:S1:16789:1	O
34	ELIQUIS.xml:S1:16809:2	O
(	ELIQUIS.xml:S1:16812:1	O
4.2	ELIQUIS.xml:S1:16813:3	O
)	ELIQUIS.xml:S1:16816:1	O
19	ELIQUIS.xml:S1:16835:2	O
(	ELIQUIS.xml:S1:16838:1	O
2.3	ELIQUIS.xml:S1:16839:3	O
)	ELIQUIS.xml:S1:16842:1	O

Major	ELIQUIS.xml:S1:16864:5	O
CRNM	ELIQUIS.xml:S1:16872:4	B-AdverseReaction
27	ELIQUIS.xml:S1:16894:2	O
(	ELIQUIS.xml:S1:16897:1	O
3.2	ELIQUIS.xml:S1:16898:3	O
)	ELIQUIS.xml:S1:16901:1	O
35	ELIQUIS.xml:S1:16921:2	O
(	ELIQUIS.xml:S1:16924:1	O
4.3	ELIQUIS.xml:S1:16925:3	O
)	ELIQUIS.xml:S1:16928:1	O
22	ELIQUIS.xml:S1:16947:2	O
(	ELIQUIS.xml:S1:16950:1	O
2.7	ELIQUIS.xml:S1:16951:3	O
)	ELIQUIS.xml:S1:16954:1	O

Minor	ELIQUIS.xml:S1:16976:5	O
75	ELIQUIS.xml:S1:17006:2	O
(	ELIQUIS.xml:S1:17009:1	O
8.9	ELIQUIS.xml:S1:17010:3	O
)	ELIQUIS.xml:S1:17013:1	O
98	ELIQUIS.xml:S1:17033:2	O
(	ELIQUIS.xml:S1:17036:1	O
12.1	ELIQUIS.xml:S1:17037:4	O
)	ELIQUIS.xml:S1:17041:1	O
58	ELIQUIS.xml:S1:17059:2	O
(	ELIQUIS.xml:S1:17062:1	O
7.0	ELIQUIS.xml:S1:17063:3	O
)	ELIQUIS.xml:S1:17066:1	O

All	ELIQUIS.xml:S1:17088:3	O
94	ELIQUIS.xml:S1:17118:2	O
(	ELIQUIS.xml:S1:17121:1	O
11.2	ELIQUIS.xml:S1:17122:4	O
)	ELIQUIS.xml:S1:17126:1	O
121	ELIQUIS.xml:S1:17145:3	O
(	ELIQUIS.xml:S1:17149:1	O
14.9	ELIQUIS.xml:S1:17150:4	O
)	ELIQUIS.xml:S1:17154:1	O
74	ELIQUIS.xml:S1:17171:2	O
(	ELIQUIS.xml:S1:17174:1	O
9.0	ELIQUIS.xml:S1:17175:3	O
)	ELIQUIS.xml:S1:17178:1	O

Adverse	ELIQUIS.xml:S1:17208:7	O
reactions	ELIQUIS.xml:S1:17216:9	O
occurring	ELIQUIS.xml:S1:17226:9	O
in	ELIQUIS.xml:S1:17236:2	O
1%	ELIQUIS.xml:S1:17241:2	O
of	ELIQUIS.xml:S1:17244:2	O
patients	ELIQUIS.xml:S1:17247:8	O
in	ELIQUIS.xml:S1:17256:2	O
the	ELIQUIS.xml:S1:17259:3	O
AMPLIFY	ELIQUIS.xml:S1:17263:7	O
-	ELIQUIS.xml:S1:17270:1	O
EXT	ELIQUIS.xml:S1:17271:3	O
study	ELIQUIS.xml:S1:17275:5	O
are	ELIQUIS.xml:S1:17281:3	O
listed	ELIQUIS.xml:S1:17285:6	O
in	ELIQUIS.xml:S1:17292:2	O
Table	ELIQUIS.xml:S1:17295:5	O
8	ELIQUIS.xml:S1:17301:1	O
.	ELIQUIS.xml:S1:17302:1	O

Table	ELIQUIS.xml:S1:17308:5	O

8	ELIQUIS.xml:S1:17314:1	O
:	ELIQUIS.xml:S1:17315:1	O
Adverse	ELIQUIS.xml:S1:17321:7	O
Reactions	ELIQUIS.xml:S1:17329:9	O
Occurring	ELIQUIS.xml:S1:17339:9	O
in	ELIQUIS.xml:S1:17349:2	O
1%	ELIQUIS.xml:S1:17354:2	O
of	ELIQUIS.xml:S1:17357:2	O
Patients	ELIQUIS.xml:S1:17360:8	O
Undergoing	ELIQUIS.xml:S1:17369:10	O
Extended	ELIQUIS.xml:S1:17380:8	O
Treatment	ELIQUIS.xml:S1:17389:9	O
for	ELIQUIS.xml:S1:17399:3	O
DVT	ELIQUIS.xml:S1:17403:3	O
and	ELIQUIS.xml:S1:17407:3	O
PE	ELIQUIS.xml:S1:17411:2	O
in	ELIQUIS.xml:S1:17414:2	O
the	ELIQUIS.xml:S1:17417:3	O
AMPLIFY	ELIQUIS.xml:S1:17421:7	O
-	ELIQUIS.xml:S1:17428:1	O
EXT	ELIQUIS.xml:S1:17429:3	O
Study	ELIQUIS.xml:S1:17433:5	O

ELIQUIS	ELIQUIS.xml:S1:17471:7	O
2.5	ELIQUIS.xml:S1:17479:3	O
mg	ELIQUIS.xml:S1:17483:2	O
bidN	ELIQUIS.xml:S1:17486:4	O
840	ELIQUIS.xml:S1:17491:3	O
n	ELIQUIS.xml:S1:17494:1	O
(	ELIQUIS.xml:S1:17496:1	O
)	ELIQUIS.xml:S1:17498:1	O
ELIQUIS	ELIQUIS.xml:S1:17501:7	O
5	ELIQUIS.xml:S1:17509:1	O
mg	ELIQUIS.xml:S1:17511:2	O
bidN	ELIQUIS.xml:S1:17514:4	O
811	ELIQUIS.xml:S1:17519:3	O
n	ELIQUIS.xml:S1:17522:1	O
(	ELIQUIS.xml:S1:17524:1	O
)	ELIQUIS.xml:S1:17526:1	O
PlaceboN	ELIQUIS.xml:S1:17529:8	O
826	ELIQUIS.xml:S1:17538:3	O
n	ELIQUIS.xml:S1:17541:1	O
(	ELIQUIS.xml:S1:17543:1	O
)	ELIQUIS.xml:S1:17545:1	O

Epistaxis	ELIQUIS.xml:S1:17562:9	B-AdverseReaction

13	ELIQUIS.xml:S1:17592:2	O
(	ELIQUIS.xml:S1:17595:1	O
1.5	ELIQUIS.xml:S1:17596:3	O
)	ELIQUIS.xml:S1:17599:1	O
29	ELIQUIS.xml:S1:17619:2	O
(	ELIQUIS.xml:S1:17622:1	O
3.6	ELIQUIS.xml:S1:17623:3	O
)	ELIQUIS.xml:S1:17626:1	O
9	ELIQUIS.xml:S1:17645:1	O
(	ELIQUIS.xml:S1:17647:1	O
1.1	ELIQUIS.xml:S1:17648:3	O
)	ELIQUIS.xml:S1:17651:1	O

Hematuria	ELIQUIS.xml:S1:17674:9	B-AdverseReaction
12	ELIQUIS.xml:S1:17704:2	O
(	ELIQUIS.xml:S1:17707:1	O
1.4	ELIQUIS.xml:S1:17708:3	O
)	ELIQUIS.xml:S1:17711:1	O
17	ELIQUIS.xml:S1:17731:2	O
(	ELIQUIS.xml:S1:17734:1	O
2.1	ELIQUIS.xml:S1:17735:3	O
)	ELIQUIS.xml:S1:17738:1	O
9	ELIQUIS.xml:S1:17757:1	O
(	ELIQUIS.xml:S1:17759:1	O
1.1	ELIQUIS.xml:S1:17760:3	O
)	ELIQUIS.xml:S1:17763:1	O

Hematoma	ELIQUIS.xml:S1:17786:8	B-AdverseReaction
13	ELIQUIS.xml:S1:17816:2	O
(	ELIQUIS.xml:S1:17819:1	O
1.5	ELIQUIS.xml:S1:17820:3	O
)	ELIQUIS.xml:S1:17823:1	O
16	ELIQUIS.xml:S1:17843:2	O
(	ELIQUIS.xml:S1:17846:1	O
2.0	ELIQUIS.xml:S1:17847:3	O
)	ELIQUIS.xml:S1:17850:1	O
10	ELIQUIS.xml:S1:17869:2	O
(	ELIQUIS.xml:S1:17872:1	O
1.2	ELIQUIS.xml:S1:17873:3	O
)	ELIQUIS.xml:S1:17876:1	O

Contusion	ELIQUIS.xml:S1:17898:9	B-AdverseReaction
18	ELIQUIS.xml:S1:17928:2	O
(	ELIQUIS.xml:S1:17931:1	O
2.1	ELIQUIS.xml:S1:17932:3	O
)	ELIQUIS.xml:S1:17935:1	O
18	ELIQUIS.xml:S1:17955:2	O
(	ELIQUIS.xml:S1:17958:1	O
2.2	ELIQUIS.xml:S1:17959:3	O
)	ELIQUIS.xml:S1:17962:1	O
18	ELIQUIS.xml:S1:17981:2	O
(	ELIQUIS.xml:S1:17984:1	O
2.2	ELIQUIS.xml:S1:17985:3	O
)	ELIQUIS.xml:S1:17988:1	O

Gingival	ELIQUIS.xml:S1:18010:8	B-AdverseReaction
bleeding	ELIQUIS.xml:S1:18019:8	I-AdverseReaction
12	ELIQUIS.xml:S1:18040:2	O
(	ELIQUIS.xml:S1:18043:1	O
1.4	ELIQUIS.xml:S1:18044:3	O
)	ELIQUIS.xml:S1:18047:1	O
9	ELIQUIS.xml:S1:18067:1	O
(	ELIQUIS.xml:S1:18069:1	O
1.1	ELIQUIS.xml:S1:18070:3	O
)	ELIQUIS.xml:S1:18073:1	O
3	ELIQUIS.xml:S1:18093:1	O
(	ELIQUIS.xml:S1:18095:1	O
0.4	ELIQUIS.xml:S1:18096:3	O
)	ELIQUIS.xml:S1:18099:1	O

Other	ELIQUIS.xml:S1:18132:5	O
Adverse	ELIQUIS.xml:S1:18138:7	O
Reactions	ELIQUIS.xml:S1:18146:9	O

Less	ELIQUIS.xml:S1:18159:4	O
common	ELIQUIS.xml:S1:18164:6	O
adverse	ELIQUIS.xml:S1:18171:7	O
reactions	ELIQUIS.xml:S1:18179:9	O
in	ELIQUIS.xml:S1:18189:2	O
ELIQUIS	ELIQUIS.xml:S1:18192:7	O
-	ELIQUIS.xml:S1:18199:1	O
treated	ELIQUIS.xml:S1:18200:7	O
patients	ELIQUIS.xml:S1:18208:8	O
in	ELIQUIS.xml:S1:18217:2	O
the	ELIQUIS.xml:S1:18220:3	O
AMPLIFY	ELIQUIS.xml:S1:18224:7	O
or	ELIQUIS.xml:S1:18232:2	O
AMPLIFY	ELIQUIS.xml:S1:18235:7	O
-	ELIQUIS.xml:S1:18242:1	O
EXT	ELIQUIS.xml:S1:18243:3	O
studies	ELIQUIS.xml:S1:18247:7	O
occurring	ELIQUIS.xml:S1:18255:9	O
at	ELIQUIS.xml:S1:18265:2	O
a	ELIQUIS.xml:S1:18268:1	O
frequency	ELIQUIS.xml:S1:18270:9	O
of	ELIQUIS.xml:S1:18280:2	O
0.1%	ELIQUIS.xml:S1:18285:4	O
to	ELIQUIS.xml:S1:18290:2	O
1%	ELIQUIS.xml:S1:18294:2	O
:	ELIQUIS.xml:S1:18296:1	O

Blood	ELIQUIS.xml:S1:18304:5	O
and	ELIQUIS.xml:S1:18310:3	O
lymphatic	ELIQUIS.xml:S1:18314:9	O
system	ELIQUIS.xml:S1:18324:6	O
disorders	ELIQUIS.xml:S1:18331:9	O
:	ELIQUIS.xml:S1:18340:1	O
hemorrhagic	ELIQUIS.xml:S1:18343:11	B-AdverseReaction
anemia	ELIQUIS.xml:S1:18355:6	I-AdverseReaction

Gastrointestinal	ELIQUIS.xml:S1:18368:16	O
disorders	ELIQUIS.xml:S1:18385:9	O
:	ELIQUIS.xml:S1:18394:1	O
hematochezia	ELIQUIS.xml:S1:18397:12	B-AdverseReaction
,	ELIQUIS.xml:S1:18409:1	O
hemorrhoidal	ELIQUIS.xml:S1:18411:12	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:18424:10	I-AdverseReaction
,	ELIQUIS.xml:S1:18434:1	O
gastrointestinal	ELIQUIS.xml:S1:18436:16	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:18453:10	I-AdverseReaction
,	ELIQUIS.xml:S1:18463:1	O
hematemesis	ELIQUIS.xml:S1:18465:11	B-AdverseReaction
,	ELIQUIS.xml:S1:18476:1	O
melena	ELIQUIS.xml:S1:18478:6	B-AdverseReaction
,	ELIQUIS.xml:S1:18484:1	O
anal	ELIQUIS.xml:S1:18486:4	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:18491:10	I-AdverseReaction

Injury	ELIQUIS.xml:S1:18508:6	O
,	ELIQUIS.xml:S1:18514:1	O
poisoning	ELIQUIS.xml:S1:18516:9	O
,	ELIQUIS.xml:S1:18525:1	O
and	ELIQUIS.xml:S1:18527:3	O
procedural	ELIQUIS.xml:S1:18531:10	O
complications	ELIQUIS.xml:S1:18542:13	O
:	ELIQUIS.xml:S1:18555:1	O
wound	ELIQUIS.xml:S1:18558:5	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:18564:10	I-AdverseReaction
,	ELIQUIS.xml:S1:18574:1	O
postprocedural	ELIQUIS.xml:S1:18576:14	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:18591:10	I-AdverseReaction
,	ELIQUIS.xml:S1:18601:1	O
traumatic	ELIQUIS.xml:S1:18603:9	B-AdverseReaction
hematoma	ELIQUIS.xml:S1:18613:8	I-AdverseReaction
,	ELIQUIS.xml:S1:18621:1	O
periorbital	ELIQUIS.xml:S1:18623:11	B-AdverseReaction
hematoma	ELIQUIS.xml:S1:18635:8	I-AdverseReaction

Musculoskeletal	ELIQUIS.xml:S1:18650:15	O
and	ELIQUIS.xml:S1:18666:3	O
connective	ELIQUIS.xml:S1:18670:10	O
tissue	ELIQUIS.xml:S1:18681:6	O
disorders	ELIQUIS.xml:S1:18688:9	O
:	ELIQUIS.xml:S1:18697:1	O
muscle	ELIQUIS.xml:S1:18700:6	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:18707:10	I-AdverseReaction

Reproductive	ELIQUIS.xml:S1:18724:12	O
system	ELIQUIS.xml:S1:18737:6	O
and	ELIQUIS.xml:S1:18744:3	O
breast	ELIQUIS.xml:S1:18748:6	O
disorders	ELIQUIS.xml:S1:18755:9	O
:	ELIQUIS.xml:S1:18764:1	O
vaginal	ELIQUIS.xml:S1:18767:7	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:18775:10	I-AdverseReaction
,	ELIQUIS.xml:S1:18785:1	O
metrorrhagia	ELIQUIS.xml:S1:18787:12	B-AdverseReaction
,	ELIQUIS.xml:S1:18799:1	O
menometrorrhagia	ELIQUIS.xml:S1:18801:16	B-AdverseReaction
,	ELIQUIS.xml:S1:18817:1	O
genital	ELIQUIS.xml:S1:18819:7	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:18827:10	I-AdverseReaction

Vascular	ELIQUIS.xml:S1:18844:8	O
disorders	ELIQUIS.xml:S1:18853:9	O
:	ELIQUIS.xml:S1:18864:1	O
hemorrhage	ELIQUIS.xml:S1:18866:10	B-AdverseReaction

Skin	ELIQUIS.xml:S1:18883:4	O
and	ELIQUIS.xml:S1:18888:3	O
subcutaneous	ELIQUIS.xml:S1:18892:12	O
tissue	ELIQUIS.xml:S1:18905:6	O
disorders	ELIQUIS.xml:S1:18912:9	O
:	ELIQUIS.xml:S1:18921:1	O
ecchymosis	ELIQUIS.xml:S1:18924:10	B-AdverseReaction
,	ELIQUIS.xml:S1:18934:1	O
skin	ELIQUIS.xml:S1:18936:4	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:18941:10	I-AdverseReaction
,	ELIQUIS.xml:S1:18951:1	O
petechiae	ELIQUIS.xml:S1:18953:9	B-AdverseReaction

Eye	ELIQUIS.xml:S1:18969:3	O
disorders	ELIQUIS.xml:S1:18973:9	O
:	ELIQUIS.xml:S1:18982:1	O
conjunctival	ELIQUIS.xml:S1:18985:12	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:18998:10	I-AdverseReaction
,	ELIQUIS.xml:S1:19008:1	O
retinal	ELIQUIS.xml:S1:19010:7	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:19018:10	I-AdverseReaction
,	ELIQUIS.xml:S1:19028:1	O
eye	ELIQUIS.xml:S1:19030:3	B-AdverseReaction
hemorrhage	ELIQUIS.xml:S1:19034:10	I-AdverseReaction

Investigations	ELIQUIS.xml:S1:19051:14	O
:	ELIQUIS.xml:S1:19065:1	O
blood	ELIQUIS.xml:S1:19068:5	B-AdverseReaction
urine	ELIQUIS.xml:S1:19074:5	I-AdverseReaction
present	ELIQUIS.xml:S1:19080:7	I-AdverseReaction
,	ELIQUIS.xml:S1:19087:1	O
occult	ELIQUIS.xml:S1:19089:6	B-AdverseReaction
blood	ELIQUIS.xml:S1:19096:5	I-AdverseReaction
positive	ELIQUIS.xml:S1:19102:8	I-AdverseReaction
,	ELIQUIS.xml:S1:19110:1	O
occult	ELIQUIS.xml:S1:19112:6	B-AdverseReaction
blood	ELIQUIS.xml:S1:19119:5	I-AdverseReaction
,	ELIQUIS.xml:S1:19124:1	O
red	ELIQUIS.xml:S1:19126:3	B-AdverseReaction
blood	ELIQUIS.xml:S1:19130:5	I-AdverseReaction
cells	ELIQUIS.xml:S1:19136:5	I-AdverseReaction
urine	ELIQUIS.xml:S1:19142:5	I-AdverseReaction
positive	ELIQUIS.xml:S1:19148:8	I-AdverseReaction

General	ELIQUIS.xml:S1:19163:7	O
disorders	ELIQUIS.xml:S1:19171:9	O
and	ELIQUIS.xml:S1:19181:3	O
administration	ELIQUIS.xml:S1:19185:14	O
-	ELIQUIS.xml:S1:19199:1	O
site	ELIQUIS.xml:S1:19200:4	O
conditions	ELIQUIS.xml:S1:19205:10	O
:	ELIQUIS.xml:S1:19215:1	O
injection	ELIQUIS.xml:S1:19218:9	B-AdverseReaction
-	ELIQUIS.xml:S1:19227:1	I-AdverseReaction
site	ELIQUIS.xml:S1:19228:4	I-AdverseReaction
hematoma	ELIQUIS.xml:S1:19233:8	I-AdverseReaction
,	ELIQUIS.xml:S1:19241:1	O
vessel	ELIQUIS.xml:S1:19243:6	B-AdverseReaction
puncture	ELIQUIS.xml:S1:19250:8	I-AdverseReaction
-	ELIQUIS.xml:S1:19258:1	I-AdverseReaction
site	ELIQUIS.xml:S1:19259:4	I-AdverseReaction
hematoma	ELIQUIS.xml:S1:19264:8	I-AdverseReaction
\n\n	ELIQUIS.xml:S2:0:2	O
BOXED	ELIQUIS.xml:S2:6:5	O
WARNING	ELIQUIS.xml:S2:12:7	O
:	ELIQUIS.xml:S2:19:1	O
WARNING	ELIQUIS.xml:S2:21:7	O
:	ELIQUIS.xml:S2:28:1	O
(	ELIQUIS.xml:S2:30:1	O
A	ELIQUIS.xml:S2:31:1	O
)	ELIQUIS.xml:S2:32:1	O
PREMATURE	ELIQUIS.xml:S2:34:9	O
DISCONTINUATION	ELIQUIS.xml:S2:44:15	O
OF	ELIQUIS.xml:S2:60:2	O
ELIQUIS	ELIQUIS.xml:S2:63:7	O
INCREASES	ELIQUIS.xml:S2:71:9	O
THE	ELIQUIS.xml:S2:81:3	O
RISK	ELIQUIS.xml:S2:85:4	B-Factor
OF	ELIQUIS.xml:S2:90:2	O
THROMBOTIC	ELIQUIS.xml:S2:93:10	B-AdverseReaction
EVENTS	ELIQUIS.xml:S2:104:6	I-AdverseReaction
(	ELIQUIS.xml:S2:110:1	O
B	ELIQUIS.xml:S2:111:1	O
)	ELIQUIS.xml:S2:112:1	O
SPINAL	ELIQUIS.xml:S2:114:6	B-AdverseReaction
EPIDURAL	ELIQUIS.xml:S2:121:8	B-AdverseReaction
HEMATOMA	ELIQUIS.xml:S2:130:8	I-AdverseReaction
\n\n	ELIQUIS.xml:S2:138:2	O
WARNING	ELIQUIS.xml:S2:142:7	O
:	ELIQUIS.xml:S2:149:1	O
(	ELIQUIS.xml:S2:151:1	O
A	ELIQUIS.xml:S2:152:1	O
)	ELIQUIS.xml:S2:153:1	O
PREMATURE	ELIQUIS.xml:S2:155:9	O
DISCONTINUATION	ELIQUIS.xml:S2:165:15	O
OF	ELIQUIS.xml:S2:181:2	O
ELIQUIS	ELIQUIS.xml:S2:184:7	O
INCREASES	ELIQUIS.xml:S2:192:9	O
THE	ELIQUIS.xml:S2:202:3	O
RISK	ELIQUIS.xml:S2:206:4	B-Factor
OF	ELIQUIS.xml:S2:211:2	O
THROMBOTIC	ELIQUIS.xml:S2:214:10	B-AdverseReaction
EVENTS	ELIQUIS.xml:S2:225:6	I-AdverseReaction
(	ELIQUIS.xml:S2:231:1	O
B	ELIQUIS.xml:S2:232:1	O
)	ELIQUIS.xml:S2:233:1	O
SPINAL	ELIQUIS.xml:S2:235:6	B-AdverseReaction
EPIDURAL	ELIQUIS.xml:S2:242:8	B-AdverseReaction
HEMATOMA	ELIQUIS.xml:S2:251:8	I-AdverseReaction
\n\n	ELIQUIS.xml:S2:259:2	O
(	ELIQUIS.xml:S2:265:1	O
A	ELIQUIS.xml:S2:266:1	O
)	ELIQUIS.xml:S2:267:1	O
PREMATURE	ELIQUIS.xml:S2:269:9	O
DISCONTINUATION	ELIQUIS.xml:S2:279:15	O
OF	ELIQUIS.xml:S2:295:2	O
ELIQUIS	ELIQUIS.xml:S2:298:7	O
INCREASES	ELIQUIS.xml:S2:306:9	O
THE	ELIQUIS.xml:S2:316:3	O
RISK	ELIQUIS.xml:S2:320:4	B-Factor
OF	ELIQUIS.xml:S2:325:2	O
THROMBOTIC	ELIQUIS.xml:S2:328:10	B-AdverseReaction
EVENTS	ELIQUIS.xml:S2:339:6	I-AdverseReaction
\n\n\n\n	ELIQUIS.xml:S2:347:4	O
Premature	ELIQUIS.xml:S2:354:9	O
discontinuation	ELIQUIS.xml:S2:364:15	O
of	ELIQUIS.xml:S2:380:2	O
any	ELIQUIS.xml:S2:383:3	O
oral	ELIQUIS.xml:S2:387:4	O
anticoagulant	ELIQUIS.xml:S2:392:13	O
,	ELIQUIS.xml:S2:405:1	O
including	ELIQUIS.xml:S2:407:9	O
ELIQUIS	ELIQUIS.xml:S2:417:7	O
,	ELIQUIS.xml:S2:424:1	O
increases	ELIQUIS.xml:S2:426:9	O
the	ELIQUIS.xml:S2:436:3	O
risk	ELIQUIS.xml:S2:440:4	B-Factor
of	ELIQUIS.xml:S2:445:2	O
thrombotic	ELIQUIS.xml:S2:448:10	B-AdverseReaction
events	ELIQUIS.xml:S2:459:6	I-AdverseReaction
.	ELIQUIS.xml:S2:465:1	O

If	ELIQUIS.xml:S2:467:2	O
anticoagulation	ELIQUIS.xml:S2:470:15	O
with	ELIQUIS.xml:S2:486:4	O
ELIQUIS	ELIQUIS.xml:S2:491:7	O
is	ELIQUIS.xml:S2:499:2	O
discontinued	ELIQUIS.xml:S2:502:12	O
for	ELIQUIS.xml:S2:515:3	O
a	ELIQUIS.xml:S2:519:1	O
reason	ELIQUIS.xml:S2:521:6	O
other	ELIQUIS.xml:S2:528:5	O
than	ELIQUIS.xml:S2:534:4	O
pathological	ELIQUIS.xml:S2:539:12	O
bleeding	ELIQUIS.xml:S2:552:8	O
or	ELIQUIS.xml:S2:561:2	O
completion	ELIQUIS.xml:S2:564:10	O
of	ELIQUIS.xml:S2:575:2	O
a	ELIQUIS.xml:S2:578:1	O
course	ELIQUIS.xml:S2:580:6	O
of	ELIQUIS.xml:S2:587:2	O
therapy	ELIQUIS.xml:S2:590:7	O
,	ELIQUIS.xml:S2:597:1	O
consider	ELIQUIS.xml:S2:599:8	O
coverage	ELIQUIS.xml:S2:608:8	O
with	ELIQUIS.xml:S2:617:4	O
another	ELIQUIS.xml:S2:622:7	O
anticoagulant	ELIQUIS.xml:S2:630:13	O
\n\n\n\n	ELIQUIS.xml:S2:645:4	O
[	ELIQUIS.xml:S2:654:1	O
see	ELIQUIS.xml:S2:655:3	O
Dosage	ELIQUIS.xml:S2:659:6	O
and	ELIQUIS.xml:S2:666:3	O
Administration	ELIQUIS.xml:S2:670:14	O
(	ELIQUIS.xml:S2:685:1	O
2.4	ELIQUIS.xml:S2:686:3	O
)	ELIQUIS.xml:S2:689:1	O
,	ELIQUIS.xml:S2:690:1	O
Warnings	ELIQUIS.xml:S2:692:8	O
and	ELIQUIS.xml:S2:701:3	O
Precautions	ELIQUIS.xml:S2:705:11	O
(	ELIQUIS.xml:S2:717:1	O
5.1	ELIQUIS.xml:S2:718:3	O
)	ELIQUIS.xml:S2:721:1	O
,	ELIQUIS.xml:S2:722:1	O
and	ELIQUIS.xml:S2:724:3	O
Clinical	ELIQUIS.xml:S2:728:8	O
Studies	ELIQUIS.xml:S2:737:7	O
(	ELIQUIS.xml:S2:745:1	O
14.1	ELIQUIS.xml:S2:746:4	O
)]	ELIQUIS.xml:S2:750:2	O
.	ELIQUIS.xml:S2:754:1	O

(	ELIQUIS.xml:S2:764:1	O
B	ELIQUIS.xml:S2:765:1	O
)	ELIQUIS.xml:S2:766:1	O
SPINAL	ELIQUIS.xml:S2:768:6	O
EPIDURAL	ELIQUIS.xml:S2:775:8	O
HEMATOMA	ELIQUIS.xml:S2:784:8	O
\n\n\n\n	ELIQUIS.xml:S2:794:4	O
Epidural	ELIQUIS.xml:S2:801:8	B-AdverseReaction
or	ELIQUIS.xml:S2:810:2	O
spinal	ELIQUIS.xml:S2:813:6	B-AdverseReaction
hematomas	ELIQUIS.xml:S2:820:9	I-AdverseReaction
may	ELIQUIS.xml:S2:830:3	B-Factor
occur	ELIQUIS.xml:S2:834:5	O
in	ELIQUIS.xml:S2:840:2	O
patients	ELIQUIS.xml:S2:843:8	O
treated	ELIQUIS.xml:S2:852:7	O
with	ELIQUIS.xml:S2:860:4	O
ELIQUIS	ELIQUIS.xml:S2:865:7	O
who	ELIQUIS.xml:S2:873:3	O
are	ELIQUIS.xml:S2:877:3	O
receiving	ELIQUIS.xml:S2:881:9	O
neuraxial	ELIQUIS.xml:S2:891:9	O
anesthesia	ELIQUIS.xml:S2:901:10	O
or	ELIQUIS.xml:S2:912:2	O
undergoing	ELIQUIS.xml:S2:915:10	O
spinal	ELIQUIS.xml:S2:926:6	O
puncture	ELIQUIS.xml:S2:933:8	O
.	ELIQUIS.xml:S2:941:1	O

These	ELIQUIS.xml:S2:943:5	O
hematomas	ELIQUIS.xml:S2:949:9	B-AdverseReaction
may	ELIQUIS.xml:S2:959:3	B-Factor
result	ELIQUIS.xml:S2:963:6	O
in	ELIQUIS.xml:S2:970:2	O
long	ELIQUIS.xml:S2:973:4	B-AdverseReaction
-	ELIQUIS.xml:S2:977:1	I-AdverseReaction
term	ELIQUIS.xml:S2:978:4	I-AdverseReaction
or	ELIQUIS.xml:S2:983:2	O
permanent	ELIQUIS.xml:S2:986:9	B-AdverseReaction
paralysis	ELIQUIS.xml:S2:996:9	I-AdverseReaction
.	ELIQUIS.xml:S2:1005:1	O

Consider	ELIQUIS.xml:S2:1007:8	O
these	ELIQUIS.xml:S2:1016:5	O
risks	ELIQUIS.xml:S2:1022:5	O
when	ELIQUIS.xml:S2:1028:4	O
scheduling	ELIQUIS.xml:S2:1033:10	O
patients	ELIQUIS.xml:S2:1044:8	O
for	ELIQUIS.xml:S2:1053:3	O
spinal	ELIQUIS.xml:S2:1057:6	O
procedures	ELIQUIS.xml:S2:1064:10	O
.	ELIQUIS.xml:S2:1074:1	O

Factors	ELIQUIS.xml:S2:1076:7	O
that	ELIQUIS.xml:S2:1084:4	O
can	ELIQUIS.xml:S2:1089:3	O
increase	ELIQUIS.xml:S2:1093:8	O
the	ELIQUIS.xml:S2:1102:3	O
risk	ELIQUIS.xml:S2:1106:4	B-Factor
of	ELIQUIS.xml:S2:1111:2	O
developing	ELIQUIS.xml:S2:1114:10	O
epidural	ELIQUIS.xml:S2:1125:8	B-AdverseReaction
or	ELIQUIS.xml:S2:1134:2	O
spinal	ELIQUIS.xml:S2:1137:6	B-AdverseReaction
hematomas	ELIQUIS.xml:S2:1144:9	I-AdverseReaction
in	ELIQUIS.xml:S2:1154:2	O
these	ELIQUIS.xml:S2:1157:5	O
patients	ELIQUIS.xml:S2:1163:8	O
include	ELIQUIS.xml:S2:1172:7	O
:	ELIQUIS.xml:S2:1179:1	O
\n\n\n\n	ELIQUIS.xml:S2:1182:4	O
?	ELIQUIS.xml:S2:1190:1	O
use	ELIQUIS.xml:S2:1191:3	O
of	ELIQUIS.xml:S2:1195:2	O
indwelling	ELIQUIS.xml:S2:1198:10	O
epidural	ELIQUIS.xml:S2:1209:8	O
catheters	ELIQUIS.xml:S2:1218:9	O
\n	ELIQUIS.xml:S2:1228:1	O
?	ELIQUIS.xml:S2:1233:1	O
concomitant	ELIQUIS.xml:S2:1234:11	O
use	ELIQUIS.xml:S2:1246:3	O
of	ELIQUIS.xml:S2:1250:2	O
other	ELIQUIS.xml:S2:1253:5	O
drugs	ELIQUIS.xml:S2:1259:5	O
that	ELIQUIS.xml:S2:1265:4	O
affect	ELIQUIS.xml:S2:1270:6	O
hemostasis	ELIQUIS.xml:S2:1277:10	O
,	ELIQUIS.xml:S2:1287:1	O
such	ELIQUIS.xml:S2:1289:4	O
as	ELIQUIS.xml:S2:1294:2	O
nonsteroidal	ELIQUIS.xml:S2:1297:12	O
anti	ELIQUIS.xml:S2:1310:4	O
-	ELIQUIS.xml:S2:1314:1	O
inflammatory	ELIQUIS.xml:S2:1315:12	O
drugs	ELIQUIS.xml:S2:1328:5	O
(	ELIQUIS.xml:S2:1334:1	O
NSAIDs	ELIQUIS.xml:S2:1335:6	O
)	ELIQUIS.xml:S2:1341:1	O
,	ELIQUIS.xml:S2:1342:1	O
platelet	ELIQUIS.xml:S2:1344:8	O
inhibitors	ELIQUIS.xml:S2:1353:10	O
,	ELIQUIS.xml:S2:1363:1	O
other	ELIQUIS.xml:S2:1365:5	O
anticoagulants	ELIQUIS.xml:S2:1371:14	O
\n	ELIQUIS.xml:S2:1386:1	O
?	ELIQUIS.xml:S2:1391:1	O
a	ELIQUIS.xml:S2:1392:1	O
history	ELIQUIS.xml:S2:1394:7	O
of	ELIQUIS.xml:S2:1402:2	O
traumatic	ELIQUIS.xml:S2:1405:9	O
or	ELIQUIS.xml:S2:1415:2	O
repeated	ELIQUIS.xml:S2:1418:8	O
epidural	ELIQUIS.xml:S2:1427:8	O
or	ELIQUIS.xml:S2:1436:2	O
spinal	ELIQUIS.xml:S2:1439:6	O
punctures	ELIQUIS.xml:S2:1446:9	O
\n	ELIQUIS.xml:S2:1456:1	O
?	ELIQUIS.xml:S2:1461:1	O
a	ELIQUIS.xml:S2:1462:1	O
history	ELIQUIS.xml:S2:1464:7	O
of	ELIQUIS.xml:S2:1472:2	O
spinal	ELIQUIS.xml:S2:1475:6	O
deformity	ELIQUIS.xml:S2:1482:9	O
or	ELIQUIS.xml:S2:1492:2	O
spinal	ELIQUIS.xml:S2:1495:6	O
surgery	ELIQUIS.xml:S2:1502:7	O
\n	ELIQUIS.xml:S2:1510:1	O
?	ELIQUIS.xml:S2:1515:1	O
optimal	ELIQUIS.xml:S2:1516:7	O
timing	ELIQUIS.xml:S2:1524:6	O
between	ELIQUIS.xml:S2:1531:7	O
the	ELIQUIS.xml:S2:1539:3	O
administration	ELIQUIS.xml:S2:1543:14	O
of	ELIQUIS.xml:S2:1558:2	O
ELIQUIS	ELIQUIS.xml:S2:1561:7	O
and	ELIQUIS.xml:S2:1569:3	O
neuraxial	ELIQUIS.xml:S2:1573:9	O
procedures	ELIQUIS.xml:S2:1583:10	O
is	ELIQUIS.xml:S2:1594:2	O
not	ELIQUIS.xml:S2:1597:3	O
known	ELIQUIS.xml:S2:1601:5	O
\n	ELIQUIS.xml:S2:1607:1	O
[	ELIQUIS.xml:S2:1616:1	O
see	ELIQUIS.xml:S2:1617:3	O
Warnings	ELIQUIS.xml:S2:1621:8	O
and	ELIQUIS.xml:S2:1630:3	O
Precautions	ELIQUIS.xml:S2:1634:11	O
(	ELIQUIS.xml:S2:1646:1	O
5.3	ELIQUIS.xml:S2:1647:3	O
)]	ELIQUIS.xml:S2:1650:2	O
\n	ELIQUIS.xml:S2:1656:1	O
\n\n	ELIQUIS.xml:S2:1658:2	O
Monitor	ELIQUIS.xml:S2:1663:7	O
patients	ELIQUIS.xml:S2:1671:8	O
frequently	ELIQUIS.xml:S2:1680:10	O
for	ELIQUIS.xml:S2:1691:3	O
signs	ELIQUIS.xml:S2:1695:5	O
and	ELIQUIS.xml:S2:1701:3	O
symptoms	ELIQUIS.xml:S2:1705:8	O
of	ELIQUIS.xml:S2:1714:2	O
neurological	ELIQUIS.xml:S2:1717:12	O
impairment	ELIQUIS.xml:S2:1730:10	O
.	ELIQUIS.xml:S2:1740:1	O

If	ELIQUIS.xml:S2:1742:2	O
neurological	ELIQUIS.xml:S2:1745:12	O
compromise	ELIQUIS.xml:S2:1758:10	O
is	ELIQUIS.xml:S2:1769:2	O
noted	ELIQUIS.xml:S2:1772:5	O
,	ELIQUIS.xml:S2:1777:1	O
urgent	ELIQUIS.xml:S2:1779:6	O
treatment	ELIQUIS.xml:S2:1786:9	O
is	ELIQUIS.xml:S2:1796:2	O
necessary	ELIQUIS.xml:S2:1799:9	O
[	ELIQUIS.xml:S2:1811:1	O
see	ELIQUIS.xml:S2:1812:3	O
Warnings	ELIQUIS.xml:S2:1816:8	O
and	ELIQUIS.xml:S2:1825:3	O
Precautions	ELIQUIS.xml:S2:1829:11	O
(	ELIQUIS.xml:S2:1841:1	O
5.3	ELIQUIS.xml:S2:1842:3	O
)]	ELIQUIS.xml:S2:1845:2	O
.	ELIQUIS.xml:S2:1849:1	O

Consider	ELIQUIS.xml:S2:1859:8	O
the	ELIQUIS.xml:S2:1868:3	O
benefits	ELIQUIS.xml:S2:1872:8	O
and	ELIQUIS.xml:S2:1881:3	O
risks	ELIQUIS.xml:S2:1885:5	O
before	ELIQUIS.xml:S2:1891:6	O
neuraxial	ELIQUIS.xml:S2:1898:9	O
intervention	ELIQUIS.xml:S2:1908:12	O
in	ELIQUIS.xml:S2:1921:2	O
patients	ELIQUIS.xml:S2:1924:8	O
anticoagulated	ELIQUIS.xml:S2:1933:14	O
or	ELIQUIS.xml:S2:1948:2	O
to	ELIQUIS.xml:S2:1951:2	O
be	ELIQUIS.xml:S2:1954:2	O
anticoagulated	ELIQUIS.xml:S2:1957:14	O
[	ELIQUIS.xml:S2:1974:1	O
see	ELIQUIS.xml:S2:1975:3	O
Warnings	ELIQUIS.xml:S2:1979:8	O
and	ELIQUIS.xml:S2:1988:3	O
Precautions	ELIQUIS.xml:S2:1992:11	O
(	ELIQUIS.xml:S2:2004:1	O
5.3	ELIQUIS.xml:S2:2005:3	O
)]	ELIQUIS.xml:S2:2008:2	O
.	ELIQUIS.xml:S2:2012:1	O

WARNING	ELIQUIS.xml:S2:2022:7	O
:	ELIQUIS.xml:S2:2029:1	O
(	ELIQUIS.xml:S2:2031:1	O
A	ELIQUIS.xml:S2:2032:1	O
)	ELIQUIS.xml:S2:2033:1	O
PREMATURE	ELIQUIS.xml:S2:2035:9	O
DISCONTINUATION	ELIQUIS.xml:S2:2045:15	O
OF	ELIQUIS.xml:S2:2061:2	O
ELIQUIS	ELIQUIS.xml:S2:2064:7	O
INCREASES	ELIQUIS.xml:S2:2072:9	O
THE	ELIQUIS.xml:S2:2082:3	O
RISK	ELIQUIS.xml:S2:2086:4	B-Factor
OF	ELIQUIS.xml:S2:2091:2	O
THROMBOTIC	ELIQUIS.xml:S2:2094:10	B-AdverseReaction
EVENTS	ELIQUIS.xml:S2:2105:6	I-AdverseReaction
(	ELIQUIS.xml:S2:2111:1	O
B	ELIQUIS.xml:S2:2112:1	O
)	ELIQUIS.xml:S2:2113:1	O
SPINAL	ELIQUIS.xml:S2:2115:6	B-AdverseReaction
EPIDURAL	ELIQUIS.xml:S2:2122:8	B-AdverseReaction
HEMATOMA	ELIQUIS.xml:S2:2131:8	I-AdverseReaction
\n\n\n\n	ELIQUIS.xml:S2:2139:4	O
See	ELIQUIS.xml:S2:2146:3	O
full	ELIQUIS.xml:S2:2150:4	O
prescribing	ELIQUIS.xml:S2:2155:11	O
information	ELIQUIS.xml:S2:2167:11	O
for	ELIQUIS.xml:S2:2179:3	O
complete	ELIQUIS.xml:S2:2183:8	O
boxed	ELIQUIS.xml:S2:2192:5	O
warning	ELIQUIS.xml:S2:2198:7	O
.	ELIQUIS.xml:S2:2205:1	O

(	ELIQUIS.xml:S2:2215:1	O
A	ELIQUIS.xml:S2:2216:1	O
)	ELIQUIS.xml:S2:2217:1	O
PREMATURE	ELIQUIS.xml:S2:2219:9	O
DISCONTINUATION	ELIQUIS.xml:S2:2229:15	O
OF	ELIQUIS.xml:S2:2245:2	O
ELIQUIS	ELIQUIS.xml:S2:2248:7	O
INCREASES	ELIQUIS.xml:S2:2256:9	O
THE	ELIQUIS.xml:S2:2266:3	O
RISK	ELIQUIS.xml:S2:2270:4	B-Factor
OF	ELIQUIS.xml:S2:2275:2	O
THROMBOTIC	ELIQUIS.xml:S2:2278:10	B-AdverseReaction
EVENTS	ELIQUIS.xml:S2:2289:6	I-AdverseReaction
:	ELIQUIS.xml:S2:2295:1	O
Premature	ELIQUIS.xml:S2:2297:9	O
discontinuation	ELIQUIS.xml:S2:2307:15	O
of	ELIQUIS.xml:S2:2323:2	O
any	ELIQUIS.xml:S2:2326:3	O
oral	ELIQUIS.xml:S2:2330:4	O
anticoagulant	ELIQUIS.xml:S2:2335:13	O
,	ELIQUIS.xml:S2:2348:1	O
including	ELIQUIS.xml:S2:2350:9	O
ELIQUIS	ELIQUIS.xml:S2:2360:7	O
,	ELIQUIS.xml:S2:2367:1	O
increases	ELIQUIS.xml:S2:2369:9	O
the	ELIQUIS.xml:S2:2379:3	O
risk	ELIQUIS.xml:S2:2383:4	B-Factor
of	ELIQUIS.xml:S2:2388:2	O
thrombotic	ELIQUIS.xml:S2:2391:10	B-AdverseReaction
events	ELIQUIS.xml:S2:2402:6	I-AdverseReaction
.	ELIQUIS.xml:S2:2408:1	O

To	ELIQUIS.xml:S2:2410:2	O
reduce	ELIQUIS.xml:S2:2413:6	O
this	ELIQUIS.xml:S2:2420:4	O
risk	ELIQUIS.xml:S2:2425:4	O
,	ELIQUIS.xml:S2:2429:1	O
consider	ELIQUIS.xml:S2:2431:8	O
coverage	ELIQUIS.xml:S2:2440:8	O
with	ELIQUIS.xml:S2:2449:4	O
another	ELIQUIS.xml:S2:2454:7	O
anticoagulant	ELIQUIS.xml:S2:2462:13	O
if	ELIQUIS.xml:S2:2476:2	O
ELIQUIS	ELIQUIS.xml:S2:2479:7	O
is	ELIQUIS.xml:S2:2487:2	O
discontinued	ELIQUIS.xml:S2:2490:12	O
for	ELIQUIS.xml:S2:2503:3	O
a	ELIQUIS.xml:S2:2507:1	O
reason	ELIQUIS.xml:S2:2509:6	O
other	ELIQUIS.xml:S2:2516:5	O
than	ELIQUIS.xml:S2:2522:4	O
pathological	ELIQUIS.xml:S2:2527:12	O
bleeding	ELIQUIS.xml:S2:2540:8	O
or	ELIQUIS.xml:S2:2549:2	O
completion	ELIQUIS.xml:S2:2552:10	O
of	ELIQUIS.xml:S2:2563:2	O
a	ELIQUIS.xml:S2:2566:1	O
course	ELIQUIS.xml:S2:2568:6	O
of	ELIQUIS.xml:S2:2575:2	O
therapy	ELIQUIS.xml:S2:2578:7	O
.	ELIQUIS.xml:S2:2585:1	O

(	ELIQUIS.xml:S2:2591:1	O
2.4	ELIQUIS.xml:S2:2592:3	O
,	ELIQUIS.xml:S2:2599:1	O
5.1	ELIQUIS.xml:S2:2601:3	O
,	ELIQUIS.xml:S2:2604:1	O
14.1	ELIQUIS.xml:S2:2610:4	O
)	ELIQUIS.xml:S2:2614:1	O
\n\n\n\n	ELIQUIS.xml:S2:2617:4	O
(	ELIQUIS.xml:S2:2624:1	O
B	ELIQUIS.xml:S2:2625:1	O
)	ELIQUIS.xml:S2:2626:1	O
SPINAL	ELIQUIS.xml:S2:2628:6	O
EPIDURAL	ELIQUIS.xml:S2:2635:8	O
HEMATOMA	ELIQUIS.xml:S2:2644:8	O
:	ELIQUIS.xml:S2:2652:1	O
Epidural	ELIQUIS.xml:S2:2654:8	B-AdverseReaction
or	ELIQUIS.xml:S2:2663:2	O
spinal	ELIQUIS.xml:S2:2666:6	B-AdverseReaction
hematomas	ELIQUIS.xml:S2:2673:9	I-AdverseReaction
may	ELIQUIS.xml:S2:2683:3	B-Factor
occur	ELIQUIS.xml:S2:2687:5	O
in	ELIQUIS.xml:S2:2693:2	O
patients	ELIQUIS.xml:S2:2696:8	O
treated	ELIQUIS.xml:S2:2705:7	O
with	ELIQUIS.xml:S2:2713:4	O
ELIQUIS	ELIQUIS.xml:S2:2718:7	O
who	ELIQUIS.xml:S2:2726:3	O
are	ELIQUIS.xml:S2:2730:3	O
receiving	ELIQUIS.xml:S2:2734:9	O
neuraxial	ELIQUIS.xml:S2:2744:9	O
anesthesia	ELIQUIS.xml:S2:2754:10	O
or	ELIQUIS.xml:S2:2765:2	O
undergoing	ELIQUIS.xml:S2:2768:10	O
spinal	ELIQUIS.xml:S2:2779:6	O
puncture	ELIQUIS.xml:S2:2786:8	O
.	ELIQUIS.xml:S2:2794:1	O

These	ELIQUIS.xml:S2:2796:5	O
hematomas	ELIQUIS.xml:S2:2802:9	B-AdverseReaction
may	ELIQUIS.xml:S2:2812:3	B-Factor
result	ELIQUIS.xml:S2:2816:6	O
in	ELIQUIS.xml:S2:2823:2	O
long	ELIQUIS.xml:S2:2826:4	B-AdverseReaction
-	ELIQUIS.xml:S2:2830:1	I-AdverseReaction
term	ELIQUIS.xml:S2:2831:4	I-AdverseReaction
or	ELIQUIS.xml:S2:2836:2	O
permanent	ELIQUIS.xml:S2:2839:9	B-AdverseReaction
paralysis	ELIQUIS.xml:S2:2849:9	I-AdverseReaction
.	ELIQUIS.xml:S2:2858:1	O

Consider	ELIQUIS.xml:S2:2860:8	O
these	ELIQUIS.xml:S2:2869:5	O
risks	ELIQUIS.xml:S2:2875:5	O
when	ELIQUIS.xml:S2:2881:4	O
scheduling	ELIQUIS.xml:S2:2886:10	O
patients	ELIQUIS.xml:S2:2897:8	O
for	ELIQUIS.xml:S2:2906:3	O
spinal	ELIQUIS.xml:S2:2910:6	O
procedures	ELIQUIS.xml:S2:2917:10	O
.	ELIQUIS.xml:S2:2927:1	O

(	ELIQUIS.xml:S2:2929:1	O
5.3	ELIQUIS.xml:S2:2930:3	O
)	ELIQUIS.xml:S2:2933:1	O
\n	ELIQUIS.xml:S2:2936:1	O
5	ELIQUIS.xml:S3:4:1	O
WARNINGS	ELIQUIS.xml:S3:6:8	O
AND	ELIQUIS.xml:S3:15:3	O
PRECAUTIONS	ELIQUIS.xml:S3:19:11	O

EXCERPT	ELIQUIS.xml:S3:35:7	O
:	ELIQUIS.xml:S3:42:1	O
?	ELIQUIS.xml:S3:50:1	O

ELIQUIS	ELIQUIS.xml:S3:53:7	O
can	ELIQUIS.xml:S3:61:3	B-Factor
cause	ELIQUIS.xml:S3:65:5	O
serious	ELIQUIS.xml:S3:71:7	B-Severity
,	ELIQUIS.xml:S3:78:1	O
potentially	ELIQUIS.xml:S3:80:11	B-Factor
fatal	ELIQUIS.xml:S3:92:5	B-AdverseReaction
bleeding	ELIQUIS.xml:S3:98:8	B-AdverseReaction
.	ELIQUIS.xml:S3:106:1	O

Promptly	ELIQUIS.xml:S3:108:8	O
evaluate	ELIQUIS.xml:S3:117:8	O
signs	ELIQUIS.xml:S3:126:5	O
and	ELIQUIS.xml:S3:132:3	O
symptoms	ELIQUIS.xml:S3:136:8	O
of	ELIQUIS.xml:S3:145:2	O
blood	ELIQUIS.xml:S3:148:5	O
loss	ELIQUIS.xml:S3:154:4	O
.	ELIQUIS.xml:S3:158:1	O

(	ELIQUIS.xml:S3:159:1	O
5.2	ELIQUIS.xml:S3:160:3	O
)	ELIQUIS.xml:S3:163:1	O

?	ELIQUIS.xml:S3:170:1	O

Prosthetic	ELIQUIS.xml:S3:173:10	O
heart	ELIQUIS.xml:S3:184:5	O
valves	ELIQUIS.xml:S3:190:6	O
:	ELIQUIS.xml:S3:196:1	O
ELIQUIS	ELIQUIS.xml:S3:198:7	O
use	ELIQUIS.xml:S3:206:3	O
not	ELIQUIS.xml:S3:210:3	O
recommended	ELIQUIS.xml:S3:214:11	O
.	ELIQUIS.xml:S3:225:1	O

(	ELIQUIS.xml:S3:226:1	O
5.4	ELIQUIS.xml:S3:227:3	O
)	ELIQUIS.xml:S3:230:1	O

5.1	ELIQUIS.xml:S3:241:3	O

Increased	ELIQUIS.xml:S3:245:9	O
Risk	ELIQUIS.xml:S3:255:4	O
of	ELIQUIS.xml:S3:260:2	O
Thrombotic	ELIQUIS.xml:S3:263:10	O
Events	ELIQUIS.xml:S3:274:6	O
after	ELIQUIS.xml:S3:281:5	O
Premature	ELIQUIS.xml:S3:287:9	O
Discontinuation	ELIQUIS.xml:S3:297:15	O

Premature	ELIQUIS.xml:S3:316:9	O
discontinuation	ELIQUIS.xml:S3:326:15	O
of	ELIQUIS.xml:S3:342:2	O
any	ELIQUIS.xml:S3:345:3	O
oral	ELIQUIS.xml:S3:349:4	O
anticoagulant	ELIQUIS.xml:S3:354:13	O
,	ELIQUIS.xml:S3:367:1	O
including	ELIQUIS.xml:S3:369:9	O
ELIQUIS	ELIQUIS.xml:S3:379:7	O
,	ELIQUIS.xml:S3:386:1	O
in	ELIQUIS.xml:S3:388:2	O
the	ELIQUIS.xml:S3:391:3	O
absence	ELIQUIS.xml:S3:395:7	O
of	ELIQUIS.xml:S3:403:2	O
adequate	ELIQUIS.xml:S3:406:8	O
alternative	ELIQUIS.xml:S3:415:11	O
anticoagulation	ELIQUIS.xml:S3:427:15	O
increases	ELIQUIS.xml:S3:443:9	O
the	ELIQUIS.xml:S3:453:3	O
risk	ELIQUIS.xml:S3:457:4	B-Factor
of	ELIQUIS.xml:S3:462:2	O
thrombotic	ELIQUIS.xml:S3:465:10	B-AdverseReaction
events	ELIQUIS.xml:S3:476:6	I-AdverseReaction
.	ELIQUIS.xml:S3:482:1	O

An	ELIQUIS.xml:S3:484:2	O
increased	ELIQUIS.xml:S3:487:9	O
rate	ELIQUIS.xml:S3:497:4	O
of	ELIQUIS.xml:S3:502:2	O
stroke	ELIQUIS.xml:S3:505:6	B-AdverseReaction
was	ELIQUIS.xml:S3:512:3	O
observed	ELIQUIS.xml:S3:516:8	O
during	ELIQUIS.xml:S3:525:6	O
the	ELIQUIS.xml:S3:532:3	O
transition	ELIQUIS.xml:S3:536:10	O
from	ELIQUIS.xml:S3:547:4	O
ELIQUIS	ELIQUIS.xml:S3:552:7	O
to	ELIQUIS.xml:S3:560:2	O
warfarin	ELIQUIS.xml:S3:563:8	O
in	ELIQUIS.xml:S3:572:2	O
clinical	ELIQUIS.xml:S3:575:8	O
trials	ELIQUIS.xml:S3:584:6	O
in	ELIQUIS.xml:S3:591:2	O
atrial	ELIQUIS.xml:S3:594:6	O
fibrillation	ELIQUIS.xml:S3:601:12	O
patients	ELIQUIS.xml:S3:614:8	O
.	ELIQUIS.xml:S3:622:1	O

If	ELIQUIS.xml:S3:624:2	O
ELIQUIS	ELIQUIS.xml:S3:627:7	O
is	ELIQUIS.xml:S3:635:2	O
discontinued	ELIQUIS.xml:S3:638:12	O
for	ELIQUIS.xml:S3:651:3	O
a	ELIQUIS.xml:S3:655:1	O
reason	ELIQUIS.xml:S3:657:6	O
other	ELIQUIS.xml:S3:664:5	O
than	ELIQUIS.xml:S3:670:4	O
pathological	ELIQUIS.xml:S3:675:12	O
bleeding	ELIQUIS.xml:S3:688:8	O
or	ELIQUIS.xml:S3:697:2	O
completion	ELIQUIS.xml:S3:700:10	O
of	ELIQUIS.xml:S3:711:2	O
a	ELIQUIS.xml:S3:714:1	O
course	ELIQUIS.xml:S3:716:6	O
of	ELIQUIS.xml:S3:723:2	O
therapy	ELIQUIS.xml:S3:726:7	O
,	ELIQUIS.xml:S3:733:1	O
consider	ELIQUIS.xml:S3:735:8	O
coverage	ELIQUIS.xml:S3:744:8	O
with	ELIQUIS.xml:S3:753:4	O
another	ELIQUIS.xml:S3:758:7	O
anticoagulant	ELIQUIS.xml:S3:766:13	O
[	ELIQUIS.xml:S3:781:1	O
see	ELIQUIS.xml:S3:782:3	O
Dosage	ELIQUIS.xml:S3:789:6	O
and	ELIQUIS.xml:S3:796:3	O
Administration	ELIQUIS.xml:S3:800:14	O
(	ELIQUIS.xml:S3:815:1	O
2.4	ELIQUIS.xml:S3:816:3	O
)	ELIQUIS.xml:S3:819:1	O
andClinical	ELIQUIS.xml:S3:824:11	O
Studies	ELIQUIS.xml:S3:836:7	O
(	ELIQUIS.xml:S3:844:1	O
14.1	ELIQUIS.xml:S3:845:4	O
)]	ELIQUIS.xml:S3:849:2	O
.	ELIQUIS.xml:S3:853:1	O

5.2	ELIQUIS.xml:S3:861:3	O
Bleeding	ELIQUIS.xml:S3:865:8	O

ELIQUIS	ELIQUIS.xml:S3:877:7	O
increases	ELIQUIS.xml:S3:885:9	O
the	ELIQUIS.xml:S3:895:3	O
risk	ELIQUIS.xml:S3:899:4	B-Factor
of	ELIQUIS.xml:S3:904:2	O
bleeding	ELIQUIS.xml:S3:907:8	B-AdverseReaction
and	ELIQUIS.xml:S3:916:3	O
can	ELIQUIS.xml:S3:920:3	B-Factor
cause	ELIQUIS.xml:S3:924:5	O
serious	ELIQUIS.xml:S3:930:7	B-Severity
,	ELIQUIS.xml:S3:937:1	O
potentially	ELIQUIS.xml:S3:939:11	B-Factor
fatal	ELIQUIS.xml:S3:951:5	B-AdverseReaction
,	ELIQUIS.xml:S3:956:1	O
bleeding	ELIQUIS.xml:S3:958:8	B-AdverseReaction
[	ELIQUIS.xml:S3:968:1	O
see	ELIQUIS.xml:S3:969:3	O
Dosage	ELIQUIS.xml:S3:976:6	O
and	ELIQUIS.xml:S3:983:3	O
Administration	ELIQUIS.xml:S3:987:14	O
(	ELIQUIS.xml:S3:1002:1	O
2.1	ELIQUIS.xml:S3:1003:3	O
)	ELIQUIS.xml:S3:1006:1	O
andAdverse	ELIQUIS.xml:S3:1011:10	O
Reactions	ELIQUIS.xml:S3:1022:9	O
(	ELIQUIS.xml:S3:1032:1	O
6.1	ELIQUIS.xml:S3:1033:3	O
)]	ELIQUIS.xml:S3:1036:2	O
.	ELIQUIS.xml:S3:1040:1	O

Concomitant	ELIQUIS.xml:S3:1046:11	O
use	ELIQUIS.xml:S3:1058:3	O
of	ELIQUIS.xml:S3:1062:2	O
drugs	ELIQUIS.xml:S3:1065:5	O
affecting	ELIQUIS.xml:S3:1071:9	O
hemostasis	ELIQUIS.xml:S3:1081:10	O
increases	ELIQUIS.xml:S3:1092:9	O
the	ELIQUIS.xml:S3:1102:3	O
risk	ELIQUIS.xml:S3:1106:4	B-Factor
of	ELIQUIS.xml:S3:1111:2	O
bleeding	ELIQUIS.xml:S3:1114:8	B-AdverseReaction
.	ELIQUIS.xml:S3:1122:1	O

These	ELIQUIS.xml:S3:1124:5	O
include	ELIQUIS.xml:S3:1130:7	O
aspirin	ELIQUIS.xml:S3:1138:7	O
and	ELIQUIS.xml:S3:1146:3	O
other	ELIQUIS.xml:S3:1150:5	O
antiplatelet	ELIQUIS.xml:S3:1156:12	O
agents	ELIQUIS.xml:S3:1169:6	O
,	ELIQUIS.xml:S3:1175:1	O
other	ELIQUIS.xml:S3:1177:5	O
anticoagulants	ELIQUIS.xml:S3:1183:14	O
,	ELIQUIS.xml:S3:1197:1	O
heparin	ELIQUIS.xml:S3:1199:7	O
,	ELIQUIS.xml:S3:1206:1	O
thrombolytic	ELIQUIS.xml:S3:1208:12	O
agents	ELIQUIS.xml:S3:1221:6	O
,	ELIQUIS.xml:S3:1227:1	O
selective	ELIQUIS.xml:S3:1229:9	O
serotonin	ELIQUIS.xml:S3:1239:9	O
reuptake	ELIQUIS.xml:S3:1249:8	O
inhibitors	ELIQUIS.xml:S3:1258:10	O
,	ELIQUIS.xml:S3:1268:1	O
serotonin	ELIQUIS.xml:S3:1270:9	O
norepinephrine	ELIQUIS.xml:S3:1280:14	O
reuptake	ELIQUIS.xml:S3:1295:8	O
inhibitors	ELIQUIS.xml:S3:1304:10	O
,	ELIQUIS.xml:S3:1314:1	O
and	ELIQUIS.xml:S3:1316:3	O
nonsteroidal	ELIQUIS.xml:S3:1320:12	O
anti	ELIQUIS.xml:S3:1333:4	O
-	ELIQUIS.xml:S3:1337:1	O
inflammatory	ELIQUIS.xml:S3:1338:12	O
drugs	ELIQUIS.xml:S3:1351:5	O
(	ELIQUIS.xml:S3:1357:1	O
NSAIDs	ELIQUIS.xml:S3:1358:6	O
)	ELIQUIS.xml:S3:1364:1	O
[	ELIQUIS.xml:S3:1367:1	O
seeDrug	ELIQUIS.xml:S3:1368:7	O
Interactions	ELIQUIS.xml:S3:1376:12	O
(	ELIQUIS.xml:S3:1389:1	O
7.3	ELIQUIS.xml:S3:1390:3	O
)]	ELIQUIS.xml:S3:1393:2	O
.	ELIQUIS.xml:S3:1397:1	O

Advise	ELIQUIS.xml:S3:1403:6	O
patients	ELIQUIS.xml:S3:1410:8	O
of	ELIQUIS.xml:S3:1419:2	O
signs	ELIQUIS.xml:S3:1422:5	O
and	ELIQUIS.xml:S3:1428:3	O
symptoms	ELIQUIS.xml:S3:1432:8	O
of	ELIQUIS.xml:S3:1441:2	O
blood	ELIQUIS.xml:S3:1444:5	O
loss	ELIQUIS.xml:S3:1450:4	O
and	ELIQUIS.xml:S3:1455:3	O
to	ELIQUIS.xml:S3:1459:2	O
report	ELIQUIS.xml:S3:1462:6	O
them	ELIQUIS.xml:S3:1469:4	O
immediately	ELIQUIS.xml:S3:1474:11	O
or	ELIQUIS.xml:S3:1486:2	O
go	ELIQUIS.xml:S3:1489:2	O
to	ELIQUIS.xml:S3:1492:2	O
an	ELIQUIS.xml:S3:1495:2	O
emergency	ELIQUIS.xml:S3:1498:9	O
room	ELIQUIS.xml:S3:1508:4	O
.	ELIQUIS.xml:S3:1512:1	O

Discontinue	ELIQUIS.xml:S3:1514:11	O
ELIQUIS	ELIQUIS.xml:S3:1526:7	O
in	ELIQUIS.xml:S3:1534:2	O
patients	ELIQUIS.xml:S3:1537:8	O
with	ELIQUIS.xml:S3:1546:4	O
active	ELIQUIS.xml:S3:1551:6	O
pathological	ELIQUIS.xml:S3:1558:12	O
hemorrhage	ELIQUIS.xml:S3:1571:10	O
.	ELIQUIS.xml:S3:1581:1	O

There	ELIQUIS.xml:S3:1587:5	O
is	ELIQUIS.xml:S3:1593:2	O
no	ELIQUIS.xml:S3:1596:2	O
established	ELIQUIS.xml:S3:1599:11	O
way	ELIQUIS.xml:S3:1611:3	O
to	ELIQUIS.xml:S3:1615:2	O
reverse	ELIQUIS.xml:S3:1618:7	O
the	ELIQUIS.xml:S3:1626:3	O
anticoagulant	ELIQUIS.xml:S3:1630:13	O
effect	ELIQUIS.xml:S3:1644:6	O
of	ELIQUIS.xml:S3:1651:2	O
apixaban	ELIQUIS.xml:S3:1654:8	O
,	ELIQUIS.xml:S3:1662:1	O
which	ELIQUIS.xml:S3:1664:5	O
can	ELIQUIS.xml:S3:1670:3	O
be	ELIQUIS.xml:S3:1674:2	O
expected	ELIQUIS.xml:S3:1677:8	O
to	ELIQUIS.xml:S3:1686:2	O
persist	ELIQUIS.xml:S3:1689:7	O
for	ELIQUIS.xml:S3:1697:3	O
at	ELIQUIS.xml:S3:1701:2	O
least	ELIQUIS.xml:S3:1704:5	O
24	ELIQUIS.xml:S3:1710:2	O
hours	ELIQUIS.xml:S3:1713:5	O
after	ELIQUIS.xml:S3:1719:5	O
the	ELIQUIS.xml:S3:1725:3	O
last	ELIQUIS.xml:S3:1729:4	O
dose	ELIQUIS.xml:S3:1734:4	O
,	ELIQUIS.xml:S3:1738:1	O
i	ELIQUIS.xml:S3:1740:1	O
.	ELIQUIS.xml:S3:1741:1	O
e	ELIQUIS.xml:S3:1742:1	O
.	ELIQUIS.xml:S3:1743:1	O
,	ELIQUIS.xml:S3:1744:1	O
for	ELIQUIS.xml:S3:1746:3	O
about	ELIQUIS.xml:S3:1750:5	O
two	ELIQUIS.xml:S3:1756:3	O
drug	ELIQUIS.xml:S3:1760:4	O
half	ELIQUIS.xml:S3:1765:4	O
-	ELIQUIS.xml:S3:1769:1	O
lives	ELIQUIS.xml:S3:1770:5	O
.	ELIQUIS.xml:S3:1775:1	O

A	ELIQUIS.xml:S3:1777:1	O
specific	ELIQUIS.xml:S3:1779:8	O
antidote	ELIQUIS.xml:S3:1788:8	O
for	ELIQUIS.xml:S3:1797:3	O
ELIQUIS	ELIQUIS.xml:S3:1801:7	O
is	ELIQUIS.xml:S3:1809:2	O
not	ELIQUIS.xml:S3:1812:3	O
available	ELIQUIS.xml:S3:1816:9	O
.	ELIQUIS.xml:S3:1825:1	O

Hemodialysis	ELIQUIS.xml:S3:1827:12	O
does	ELIQUIS.xml:S3:1840:4	O
not	ELIQUIS.xml:S3:1845:3	O
appear	ELIQUIS.xml:S3:1849:6	O
to	ELIQUIS.xml:S3:1856:2	O
have	ELIQUIS.xml:S3:1859:4	O
a	ELIQUIS.xml:S3:1864:1	O
substantial	ELIQUIS.xml:S3:1866:11	O
impact	ELIQUIS.xml:S3:1878:6	O
on	ELIQUIS.xml:S3:1885:2	O
apixaban	ELIQUIS.xml:S3:1888:8	O
exposure	ELIQUIS.xml:S3:1897:8	O
[	ELIQUIS.xml:S3:1907:1	O
seeClinical	ELIQUIS.xml:S3:1908:11	O
Pharmacology	ELIQUIS.xml:S3:1920:12	O
(	ELIQUIS.xml:S3:1933:1	O
12.3	ELIQUIS.xml:S3:1934:4	O
)]	ELIQUIS.xml:S3:1938:2	O
.	ELIQUIS.xml:S3:1942:1	O

Protamine	ELIQUIS.xml:S3:1944:9	O
sulfate	ELIQUIS.xml:S3:1954:7	O
and	ELIQUIS.xml:S3:1962:3	O
vitamin	ELIQUIS.xml:S3:1966:7	O
K	ELIQUIS.xml:S3:1974:1	O
are	ELIQUIS.xml:S3:1976:3	O
not	ELIQUIS.xml:S3:1980:3	O
expected	ELIQUIS.xml:S3:1984:8	O
to	ELIQUIS.xml:S3:1993:2	O
affect	ELIQUIS.xml:S3:1996:6	O
the	ELIQUIS.xml:S3:2003:3	O
anticoagulant	ELIQUIS.xml:S3:2007:13	O
activity	ELIQUIS.xml:S3:2021:8	O
of	ELIQUIS.xml:S3:2030:2	O
apixaban	ELIQUIS.xml:S3:2033:8	O
.	ELIQUIS.xml:S3:2041:1	O

There	ELIQUIS.xml:S3:2043:5	O
is	ELIQUIS.xml:S3:2049:2	O
no	ELIQUIS.xml:S3:2052:2	O
experience	ELIQUIS.xml:S3:2055:10	O
with	ELIQUIS.xml:S3:2066:4	O
antifibrinolytic	ELIQUIS.xml:S3:2071:16	O
agents	ELIQUIS.xml:S3:2088:6	O
(	ELIQUIS.xml:S3:2095:1	O
tranexamic	ELIQUIS.xml:S3:2096:10	O
acid	ELIQUIS.xml:S3:2107:4	O
,	ELIQUIS.xml:S3:2111:1	O
aminocaproic	ELIQUIS.xml:S3:2113:12	O
acid	ELIQUIS.xml:S3:2126:4	O
)	ELIQUIS.xml:S3:2130:1	O
in	ELIQUIS.xml:S3:2132:2	O
individuals	ELIQUIS.xml:S3:2135:11	O
receiving	ELIQUIS.xml:S3:2147:9	O
apixaban	ELIQUIS.xml:S3:2157:8	O
.	ELIQUIS.xml:S3:2165:1	O

There	ELIQUIS.xml:S3:2167:5	O
is	ELIQUIS.xml:S3:2173:2	O
neither	ELIQUIS.xml:S3:2176:7	O
scientific	ELIQUIS.xml:S3:2184:10	O
rationale	ELIQUIS.xml:S3:2195:9	O
for	ELIQUIS.xml:S3:2205:3	O
reversal	ELIQUIS.xml:S3:2209:8	O
nor	ELIQUIS.xml:S3:2218:3	O
experience	ELIQUIS.xml:S3:2222:10	O
with	ELIQUIS.xml:S3:2233:4	O
systemic	ELIQUIS.xml:S3:2238:8	O
hemostatics	ELIQUIS.xml:S3:2247:11	O
(	ELIQUIS.xml:S3:2259:1	O
desmopressin	ELIQUIS.xml:S3:2260:12	O
and	ELIQUIS.xml:S3:2273:3	O
aprotinin	ELIQUIS.xml:S3:2277:9	O
)	ELIQUIS.xml:S3:2286:1	O
in	ELIQUIS.xml:S3:2288:2	O
individuals	ELIQUIS.xml:S3:2291:11	O
receiving	ELIQUIS.xml:S3:2303:9	O
apixaban	ELIQUIS.xml:S3:2313:8	O
.	ELIQUIS.xml:S3:2321:1	O

Use	ELIQUIS.xml:S3:2323:3	O
of	ELIQUIS.xml:S3:2327:2	O
procoagulant	ELIQUIS.xml:S3:2330:12	O
reversal	ELIQUIS.xml:S3:2343:8	O
agents	ELIQUIS.xml:S3:2352:6	O
such	ELIQUIS.xml:S3:2359:4	O
as	ELIQUIS.xml:S3:2364:2	O
prothrombin	ELIQUIS.xml:S3:2367:11	O
complex	ELIQUIS.xml:S3:2379:7	O
concentrate	ELIQUIS.xml:S3:2387:11	O
,	ELIQUIS.xml:S3:2398:1	O
activated	ELIQUIS.xml:S3:2400:9	O
prothrombin	ELIQUIS.xml:S3:2410:11	O
complex	ELIQUIS.xml:S3:2422:7	O
concentrate	ELIQUIS.xml:S3:2430:11	O
,	ELIQUIS.xml:S3:2441:1	O
or	ELIQUIS.xml:S3:2443:2	O
recombinant	ELIQUIS.xml:S3:2446:11	O
factor	ELIQUIS.xml:S3:2458:6	O
VIIa	ELIQUIS.xml:S3:2465:4	O
may	ELIQUIS.xml:S3:2470:3	O
be	ELIQUIS.xml:S3:2474:2	O
considered	ELIQUIS.xml:S3:2477:10	O
but	ELIQUIS.xml:S3:2488:3	O
has	ELIQUIS.xml:S3:2492:3	O
not	ELIQUIS.xml:S3:2496:3	O
been	ELIQUIS.xml:S3:2500:4	O
evaluated	ELIQUIS.xml:S3:2505:9	O
in	ELIQUIS.xml:S3:2515:2	O
clinical	ELIQUIS.xml:S3:2518:8	O
studies	ELIQUIS.xml:S3:2527:7	O
.	ELIQUIS.xml:S3:2534:1	O

Activated	ELIQUIS.xml:S3:2536:9	O
oral	ELIQUIS.xml:S3:2546:4	O
charcoal	ELIQUIS.xml:S3:2551:8	O
reduces	ELIQUIS.xml:S3:2560:7	O
absorption	ELIQUIS.xml:S3:2568:10	O
of	ELIQUIS.xml:S3:2579:2	O
apixaban	ELIQUIS.xml:S3:2582:8	O
,	ELIQUIS.xml:S3:2590:1	O
thereby	ELIQUIS.xml:S3:2592:7	O
lowering	ELIQUIS.xml:S3:2600:8	O
apixaban	ELIQUIS.xml:S3:2609:8	O
plasma	ELIQUIS.xml:S3:2618:6	O
concentration	ELIQUIS.xml:S3:2625:13	O
[	ELIQUIS.xml:S3:2640:1	O
seeOverdosage	ELIQUIS.xml:S3:2641:13	O
(	ELIQUIS.xml:S3:2655:1	O
10	ELIQUIS.xml:S3:2656:2	O
)]	ELIQUIS.xml:S3:2658:2	O
.	ELIQUIS.xml:S3:2662:1	O

5.3	ELIQUIS.xml:S3:2670:3	O
Spinal	ELIQUIS.xml:S3:2674:6	O
Epidural	ELIQUIS.xml:S3:2681:8	O
Anesthesia	ELIQUIS.xml:S3:2690:10	O
or	ELIQUIS.xml:S3:2701:2	O
Puncture	ELIQUIS.xml:S3:2704:8	O

When	ELIQUIS.xml:S3:2716:4	O
neuraxial	ELIQUIS.xml:S3:2721:9	O
anesthesia	ELIQUIS.xml:S3:2731:10	O
(	ELIQUIS.xml:S3:2742:1	O
spinal	ELIQUIS.xml:S3:2743:6	O
epidural	ELIQUIS.xml:S3:2750:8	O
anesthesia	ELIQUIS.xml:S3:2759:10	O
)	ELIQUIS.xml:S3:2769:1	O
or	ELIQUIS.xml:S3:2771:2	O
spinal	ELIQUIS.xml:S3:2774:6	O
epidural	ELIQUIS.xml:S3:2781:8	O
puncture	ELIQUIS.xml:S3:2790:8	O
is	ELIQUIS.xml:S3:2799:2	O
employed	ELIQUIS.xml:S3:2802:8	O
,	ELIQUIS.xml:S3:2810:1	O
patients	ELIQUIS.xml:S3:2812:8	O
treated	ELIQUIS.xml:S3:2821:7	O
with	ELIQUIS.xml:S3:2829:4	O
antithrombotic	ELIQUIS.xml:S3:2834:14	O
agents	ELIQUIS.xml:S3:2849:6	O
for	ELIQUIS.xml:S3:2856:3	O
prevention	ELIQUIS.xml:S3:2860:10	O
of	ELIQUIS.xml:S3:2871:2	O
thromboembolic	ELIQUIS.xml:S3:2874:14	O
complications	ELIQUIS.xml:S3:2889:13	O
are	ELIQUIS.xml:S3:2903:3	O
at	ELIQUIS.xml:S3:2907:2	O
risk	ELIQUIS.xml:S3:2910:4	B-Factor
of	ELIQUIS.xml:S3:2915:2	O
developing	ELIQUIS.xml:S3:2918:10	O
an	ELIQUIS.xml:S3:2929:2	O
epidural	ELIQUIS.xml:S3:2932:8	B-AdverseReaction
or	ELIQUIS.xml:S3:2941:2	O
spinal	ELIQUIS.xml:S3:2944:6	B-AdverseReaction
hematoma	ELIQUIS.xml:S3:2951:8	I-AdverseReaction
which	ELIQUIS.xml:S3:2960:5	O
can	ELIQUIS.xml:S3:2966:3	B-Factor
result	ELIQUIS.xml:S3:2970:6	O
in	ELIQUIS.xml:S3:2977:2	O
long	ELIQUIS.xml:S3:2980:4	B-AdverseReaction
-	ELIQUIS.xml:S3:2984:1	I-AdverseReaction
term	ELIQUIS.xml:S3:2985:4	I-AdverseReaction
or	ELIQUIS.xml:S3:2990:2	O
permanent	ELIQUIS.xml:S3:2993:9	B-AdverseReaction
paralysis	ELIQUIS.xml:S3:3003:9	I-AdverseReaction
.	ELIQUIS.xml:S3:3012:1	O

The	ELIQUIS.xml:S3:3018:3	O
risk	ELIQUIS.xml:S3:3022:4	O
of	ELIQUIS.xml:S3:3027:2	O
these	ELIQUIS.xml:S3:3030:5	O
events	ELIQUIS.xml:S3:3036:6	O
may	ELIQUIS.xml:S3:3043:3	O
be	ELIQUIS.xml:S3:3047:2	O
increased	ELIQUIS.xml:S3:3050:9	O
by	ELIQUIS.xml:S3:3060:2	O
the	ELIQUIS.xml:S3:3063:3	O
postoperative	ELIQUIS.xml:S3:3067:13	O
use	ELIQUIS.xml:S3:3081:3	O
of	ELIQUIS.xml:S3:3085:2	O
indwelling	ELIQUIS.xml:S3:3088:10	O
epidural	ELIQUIS.xml:S3:3099:8	O
catheters	ELIQUIS.xml:S3:3108:9	O
or	ELIQUIS.xml:S3:3118:2	O
the	ELIQUIS.xml:S3:3121:3	O
concomitant	ELIQUIS.xml:S3:3125:11	O
use	ELIQUIS.xml:S3:3137:3	O
of	ELIQUIS.xml:S3:3141:2	O
medicinal	ELIQUIS.xml:S3:3144:9	O
products	ELIQUIS.xml:S3:3154:8	O
affecting	ELIQUIS.xml:S3:3163:9	O
hemostasis	ELIQUIS.xml:S3:3173:10	O
.	ELIQUIS.xml:S3:3183:1	O

Indwelling	ELIQUIS.xml:S3:3185:10	O
epidural	ELIQUIS.xml:S3:3196:8	O
or	ELIQUIS.xml:S3:3205:2	O
intrathecal	ELIQUIS.xml:S3:3208:11	O
catheters	ELIQUIS.xml:S3:3220:9	O
should	ELIQUIS.xml:S3:3230:6	O
not	ELIQUIS.xml:S3:3237:3	O
be	ELIQUIS.xml:S3:3241:2	O
removed	ELIQUIS.xml:S3:3244:7	O
earlier	ELIQUIS.xml:S3:3252:7	O
than	ELIQUIS.xml:S3:3260:4	O
24	ELIQUIS.xml:S3:3265:2	O
hours	ELIQUIS.xml:S3:3268:5	O
after	ELIQUIS.xml:S3:3274:5	O
the	ELIQUIS.xml:S3:3280:3	O
last	ELIQUIS.xml:S3:3284:4	O
administration	ELIQUIS.xml:S3:3289:14	O
of	ELIQUIS.xml:S3:3304:2	O
ELIQUIS	ELIQUIS.xml:S3:3307:7	O
.	ELIQUIS.xml:S3:3314:1	O

The	ELIQUIS.xml:S3:3316:3	O
next	ELIQUIS.xml:S3:3320:4	O
dose	ELIQUIS.xml:S3:3325:4	O
of	ELIQUIS.xml:S3:3330:2	O
ELIQUIS	ELIQUIS.xml:S3:3333:7	O
should	ELIQUIS.xml:S3:3341:6	O
not	ELIQUIS.xml:S3:3348:3	O
be	ELIQUIS.xml:S3:3352:2	O
administered	ELIQUIS.xml:S3:3355:12	O
earlier	ELIQUIS.xml:S3:3368:7	O
than	ELIQUIS.xml:S3:3376:4	O
5	ELIQUIS.xml:S3:3381:1	O
hours	ELIQUIS.xml:S3:3383:5	O
after	ELIQUIS.xml:S3:3389:5	O
the	ELIQUIS.xml:S3:3395:3	O
removal	ELIQUIS.xml:S3:3399:7	O
of	ELIQUIS.xml:S3:3407:2	O
the	ELIQUIS.xml:S3:3410:3	O
catheter	ELIQUIS.xml:S3:3414:8	O
.	ELIQUIS.xml:S3:3422:1	O

The	ELIQUIS.xml:S3:3424:3	O
risk	ELIQUIS.xml:S3:3428:4	O
may	ELIQUIS.xml:S3:3433:3	O
also	ELIQUIS.xml:S3:3437:4	O
be	ELIQUIS.xml:S3:3442:2	O
increased	ELIQUIS.xml:S3:3445:9	O
by	ELIQUIS.xml:S3:3455:2	O
traumatic	ELIQUIS.xml:S3:3458:9	O
or	ELIQUIS.xml:S3:3468:2	O
repeated	ELIQUIS.xml:S3:3471:8	O
epidural	ELIQUIS.xml:S3:3480:8	O
or	ELIQUIS.xml:S3:3489:2	O
spinal	ELIQUIS.xml:S3:3492:6	O
puncture	ELIQUIS.xml:S3:3499:8	O
.	ELIQUIS.xml:S3:3507:1	O

If	ELIQUIS.xml:S3:3509:2	O
traumatic	ELIQUIS.xml:S3:3512:9	O
puncture	ELIQUIS.xml:S3:3522:8	O
occurs	ELIQUIS.xml:S3:3531:6	O
,	ELIQUIS.xml:S3:3537:1	O
delay	ELIQUIS.xml:S3:3539:5	O
the	ELIQUIS.xml:S3:3545:3	O
administration	ELIQUIS.xml:S3:3549:14	O
of	ELIQUIS.xml:S3:3564:2	O
ELIQUIS	ELIQUIS.xml:S3:3567:7	O
for	ELIQUIS.xml:S3:3575:3	O
48	ELIQUIS.xml:S3:3579:2	O
hours	ELIQUIS.xml:S3:3582:5	O
.	ELIQUIS.xml:S3:3587:1	O

Monitor	ELIQUIS.xml:S3:3593:7	O
patients	ELIQUIS.xml:S3:3601:8	O
frequently	ELIQUIS.xml:S3:3610:10	O
for	ELIQUIS.xml:S3:3621:3	O
signs	ELIQUIS.xml:S3:3625:5	O
and	ELIQUIS.xml:S3:3631:3	O
symptoms	ELIQUIS.xml:S3:3635:8	O
of	ELIQUIS.xml:S3:3644:2	O
neurological	ELIQUIS.xml:S3:3647:12	O
impairment	ELIQUIS.xml:S3:3660:10	O
(	ELIQUIS.xml:S3:3671:1	O
e	ELIQUIS.xml:S3:3672:1	O
.	ELIQUIS.xml:S3:3673:1	O
g	ELIQUIS.xml:S3:3674:1	O
.	ELIQUIS.xml:S3:3675:1	O
,	ELIQUIS.xml:S3:3676:1	O
numbness	ELIQUIS.xml:S3:3678:8	O
or	ELIQUIS.xml:S3:3687:2	O
weakness	ELIQUIS.xml:S3:3690:8	O
of	ELIQUIS.xml:S3:3699:2	O
the	ELIQUIS.xml:S3:3702:3	O
legs	ELIQUIS.xml:S3:3706:4	O
,	ELIQUIS.xml:S3:3710:1	O
bowel	ELIQUIS.xml:S3:3712:5	O
,	ELIQUIS.xml:S3:3717:1	O
or	ELIQUIS.xml:S3:3719:2	O
bladder	ELIQUIS.xml:S3:3722:7	O
dysfunction	ELIQUIS.xml:S3:3730:11	O
)	ELIQUIS.xml:S3:3741:1	O
.	ELIQUIS.xml:S3:3742:1	O

If	ELIQUIS.xml:S3:3744:2	O
neurological	ELIQUIS.xml:S3:3747:12	O
compromise	ELIQUIS.xml:S3:3760:10	O
is	ELIQUIS.xml:S3:3771:2	O
noted	ELIQUIS.xml:S3:3774:5	O
,	ELIQUIS.xml:S3:3779:1	O
urgent	ELIQUIS.xml:S3:3781:6	O
diagnosis	ELIQUIS.xml:S3:3788:9	O
and	ELIQUIS.xml:S3:3798:3	O
treatment	ELIQUIS.xml:S3:3802:9	O
is	ELIQUIS.xml:S3:3812:2	O
necessary	ELIQUIS.xml:S3:3815:9	O
.	ELIQUIS.xml:S3:3824:1	O

Prior	ELIQUIS.xml:S3:3826:5	O
to	ELIQUIS.xml:S3:3832:2	O
neuraxial	ELIQUIS.xml:S3:3835:9	O
intervention	ELIQUIS.xml:S3:3845:12	O
the	ELIQUIS.xml:S3:3858:3	O
physician	ELIQUIS.xml:S3:3862:9	O
should	ELIQUIS.xml:S3:3872:6	O
consider	ELIQUIS.xml:S3:3879:8	O
the	ELIQUIS.xml:S3:3888:3	O
potential	ELIQUIS.xml:S3:3892:9	O
benefit	ELIQUIS.xml:S3:3902:7	O
versus	ELIQUIS.xml:S3:3910:6	O
the	ELIQUIS.xml:S3:3917:3	O
risk	ELIQUIS.xml:S3:3921:4	O
in	ELIQUIS.xml:S3:3926:2	O
anticoagulated	ELIQUIS.xml:S3:3929:14	O
patients	ELIQUIS.xml:S3:3944:8	O
or	ELIQUIS.xml:S3:3953:2	O
in	ELIQUIS.xml:S3:3956:2	O
patients	ELIQUIS.xml:S3:3959:8	O
to	ELIQUIS.xml:S3:3968:2	O
be	ELIQUIS.xml:S3:3971:2	O
anticoagulated	ELIQUIS.xml:S3:3974:14	O
for	ELIQUIS.xml:S3:3989:3	O
thromboprophylaxis	ELIQUIS.xml:S3:3993:18	O
.	ELIQUIS.xml:S3:4011:1	O

5.4	ELIQUIS.xml:S3:4019:3	O
Patients	ELIQUIS.xml:S3:4023:8	O
with	ELIQUIS.xml:S3:4032:4	O
Prosthetic	ELIQUIS.xml:S3:4037:10	O
Heart	ELIQUIS.xml:S3:4048:5	O
Valves	ELIQUIS.xml:S3:4054:6	O

The	ELIQUIS.xml:S3:4064:3	O
safety	ELIQUIS.xml:S3:4068:6	O
and	ELIQUIS.xml:S3:4075:3	O
efficacy	ELIQUIS.xml:S3:4079:8	O
of	ELIQUIS.xml:S3:4088:2	O
ELIQUIS	ELIQUIS.xml:S3:4091:7	O
have	ELIQUIS.xml:S3:4099:4	O
not	ELIQUIS.xml:S3:4104:3	O
been	ELIQUIS.xml:S3:4108:4	O
studied	ELIQUIS.xml:S3:4113:7	O
in	ELIQUIS.xml:S3:4121:2	O
patients	ELIQUIS.xml:S3:4124:8	O
with	ELIQUIS.xml:S3:4133:4	O
prosthetic	ELIQUIS.xml:S3:4138:10	O
heart	ELIQUIS.xml:S3:4149:5	O
valves	ELIQUIS.xml:S3:4155:6	O
.	ELIQUIS.xml:S3:4161:1	O

Therefore	ELIQUIS.xml:S3:4163:9	O
,	ELIQUIS.xml:S3:4172:1	O
use	ELIQUIS.xml:S3:4174:3	O
of	ELIQUIS.xml:S3:4178:2	O
ELIQUIS	ELIQUIS.xml:S3:4181:7	O
is	ELIQUIS.xml:S3:4189:2	O
not	ELIQUIS.xml:S3:4192:3	O
recommended	ELIQUIS.xml:S3:4196:11	O
in	ELIQUIS.xml:S3:4208:2	O
these	ELIQUIS.xml:S3:4211:5	O
patients	ELIQUIS.xml:S3:4217:8	O
.	ELIQUIS.xml:S3:4225:1	O

5.5	ELIQUIS.xml:S3:4233:3	O
Acute	ELIQUIS.xml:S3:4237:5	O
PE	ELIQUIS.xml:S3:4243:2	O
in	ELIQUIS.xml:S3:4246:2	O
Hemodynamically	ELIQUIS.xml:S3:4249:15	O
Unstable	ELIQUIS.xml:S3:4265:8	O
Patients	ELIQUIS.xml:S3:4274:8	O
or	ELIQUIS.xml:S3:4283:2	O
Patients	ELIQUIS.xml:S3:4286:8	O
who	ELIQUIS.xml:S3:4295:3	O
Require	ELIQUIS.xml:S3:4299:7	O
Thrombolysis	ELIQUIS.xml:S3:4307:12	O
or	ELIQUIS.xml:S3:4320:2	O
Pulmonary	ELIQUIS.xml:S3:4323:9	O
Embolectomy	ELIQUIS.xml:S3:4333:11	O

Initiation	ELIQUIS.xml:S3:4348:10	O
of	ELIQUIS.xml:S3:4359:2	O
ELIQUIS	ELIQUIS.xml:S3:4362:7	O
is	ELIQUIS.xml:S3:4370:2	O
not	ELIQUIS.xml:S3:4373:3	O
recommended	ELIQUIS.xml:S3:4377:11	O
as	ELIQUIS.xml:S3:4389:2	O
an	ELIQUIS.xml:S3:4392:2	O
alternative	ELIQUIS.xml:S3:4395:11	O
to	ELIQUIS.xml:S3:4407:2	O
unfractionated	ELIQUIS.xml:S3:4410:14	O
heparin	ELIQUIS.xml:S3:4425:7	O
for	ELIQUIS.xml:S3:4433:3	O
the	ELIQUIS.xml:S3:4437:3	O
initial	ELIQUIS.xml:S3:4441:7	O
treatment	ELIQUIS.xml:S3:4449:9	O
of	ELIQUIS.xml:S3:4459:2	O
patients	ELIQUIS.xml:S3:4462:8	O
with	ELIQUIS.xml:S3:4471:4	O
PE	ELIQUIS.xml:S3:4476:2	O
who	ELIQUIS.xml:S3:4479:3	O
present	ELIQUIS.xml:S3:4483:7	O
with	ELIQUIS.xml:S3:4491:4	O
hemodynamic	ELIQUIS.xml:S3:4496:11	O
instability	ELIQUIS.xml:S3:4508:11	O
or	ELIQUIS.xml:S3:4520:2	O
who	ELIQUIS.xml:S3:4523:3	O
may	ELIQUIS.xml:S3:4527:3	O
receive	ELIQUIS.xml:S3:4531:7	O
thrombolysis	ELIQUIS.xml:S3:4539:12	O
or	ELIQUIS.xml:S3:4552:2	O
pulmonary	ELIQUIS.xml:S3:4555:9	O
embolectomy	ELIQUIS.xml:S3:4565:11	O
.	ELIQUIS.xml:S3:4576:1	O
